falseDecember 31Q220230001762359http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#DebtCurrenthttp://fasb.org/us-gaap/2023#DebtCurrenthttp://fasb.org/us-gaap/2023#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2023#LongTermDebtNoncurrent00017623592023-01-012023-06-300001762359acrg:ClassESubordinateVotingSharesMember2023-08-02xbrli:shares0001762359acrg:ClassDSubordinateVotingSharesMember2023-08-020001762359acrg:ClassFMultipleVotingSharesMember2023-08-0200017623592023-06-30iso4217:USD00017623592022-12-310001762359us-gaap:RetailMember2023-04-012023-06-300001762359us-gaap:RetailMember2022-04-012022-06-300001762359us-gaap:RetailMember2023-01-012023-06-300001762359us-gaap:RetailMember2022-01-012022-06-300001762359acrg:WholesaleMember2023-04-012023-06-300001762359acrg:WholesaleMember2022-04-012022-06-300001762359acrg:WholesaleMember2023-01-012023-06-300001762359acrg:WholesaleMember2022-01-012022-06-300001762359acrg:OtherMember2023-04-012023-06-300001762359acrg:OtherMember2022-04-012022-06-300001762359acrg:OtherMember2023-01-012023-06-300001762359acrg:OtherMember2022-01-012022-06-3000017623592023-04-012023-06-3000017623592022-04-012022-06-3000017623592022-01-012022-06-300001762359acrg:MedfordAndPowellOregonMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2022-01-012022-06-30iso4217:USDxbrli:shares0001762359acrg:HSCPLLCMembershipUnitsMember2021-12-310001762359us-gaap:CommonStockMember2021-12-310001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-12-310001762359us-gaap:TreasuryStockCommonMember2021-12-310001762359us-gaap:RetainedEarningsMember2021-12-310001762359us-gaap:ParentMember2021-12-310001762359us-gaap:NoncontrollingInterestMember2021-12-3100017623592021-12-310001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-01-012022-03-310001762359us-gaap:ParentMember2022-01-012022-03-310001762359us-gaap:NoncontrollingInterestMember2022-01-012022-03-3100017623592022-01-012022-03-310001762359us-gaap:CommonStockMember2022-01-012022-03-310001762359us-gaap:RetainedEarningsMember2022-01-012022-03-310001762359acrg:HSCPLLCMembershipUnitsMember2022-03-310001762359us-gaap:CommonStockMember2022-03-310001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-03-310001762359us-gaap:TreasuryStockCommonMember2022-03-310001762359us-gaap:RetainedEarningsMember2022-03-310001762359us-gaap:ParentMember2022-03-310001762359us-gaap:NoncontrollingInterestMember2022-03-3100017623592022-03-310001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-04-012022-06-300001762359us-gaap:ParentMember2022-04-012022-06-300001762359us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001762359us-gaap:CommonStockMember2022-04-012022-06-300001762359us-gaap:RetainedEarningsMember2022-04-012022-06-300001762359acrg:HSCPLLCMembershipUnitsMember2022-06-300001762359us-gaap:CommonStockMember2022-06-300001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-06-300001762359us-gaap:TreasuryStockCommonMember2022-06-300001762359us-gaap:RetainedEarningsMember2022-06-300001762359us-gaap:ParentMember2022-06-300001762359us-gaap:NoncontrollingInterestMember2022-06-3000017623592022-06-300001762359acrg:HSCPLLCMembershipUnitsMember2022-12-310001762359us-gaap:CommonStockMember2022-12-310001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-12-310001762359us-gaap:TreasuryStockCommonMember2022-12-310001762359us-gaap:RetainedEarningsMember2022-12-310001762359us-gaap:ParentMember2022-12-310001762359us-gaap:NoncontrollingInterestMember2022-12-310001762359srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2022-12-310001762359srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:ParentMember2022-12-310001762359srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-12-310001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-01-012023-03-310001762359us-gaap:ParentMember2023-01-012023-03-310001762359us-gaap:NoncontrollingInterestMember2023-01-012023-03-3100017623592023-01-012023-03-310001762359us-gaap:CommonStockMember2023-01-012023-03-310001762359us-gaap:RetainedEarningsMember2023-01-012023-03-310001762359acrg:HSCPLLCMembershipUnitsMember2023-03-310001762359us-gaap:CommonStockMember2023-03-310001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-03-310001762359us-gaap:TreasuryStockCommonMember2023-03-310001762359us-gaap:RetainedEarningsMember2023-03-310001762359us-gaap:ParentMember2023-03-310001762359us-gaap:NoncontrollingInterestMember2023-03-3100017623592023-03-310001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-04-012023-06-300001762359us-gaap:ParentMember2023-04-012023-06-300001762359us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001762359us-gaap:CommonStockMember2023-04-012023-06-300001762359us-gaap:RetainedEarningsMember2023-04-012023-06-300001762359acrg:HSCPLLCMembershipUnitsMember2023-06-300001762359us-gaap:CommonStockMember2023-06-300001762359us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-06-300001762359us-gaap:TreasuryStockCommonMember2023-06-300001762359us-gaap:RetainedEarningsMember2023-06-300001762359us-gaap:ParentMember2023-06-300001762359us-gaap:NoncontrollingInterestMember2023-06-3000017623592019-06-272019-06-27xbrli:pure0001762359acrg:CommonStockFixedSharesMember2020-09-230001762359acrg:CommonStockFloatingSharesMember2020-09-230001762359acrg:ProportionateVotingSharesFixedSharesMember2020-09-230001762359acrg:ProportionateVotingSharesFloatingSharesMember2020-09-230001762359acrg:FixedMultipleShareMember2020-09-230001762359acrg:FloatingMultipleShareMember2020-09-2300017623592020-09-230001762359acrg:UniversalHempMemberacrg:CanopyGrowthMemberacrg:CanopyGrowthMemberacrg:DebentureMemberacrg:UniversalHempMember2020-09-232020-09-230001762359acrg:UniversalHempMemberacrg:A61SecuredDebentureDue2030Member2023-06-300001762359acrg:AcreageHoldingsMemberacrg:CanopyGrowthAndCanopyUSALLCMember2022-10-242022-10-24utr:Rate0001762359acrg:NortheastPatientsGroupMember2023-01-022023-01-020001762359acrg:NortheastPatientsGroupMember2023-01-0200017623592022-01-012022-12-31acrg:businessacrg:divestiture0001762359acrg:CWGBotanicalsIncMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-06-300001762359us-gaap:CustomerRelatedIntangibleAssetsMember2023-06-300001762359us-gaap:CustomerRelatedIntangibleAssetsMember2022-12-310001762359us-gaap:ShortTermDebtMember2023-04-012023-06-300001762359us-gaap:ShortTermDebtMember2022-04-012022-06-300001762359us-gaap:ShortTermDebtMember2023-01-012023-06-300001762359us-gaap:ShortTermDebtMember2022-01-012022-06-300001762359acrg:EquitysecuritiesFVNIMember2023-04-012023-06-300001762359acrg:EquitysecuritiesFVNIMember2022-04-012022-06-300001762359acrg:EquitysecuritiesFVNIMember2023-01-012023-06-300001762359acrg:EquitysecuritiesFVNIMember2022-01-012022-06-300001762359acrg:A610SecuredDebentureDueSeptember2030Member2020-09-2300017623592020-09-232020-09-2300017623592020-09-282020-09-280001762359acrg:UniversalHempMemberacrg:InvestmentPartnershipMemberacrg:ClassBUnitsMember2020-09-280001762359acrg:UniversalHempMemberacrg:InvestmentPartnershipMemberacrg:InvestmentPartnershipMember2020-09-280001762359acrg:PromissoryNotesMember2023-06-300001762359acrg:PromissoryNotesMember2022-12-310001762359acrg:LineOfCreditReceivableMember2023-06-300001762359acrg:LineOfCreditReceivableMember2022-12-310001762359acrg:NotesReceivablePrincipalMember2023-06-300001762359acrg:NotesReceivablePrincipalMember2022-12-310001762359acrg:NotesReceivableAccruedInterestMember2023-06-300001762359acrg:NotesReceivableAccruedInterestMember2022-12-310001762359acrg:PrimeAlternativeTreatmentCenterIncPATCMemberacrg:PrimeAlternativeTreatmentCenterConsultingLLCNHPATCCMember2023-04-012023-04-300001762359acrg:GrownRogueMember2023-05-012023-05-310001762359acrg:PatientCentricMarthasVineyardMember2022-02-012022-02-280001762359us-gaap:LandMember2023-06-300001762359us-gaap:LandMember2022-12-310001762359us-gaap:BuildingMember2023-06-300001762359us-gaap:BuildingMember2022-12-310001762359us-gaap:FurnitureAndFixturesMember2023-06-300001762359us-gaap:FurnitureAndFixturesMember2022-12-310001762359us-gaap:LeaseholdImprovementsMember2023-06-300001762359us-gaap:LeaseholdImprovementsMember2022-12-310001762359us-gaap:ConstructionInProgressMember2023-06-300001762359us-gaap:ConstructionInProgressMember2022-12-310001762359acrg:AssetsRelatedToMichiganOperationsMember2022-06-300001762359acrg:AssetsRelatedToMichiganOperationsMember2022-01-012022-06-30acrg:lease0001762359acrg:A75LoanDue2026Member2023-06-300001762359acrg:A75LoanDue2026Member2022-12-310001762359acrg:A61SecuredDebentureDue2030Member2023-06-300001762359acrg:A61SecuredDebentureDue2030Member2022-12-310001762359acrg:NoteDueDecember2024Member2023-06-300001762359acrg:NoteDueDecember2024Member2022-12-310001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026Member2023-06-300001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026Member2022-12-310001762359acrg:NoteBackedByEmployeeRetentionTaxCreditsMember2023-06-300001762359acrg:NoteBackedByEmployeeRetentionTaxCreditsMember2022-12-310001762359acrg:UniversalHempMemberacrg:CanopyGrowthMemberacrg:CanopyGrowthMemberacrg:DebentureMemberacrg:UniversalHempMember2020-09-230001762359acrg:A11065220CanadaIncMemberacrg:CanopyGrowthMemberacrg:CanopyGrowthMemberacrg:DebentureMember2020-09-230001762359acrg:A11065220CanadaIncMemberacrg:CanopyGrowthMemberacrg:CanopyGrowthMemberacrg:DebentureMember2020-09-232020-09-230001762359acrg:UniversalHempMemberacrg:UniversalHempMember2020-09-282020-09-280001762359acrg:UniversalHempMemberacrg:InvestmentPartnershipMemberacrg:InvestmentPartnershipMemberacrg:ClassBUnitsMember2020-09-280001762359acrg:UniversalHempMemberacrg:ClassAUnitsMemberacrg:InvestmentPartnershipMember2020-09-280001762359acrg:A75LoanDue2026Member2020-09-280001762359acrg:A75LoanDue2026Member2020-09-282020-09-280001762359acrg:SecuritiesPurchaseAgreementMemberus-gaap:ConvertibleDebtMember2020-09-282020-09-2800017623592021-12-162021-12-1600017623592020-11-012020-11-30acrg:payment0001762359acrg:CanwellSettlementPromissoryNoteMember2020-11-012020-11-300001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026Member2021-12-160001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026InitialDrawMember2021-12-160001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026DelayedDrawMember2021-12-160001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026DelayedDrawMember2022-04-012022-04-300001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026DelayedDrawMember2021-12-162021-12-160001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026CommittedAccordionFacilityMember2021-12-160001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026Member2021-12-162021-12-160001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026CommittedAccordionFacilityMember2022-10-240001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026CommittedAccordionFacilityMember2023-01-012023-03-310001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026CommittedAccordionFacilityMember2023-01-010001762359acrg:AmendedCreditFacilityMember2022-10-240001762359acrg:AmendedCreditFacilityMember2023-04-280001762359us-gaap:PrimeMemberacrg:AmendedCreditFacilityMember2022-10-242022-10-240001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026Memberus-gaap:PrimeMemberacrg:AmendedCreditFacilityMember2022-10-242022-10-24acrg:leverage_ratio0001762359acrg:NoteBackedByEmployeeRetentionTaxCreditsMemberacrg:EmployeeRetentionTaxCreditFactoringAgreementMember2023-04-112023-04-110001762359acrg:NoteBackedByEmployeeRetentionTaxCreditsMemberacrg:EmployeeRetentionTaxCreditFactoringAgreementMember2023-04-110001762359acrg:CommonStockFixedSharesMemberacrg:PubcoMember2022-12-310001762359acrg:CommonStockFloatingSharesMemberacrg:PubcoMember2022-12-310001762359us-gaap:TreasuryStockCommonMemberacrg:PubcoMember2022-12-310001762359acrg:TreasuryStockFloatingMemberacrg:PubcoMember2022-12-310001762359us-gaap:CommonClassCMemberacrg:PubcoMember2022-12-310001762359us-gaap:CommonStockMemberacrg:PubcoMember2022-12-310001762359acrg:CommonStockFixedSharesMemberacrg:PubcoMember2023-01-012023-06-300001762359acrg:CommonStockFloatingSharesMemberacrg:PubcoMember2023-01-012023-06-300001762359us-gaap:TreasuryStockCommonMemberacrg:PubcoMember2023-01-012023-06-300001762359acrg:TreasuryStockFloatingMemberacrg:PubcoMember2023-01-012023-06-300001762359us-gaap:CommonClassCMemberacrg:PubcoMember2023-01-012023-06-300001762359us-gaap:CommonStockMemberacrg:PubcoMember2023-01-012023-06-300001762359acrg:CommonStockFixedSharesMemberacrg:PubcoMember2023-06-300001762359acrg:CommonStockFloatingSharesMemberacrg:PubcoMember2023-06-300001762359us-gaap:TreasuryStockCommonMemberacrg:PubcoMember2023-06-300001762359acrg:TreasuryStockFloatingMemberacrg:PubcoMember2023-06-300001762359us-gaap:CommonClassCMemberacrg:PubcoMember2023-06-300001762359us-gaap:CommonStockMemberacrg:PubcoMember2023-06-300001762359acrg:WarrantFixedSharesMember2022-12-310001762359acrg:WarrantFloatingSharesMember2022-12-310001762359acrg:WarrantFixedSharesMember2023-01-012023-06-300001762359acrg:WarrantFloatingSharesMember2023-01-012023-06-300001762359acrg:WarrantFixedSharesMember2023-06-300001762359acrg:WarrantFloatingSharesMember2023-06-300001762359acrg:WarrantFixedSharesMembersrt:MinimumMember2023-06-300001762359acrg:WarrantFixedSharesMembersrt:MaximumMember2023-06-300001762359acrg:WarrantFloatingSharesMembersrt:MinimumMember2023-06-300001762359srt:MaximumMemberacrg:WarrantFloatingSharesMember2023-06-300001762359acrg:HSCPLLCMember2023-06-300001762359acrg:HSCPLLCMember2022-12-310001762359acrg:HSCPUSCo2Memberacrg:HSCPLLCMember2023-06-300001762359acrg:HSCPUSCo2Memberacrg:HSCPLLCMember2022-12-310001762359acrg:HSCPLLCMember2023-04-012023-06-300001762359acrg:HSCPLLCMember2022-04-012022-06-300001762359acrg:HSCPLLCMember2023-01-012023-06-300001762359acrg:HSCPLLCMember2022-01-012022-06-300001762359acrg:ACRGOmnibusIncentivePlanMember2023-01-012023-06-300001762359acrg:ACRGOmnibusIncentivePlanMember2023-06-300001762359acrg:RestrictedStockUnitsFixedMember2022-12-310001762359acrg:RestrictedStockUnitsFloatingMember2022-12-310001762359acrg:RestrictedStockUnitsFixedMember2023-01-012023-06-300001762359acrg:RestrictedStockUnitsFloatingMember2023-01-012023-06-300001762359acrg:RestrictedStockUnitsFixedMember2023-06-300001762359acrg:RestrictedStockUnitsFloatingMember2023-06-300001762359us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001762359us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001762359us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001762359us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001762359us-gaap:RestrictedStockUnitsRSUMember2023-06-300001762359acrg:ShareBasedPaymentArrangementOptionFixedMember2022-12-310001762359acrg:ShareBasedPaymentArrangementOptionFloatingMember2022-12-310001762359acrg:ShareBasedPaymentArrangementOptionFixedMember2023-01-012023-06-300001762359acrg:ShareBasedPaymentArrangementOptionFloatingMember2023-01-012023-06-300001762359acrg:ShareBasedPaymentArrangementOptionFixedMember2023-06-300001762359acrg:ShareBasedPaymentArrangementOptionFloatingMember2023-06-300001762359us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001762359srt:MinimumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001762359srt:MaximumMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001762359us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001762359us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001762359us-gaap:EmployeeStockOptionMember2022-01-012022-06-30acrg:line_of_credit00017623592019-06-19acrg:company0001762359acrg:CanopyGrowthMember2020-09-232020-09-230001762359acrg:AcreageHoldingsMemberacrg:CanopyGrowthAndCanopyUSALLCMemberacrg:AmendedCreditFacilityMember2022-10-250001762359acrg:AcreageHoldingsMemberacrg:CanopyGrowthAndCanopyUSALLCMemberacrg:AmendedCreditFacilityMember2022-10-252022-10-250001762359acrg:CanopyGrowthCorporationMemberacrg:CurrentAndFormerUnitHoldersMemberacrg:CanopyGrowthAndCanopyUSALLCMember2022-10-242022-10-240001762359acrg:CanopyGrowthCorporationMemberacrg:DirectorsOfficersAndConsultantsMemberacrg:HighStreetCapitalPartnersLLCHSCPMember2022-10-242022-10-240001762359acrg:CanopyGrowthCorporationMemberacrg:DirectorsOfficersAndConsultantsMemberacrg:HighStreetCapitalPartnersLLCHSCPMember2022-10-240001762359acrg:CurrentHoldersMemberacrg:CanopyGrowthCorporationMemberacrg:TaxReceivableAgreementMemberacrg:HighStreetCapitalPartnersLLCHSCPMember2022-11-042022-11-040001762359acrg:CurrentHoldersMemberacrg:CanopyGrowthCorporationMemberacrg:TaxReceivableAgreementMemberacrg:HighStreetCapitalPartnersLLCHSCPMember2023-03-172023-03-170001762359acrg:CanopyGrowthCorporationMemberacrg:TaxReceivableAgreementEligibleParticipantsMemberacrg:CanopyGrowthAndCanopyUSALLCMember2022-10-242022-10-240001762359acrg:A11065220CanadaIncMemberacrg:CanopyGrowthMemberacrg:CanopyGrowthMember2020-09-2300017623592022-10-012022-12-310001762359acrg:CanwellSettlementPromissoryNoteMember2020-11-012023-06-300001762359acrg:NewYorkOutstandingLitigationMember2018-11-022018-11-02acrg:defendant0001762359acrg:AlfredsFinestIncMember2023-06-222023-06-220001762359acrg:A610SecuredDebentureDueSeptember2030Member2023-06-300001762359us-gaap:RelatedPartyMemberacrg:A610SecuredDebentureDueSeptember2030Member2023-04-012023-06-300001762359us-gaap:RelatedPartyMemberacrg:A610SecuredDebentureDueSeptember2030Member2023-01-012023-06-300001762359acrg:UniversalHempMemberacrg:InvestmentPartnershipMemberacrg:ClassBUnitsMemberacrg:MBMelodyLPMember2020-09-280001762359acrg:UniversalHempMemberacrg:InvestmentPartnershipMember2020-09-280001762359acrg:ViridescentRealtyTrustIncMemberacrg:AmendedCreditFacilityMember2022-10-240001762359acrg:ViridescentRealtyTrustIncMemberacrg:PrimeRateCreditFacilitiesDueJanuary2026Member2021-12-160001762359acrg:ViridescentRealtyTrustIncMemberacrg:PrimeRateCreditFacilitiesDueJanuary2026InitialDrawMember2021-12-160001762359acrg:PrimeRateCreditFacilitiesDueJanuary2026Memberacrg:ThirdPartySyndicatedAffiliatesMember2021-12-160001762359acrg:ViridescentRealtyTrustIncMemberacrg:PrimeRateCreditFacilitiesDueJanuary2026Memberus-gaap:RelatedPartyMember2023-01-012023-06-30acrg:segment0001762359acrg:FixedWarrantsMember2023-01-012023-06-300001762359acrg:FloatingWarrantsMember2023-01-012023-06-300001762359acrg:RestrictedStockUnitsFixedMember2023-01-012023-06-300001762359acrg:RestrictedStockUnitsFloatingMember2023-01-012023-06-300001762359acrg:ShareBasedPaymentArrangementOptionFixedMember2023-01-012023-06-300001762359acrg:ShareBasedPaymentArrangementOptionFloatingMember2023-01-012023-06-300001762359acrg:NonControllingInterestConvertibleUnitsMember2023-01-012023-06-300001762359acrg:FixedWarrantsMember2022-01-012022-06-300001762359acrg:FloatingWarrantsMember2022-01-012022-06-300001762359acrg:RestrictedStockUnitsFixedMember2022-01-012022-06-300001762359acrg:RestrictedStockUnitsFloatingMember2022-01-012022-06-300001762359acrg:ShareBasedPaymentArrangementOptionFixedMember2022-01-012022-06-300001762359acrg:ShareBasedPaymentArrangementOptionFloatingMember2022-01-012022-06-300001762359acrg:NonControllingInterestConvertibleUnitsMember2022-01-012022-06-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023

OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from  to


Commission file number 000-56021

ACREAGE HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
British Columbia, Canada98-1463868
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
366 Madison Ave, 14th floor
New YorkNew York10017
(Address of Principal Executive Offices)
(Zip Code)
(646) 600-9181
Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to section 12(g) of the Act: Class D Subordinate Voting Shares, no par value; Class E Subordinate Voting Shares, no par value.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes o No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes o No x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes  x   No  o 







Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
o
Accelerated filer
Non-accelerated filer
o
Smaller reporting company
Emerging growth company
                
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes ☐   No  x

The Company has three classes of issued and outstanding shares: the Class E subordinate voting shares (the “Fixed Shares”), the Class D subordinate voting shares (the “Floating Shares”) and the Class F multiple voting shares (the “Fixed Multiple Shares”). The Fixed Shares and Floating Shares each entitle the holders to notice of and to attend at any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company have the right to vote. Each Fixed Share is entitled to one vote per Fixed Share, each Floating Share is entitled to one vote per Floating Share and each Fixed Multiple Share is entitled to 4,300 votes per Fixed Multiple Share on all matters upon which the holders of shares are entitled to vote. As of August 2, 2023, there were 80,652,047 Fixed shares, 34,274,128 Floating Shares, and 117,600 Fixed Multiple Shares, in each case, issued and outstanding.




























TABLE OF CONTENTS
Acreage Holdings, Inc.
Form 10-Q
For the Three and Six Months Ended June 30, 2023
PART IFinancial Information
Item 1.
Item 2.
Item 3.
Item 4.
PART IIOther Information
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.















PART I
Item 1. Financial Statements and Supplementary Data.
ACREAGE HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands)June 30, 2023December 31, 2022
(unaudited)(audited)
ASSETS
Cash and cash equivalents$16,401 $24,067 
Restricted cash13,628  
Accounts receivable, net8,953 10,512 
Inventory47,938 49,446 
Notes receivable, net 29,191 
Assets held-for-sale1,788  
Other current assets5,418 4,977 
Total current assets94,126 118,193 
Long-term investments33,287 34,046 
Capital assets, net136,085 133,405 
Operating lease right-of-use assets19,067 22,443 
Intangible assets, net35,124 35,124 
Goodwill38,694 13,761 
Other non-current assets3,531 3,601 
Total non-current assets265,788 242,380 
TOTAL ASSETS$359,914 $360,573 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts payable and accrued liabilities$31,078 $29,566 
Taxes payable33,959 24,226 
Interest payable2,824 2,575 
Operating lease liability, current2,268 2,443 
Debt, current13,805 1,584 
Liabilities related to assets held for sale1,288  
Other current liabilities9,071 11,939 
Total current liabilities94,293 72,333 
Debt, non-current230,163 213,496 
Operating lease liability, non-current18,839 21,692 
Deferred tax liability10,620 9,623 
Other liabilities3,004 3,250 
Total non-current liabilities262,626 248,061 
TOTAL LIABILITIES356,919 320,394 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
F-1

ACREAGE HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Commitments and contingencies
Common stock, no par value - unlimited authorized, 113,203 and 112,437 issued and outstanding, respectively
  
Additional paid-in capital758,702 760,529 
Treasury stock, 842 common stock held in treasury
(21,054)(21,054)
Accumulated deficit(709,204)(678,091)
Total Acreage Shareholders' equity28,444 61,384 
Non-controlling interests(25,449)(21,205)
TOTAL EQUITY2,995 40,179 
TOTAL LIABILITIES AND EQUITY$359,914 $360,573 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
F-2

ACREAGE HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended June 30,Six Months Ended June 30,
(in thousands, except per share amounts)2023202220232022
REVENUE
Retail revenue, net$44,913 $46,685 $86,794 $88,112 
Wholesale revenue, net13,202 14,360 27,200 29,532 
Other revenue, net 306 84 586 
Total revenues, net58,115 61,351 114,078 118,230 
Cost of goods sold, retail(23,484)(23,466)(43,898)(44,234)
Cost of goods sold, wholesale(13,509)(7,271)(22,473)(13,872)
Total cost of goods sold(36,993)(30,737)(66,371)(58,106)
Gross profit21,122 30,614 47,707 60,124 
OPERATING EXPENSES
General and administrative7,073 8,922 17,585 17,309 
Compensation expense13,203 12,579 25,406 26,774 
Equity-based compensation expense694 1,655 1,678 5,814 
Marketing656 964 1,400 1,661 
Impairments, net 329  2,467 
Write down of assets held-for-sale3,557  3,557 874 
Legal recoveries (310) (335)
Depreciation and amortization994 3,165 1,991 4,972 
Total operating expenses26,177 27,304 51,617 59,536 
Net operating income (loss)$(5,055)$3,310 $(3,910)$588 
Income (loss) from investments, net322 (996)(20)137 
Interest income (loss) from loans receivable(6)365 10 782 
Interest expense(8,862)(5,520)(16,936)(10,301)
Other income (loss), net1,355 286 (198)276 
Total other loss(7,191)(5,865)(17,144)(9,106)
Loss before income taxes$(12,246)$(2,555)$(21,054)$(8,518)
Income tax expense(5,994)(8,048)(13,343)(15,996)
Net loss$(18,240)$(10,603)$(34,397)$(24,514)
Less: net loss attributable to non-controlling interests(2,084)(674)(3,651)(1,891)
Net loss attributable to Acreage Holdings, Inc.$(16,156)$(9,929)$(30,746)$(22,623)
Net loss per share attributable to Acreage Holdings, Inc. - basic and diluted:$(0.14)$(0.09)
(1)
$(0.27)$(0.21)
Weighted average shares outstanding - basic and diluted112,810 108,230 
(1)
112,679 107,569 

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
F-3

ACREAGE HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY



Attributable to shareholders of the parent
(in thousands)LLC Membership UnitsPubco Shares (as converted)Share CapitalTreasury StockAccumulated DeficitShareholders’ EquityNon-controlling InterestsTotal Equity
December 31, 20213,861 106,903 $756,536 $(21,054)$(538,215)$197,267 $7,003 $204,270 
NCI adjustments for changes in ownership— — 5 — — 5 (5) 
Equity-based compensation expense and related issuances— 508 4,159 — — 4,159 — 4,159 
Net loss— — — — (12,694)(12,694)(1,217)(13,911)
March 31, 20223,861 107,411 $760,700 $(21,054)$(550,909)$188,737 $5,781 $194,518 
NCI adjustments for changes in ownership— — (4,524)— — (4,524)4,524  
Capital distributions, net— — — — — — (5,534)(5,534)
Equity-based compensation expense and related issuances— 1,778 1,655 — — 1,655 — 1,655 
Net loss— — — — (9,929)(9,929)(674)(10,603)
June 30, 20223,861 109,189 $757,831 $(21,054)$(560,838)$175,939 $4,097 $180,036 

Attributable to shareholders of the parent
(in thousands)LLC Membership UnitsPubco Shares (as converted)Share CapitalTreasury StockAccumulated DeficitShareholders’ EquityNon-controlling InterestsTotal Equity
December 31, 20223,861 112,437 $760,529 $(21,054)$(678,091)$61,384 $(21,205)$40,179 
Cumulative effect of change in accounting principle for current expected credit losses, net of tax— — — (367)(367)— (367)
NCI adjustments for changes in ownership— — 14 — — 14 (14) 
Equity-based compensation expense and related issuances— 287 984 — — 984 — 984 
Net loss— — — — (14,590)(14,590)(1,567)(16,157)
March 31, 20233,861 112,724 $761,527 $(21,054)$(693,048)$47,425 $(22,786)$24,639 
NCI adjustments for changes in ownership— — (3,389)— — (3,389)3,389  
Capital distributions, net— — — — — — (3,968)(3,968)
Other equity transactions— — (130)— — (130)— (130)
Equity-based compensation expense and related issuances— 479 694 — — 694 — 694 
Net loss— — — — (16,156)(16,156)(2,084)(18,240)
June 30, 20233,861 113,203 $758,702 $(21,054)$(709,204)$28,444 $(25,449)$2,995 



See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
F-4

ACREAGE HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Six Months Ended June 30,
(in thousands)20232022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(34,397)$(24,514)
Adjustments for:
Depreciation and amortization1,991 4,972 
Depreciation and amortization included in COGS8,935 2,877 
Equity-based compensation expense1,678 5,814 
Gain on business divestiture (290)
Loss on disposal of capital assets 49 
Loss on impairment 2,467 
Bad debt expense339 14 
Non-cash interest expense2,457 1,470 
Non-cash operating lease expense(112)(55)
Loss on lease termination(200)338 
Deferred tax income(18)(791)
Non-cash loss from investments, net759 552 
Write-down of assets held-for-sale3,557 874 
Change, net of acquisitions in:
Accounts receivable, net6,068 (2,304)
Inventory(5,194)(10,460)
Other assets(469)(197)
Interest receivable(360)(782)
Accounts payable and accrued liabilities(5,670)(2,331)
Taxes payable8,540 (3,246)
Interest payable249 2,022 
Other liabilities(3,260)55 
Net cash used in operating activities$(15,107)$(23,466)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of capital assets$(3,232)$(11,876)
Collection of notes receivable2,000 5,999 
Business acquisitions, net of cash acquired516  
Purchases of intangible assets (900)
Distributions from investments 689 
Cash paid for short-term investment (3,400)
Net cash used in investing activities$(716)$(9,488)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from financing (refer to Note 14 for related party financing)$27,121 $25,000 
Deferred financing costs paid(500)(511)
Repayment of debt(868)(938)
Capital distributions - non-controlling interests(3,968)(5,534)
Net cash provided by financing activities$21,785 $18,017 
Net increase (decrease) in cash, cash equivalents, restricted cash, and cash held for sale$5,962 $(14,937)
Cash, cash equivalents, restricted cash, and cash held for sale - Beginning of period24,067 44,501 
Cash, cash equivalents, restricted cash, and cash held for sale - End of period$30,029 $29,564 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
F-5

ACREAGE HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
RECONCILIATION OF CASH FLOW INFORMATION:
Cash and cash equivalents$16,401 $29,235 
Restricted cash13,628 95 
Cash held for sale$ $234 
Total cash, cash equivalents, restricted cash, and cash held for sale at end of period$30,029 $29,564 

Six Months Ended June 30,
(in thousands)20232022
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid - non-lease$14,222 $5,586 
Income taxes paid4,280 21,476 
OTHER NON-CASH INVESTING AND FINANCING ACTIVITIES:
Capital assets not yet paid for$3,729 $5,505 
Non-cash proceeds from business divestiture 2,000 
Non-cash proceeds from finance lease 5,785 
Reclassification of assets held-for-sale to in-use  
Cumulative effect of change in accounting principle for current expected credit losses, net of tax121  
NCI adjustments for changes in ownership(14) 


See accompanying Notes to Unaudited Condensed Consolidated Financial Statements
F-6

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)

1.    NATURE OF OPERATIONS
Acreage Holdings, Inc. (the “Company”, “Pubco” or “Acreage”) is a vertically integrated, multi-state operator in the United States (“U.S.”) cannabis industry and has contractual relationships with cannabis cultivation facilities, dispensaries and other cannabis-related companies in the U.S. The Company’s operations include (i) cultivating and processing cannabis plants, (ii) manufacturing branded consumer products, (iii) distributing cannabis flower and manufactured products, and (iv) retailing dosable cannabis products to consumers. The Company’s products appeal to medical and adult recreational use customers through brand strategies intended to build trust and loyalty. The Company’s Class E subordinate voting shares (“Fixed Shares”) and Class D subordinate voting shares (“Floating Shares”) are listed on the Canadian Securities Exchange under the symbols “ACRG.A.U” and “ACRG.B.U”, respectively, quoted on the OTCQX under the symbols “ACRHF” and “ACRDF”, respectively, and traded on the Frankfurt Stock Exchange under the symbols “0VZ1” and “0VZ2”, respectively.
High Street Capital Partners, LLC, a Delaware limited liability company doing business as “Acreage Holdings” (“HSCP”), was formed on April 29, 2014. The Company became the indirect parent of HSCP on November 14, 2018 in connection with the reverse takeover (“RTO”) transaction described below.
The Company’s principal place of business is located at 366 Madison Ave, 14th floor, New York, New York in the U.S. The Company’s registered and records office address is Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia in Canada.
The RTO transaction

On September 21, 2018, the Company, HSCP, HSCP Merger Corp. (a wholly-owned subsidiary of the Company), Acreage Finco B.C. Ltd. (a special purpose corporation) (“Finco”), Acreage Holdings America, Inc. (“USCo”) and Acreage Holdings WC, Inc. (“USCo2”) entered into a business combination agreement (the “Business Combination Agreement”) whereby the parties thereto agreed to combine their respective businesses, which would result in the RTO of Pubco by the security holders of HSCP, which was deemed to be the accounting acquiror. On November 14, 2018, the parties to the Business Combination Agreement completed the RTO.
Canopy Growth Corporation transaction

On June 27, 2019, the Company and Canopy Growth Corporation (“Canopy Growth” or “CGC”) implemented the Prior Plan of Arrangement (as defined in Note 13) contemplated by the Original Arrangement Agreement (as defined in Note 13). Pursuant to the Prior Plan of Arrangement, Canopy Growth was granted an option to acquire all of the issued and outstanding shares of the Company in exchange for the payment of 0.5818 of a common share in the capital of Canopy Growth for each Class A subordinate voting share (each, a “SVS”) held (with the Class B proportionate voting shares (the “PVS”) and Class C multiple voting shares (the “MVS”) being automatically converted to SVS immediately prior to consummation of the Acquisition (as defined in Note 13), which original exchange ratio was subject to adjustment in accordance with the Original Arrangement Agreement. Canopy Growth was required to exercise the option upon a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”) and, subject to the satisfaction or waiver of certain closing conditions set out in the Original Arrangement Agreement, Canopy Growth was required to acquire all of the issued and outstanding SVS (following the mandatory conversion of the PVS and MVS into SVS).
On June 24, 2020, Canopy Growth and the Company entered into an agreement to, among other things, amend the terms of the Original Arrangement Agreement and the terms of the Prior Plan of Arrangement (the “Amended Arrangement”). On September 16, 2020, the Company’s shareholders voted in favor of a special resolution authorizing and approving the terms of, among other things, the Amended Arrangement. Subsequently, on September 18, 2020, the Company obtained a final order from the Supreme Court of British Columbia approving the Amended Arrangement, and on September 23, 2020 the Company and Canopy Growth entered into the Amending Agreement (as defined in Note 13) and implemented the Amended Arrangement. Pursuant to the Amended Arrangement, the Company’s articles were amended to create the Fixed Shares, the Floating Shares and the Class F multiple voting shares (the “Fixed Multiple Shares”), and each outstanding SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share, each outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and each outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share. Pursuant to the Amended Arrangement, Canopy Growth was granted the option to acquire all of the issued and outstanding Fixed Shares on the basis of 0.3048 (the “Fixed Exchange Ratio”) of a common share of Canopy Growth (each, a “Canopy Share”) for each Fixed Share held at the time of the acquisition of the Fixed Shares (the “Acquisition” or “Acquisition Time”), subject to
F-7

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
adjustment in accordance with the terms of the Amended Arrangement (the “Canopy Call Option”), which Canopy Growth is required to exercise upon the occurrence, or waiver (at the discretion of Canopy Growth), of a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event” and the date on which the Triggering Event occurs, the “Triggering Event Date”). Refer to Note 13 for further discussion.
Pursuant to the implementation of the Amended Arrangement, on September 23, 2020, a subsidiary of Canopy Growth advanced gross proceeds of $50,000 to Universal Hemp, LLC, an affiliate of the Company. The debenture bears interest at a rate of 6.1% per annum. Refer to Note 10 for further discussion.
On October 24, 2022, the Company entered into an arrangement agreement (the “Floating Share Agreement”) with Canopy Growth and Canopy USA, LLC (“Canopy USA”), Canopy Growth’s newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the “Floating Shares”) and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the “Floating Share Arrangement”) for consideration of 0.4500 of a common share of Canopy Growth (each whole share a “Canopy Share”) in exchange for each Floating Share. On March 15, 2023, the Company received the required approval of the holders of Floating Shares in connection with the Floating Share Arrangement at its special meeting of holders of Floating Shares. On March 21, 2023, the Corporation obtained a final order form from the Supreme Court of British Columbia approving the Floating Share Arrangement. Upon the satisfaction or waiver of all other conditions set out in the Floating Share Arrangement Agreement, which the parties continue to work towards, the parties will complete the Floating Share Arrangement. Refer to Note 13 for further discussion.
2.    SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation and going concern

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair presentation have been reflected in these unaudited condensed consolidated financial statements. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any other period.

As reflected in the unaudited condensed consolidated financial statements, the Company had an accumulated deficit as of June 30, 2023, as well as a net loss and negative cash flow from operating activities for the six months ended June 30, 2023. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements.

However, management believes that substantial doubt about the Company’s ability to meet its obligations for the next twelve months from the date these financial statements are issued, can be mitigated by, but not limited to, (i) expected long-term sales growth from the Company’s consolidated operations, (ii) latitude as to the timing and amount of certain operating expenses as well as capital expenditures, (iii) expense reduction plans that have already been put in place to improve the Company’s results, (iv) access to the U.S. and Canadian public equity markets.

If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its footprint build-out or other operational activities until such time as additional capital becomes available. Such limitation of the Company’s activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase the Company’s need to raise additional capital on an immediate basis.

These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, dated May 1, 2023, as filed with the Securities and Exchange Commission (the “2022 Form 10-K”).

F-8

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Use of estimates

Preparation of financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the dates presented and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates. Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include the fair value of assets acquired and liabilities assumed in business combinations, assumptions relating to equity-based compensation expense, estimated useful lives for property, plant and equipment and intangible assets, the valuation allowance against deferred tax assets and the assessment of potential charges on goodwill, intangible assets and investments in equity and notes receivable.
Emerging growth company
The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.
Functional and presentation currency

The unaudited condensed consolidated financial statements and the accompanying notes are expressed in U.S. dollars. Financial metrics are presented in thousands. Other metrics, such as shares outstanding, are presented in thousands unless otherwise noted.
Basis of consolidation

The Company’s unaudited condensed consolidated financial statements include the accounts of Acreage, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in business entities in which Acreage lacks control but is able to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations.
Non-controlling interests (“NCI”)

Non-controlling interests represent ownership interests in consolidated subsidiaries by parties that are not shareholders of Pubco. They are shown as a component of Total equity in the Unaudited Condensed Consolidated Statements of Financial Position, and the share of loss attributable to non-controlling interests is shown as a component of Net loss in the Unaudited Condensed Consolidated Statements of Operations. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions.
Cash and cash equivalents

The Company defines cash equivalents as highly liquid investments held for the purpose of meeting short-term cash commitments that are readily convertible into known amounts of cash, with original maturities of three months or less. The Company maintains cash with various U.S. banks and credit unions with balances in excess of the Federal Deposit Insurance Corporation and National Credit Union Share Insurance Fund limits, respectively. The failure of a bank or credit union where the Company has significant deposits could result in a loss of a portion of such cash balances in excess of the insured limit, which could materially and adversely affect the Company’s business, financial condition, results of operations and the market price of the Company’s Fixed Shares and Floating Shares. Cash and cash equivalents belonging to entities the Company has classified as held-for-sale have been reclassified to Assets held-for-sale on the Unaudited Condensed Consolidated Statements of Financial Position. Refer to Note 3 for further discussion.
Restricted cash
Restricted cash represents funds contractually held for specific purposes and, as such, not available for general corporate purposes.
Cash and restricted cash, as presented on the Unaudited Condensed Consolidated Statements of Cash Flows, consists of $16,401 and $13,628 as of June 30, 2023, respectively, and $29,235 and $95 as of June 30, 2022, respectively.
F-9

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)

Accounts receivable and notes receivable valuations

The Company reports accounts receivable at their net realizable value, which is management’s best estimate of the cash that will ultimately be received from customers. The Company's notes receivable represent notes due from various third parties. The Company maintains an allowance for expected credit losses to reflect the expected uncollectability of accounts receivable and notes receivable based on historical collection data and specific risks identified among uncollected accounts, as well as management’s expectation of future economic conditions. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the companies receivables and the expected future losses. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Trade accounts receivable and notes receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible. As of June 30, 2023, the Company’s allowance for doubtful accounts was $373, all of which relates to the allowance for credit losses over accounts receivable. As of June 30, 2023, the allowance on loans receivable was $15,095, of which the allowance for credit losses over notes receivable was nil as the receivables were fully reserved for. Refer to Note 6 for further discussion.

Net loss per share
Net loss per share represents the net loss attributable to shareholders divided by the weighted average number of shares outstanding during the period on an as converted basis. Basic and diluted loss per share are the same as of June 30, 2023, 2022 and 2021, as the issuance of shares upon conversion, exercise or vesting of outstanding units would be anti-dilutive in each period. There were 46,243 and 37,472 anti-dilutive shares outstanding as of June 30, 2023 and 2022, respectively.
Accounting Pronouncements Recently Adopted
As of January 1, 2023, the Company adopted ASU 2016-13 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which was subsequently revised by ASU 2018-19 and ASU 2020-02. This standard applies to financial assets, measured at amortized cost, including loans, held-to-maturity debt securities, net investments in leases and trade accounts receivable. The guidance must be adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings in the period of adoption. The adoption of ASU 2016-13 did not have a material effect on the Company’s unaudited condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted
In October 2021, the FASB issued ASU 2021-08 - Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The new standard requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606 - Revenue from Contracts with Customers. The ASU will be effective for the Company’s first interim period of fiscal 2024. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company does not anticipate a material impact on the Company’s unaudited condensed consolidated financial statements upon adoption.
F-10

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
3.    ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE
Acquisitions

On January 2, 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine. Under the terms of the agreement, the consideration paid consisted of the settlement of a pre-existing relationship, which included a line-of credit, other advances and the related interest receivable, all totaling $27,691, which were previously recorded in Notes receivable, net on the Statements of Financial Position.
The purchase price allocation is based upon preliminary valuations, estimates and assumptions which are subject to change within the measurement period, generally one year from the acquisition date. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the capital assets, tangible assets acquired and the residual goodwill resulting from the transaction.
Purchase Price AllocationNortheast Patients Group
Assets acquired:
Cash and cash equivalents$516 
Inventory384 
Other current assets5,580 
Capital assets2,404 
Operating lease right-of-use asset1,695 
Goodwill24,933 
Liabilities assumed:
Accounts payable and accrued liabilities(3,679)
Taxes payable(1,112)
Operating lease liability, current(160)
Operating lease liability, non-current(1,844)
Notes payable(11)
Deferred tax liability(1,015)
Fair value of net assets acquired$27,691 
Consideration paid:
Settlement of pre-existing relationship27,691 
Total consideration$27,691 
During the year ended December 31, 2022, the Company did not complete any business acquisitions.
Divestitures
During the three and six months ended June 30, 2023 and 2022, the Company did not complete any divestitures.
Assets Held for Sale
The Company determined certain businesses and assets met the held-for-sale criteria. As such, the related assets and liabilities within these disposal groups were transferred into Assets held-for-sale and Liabilities related to assets held for sale on the Unaudited Condensed Consolidated Statements of Financial Position.

The tables below present the assets and liabilities classified as held for sale on the Unaudited Condensed Consolidated Statements of Financial Position as of June 30, 2023, and are subject to change based on developments during the sales process. As of December 31, 2022, the Company did not have any business or assets that met the held-for-sale criteria.

F-11

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
June 30, 2023
CWG
Cash165 
Accounts receivable, net53 
Inventory685 
Other current assets64 
Total current assets classified as held-for-sale967 
Capital assets, net471 
Operating lease right-of-use assets310 
Non-current assets40 
Total assets classified as held for sale1,788 
Accounts payable and accrued liabilities(242)
Taxes payable81 
Operating lease liability, current(271)
Total current liabilities classified as held-for-sale(432)
Operating lease liability, non-current(856)
Total liabilities classified as held-for-sale(1,288)
The Company determined certain businesses and assets met the held-for-sale criteria. Upon classification of the disposal groups as held for sale, the Company tested each disposal group for impairment and recognized charges of $3,557 within Write down of assets held-for-sale on the Unaudited Condensed Consolidated Statements of Operations related to CWG for three and six months ended June 30, 2023, respectively. Additionally, all assets and liabilities determined within these disposal groups were transferred into Assets held-for-sale and Liabilities related to assets held for sale on the Consolidated Statements of Financial Position as of June 30, 2023

During the three and six months ended June 30, 2022, the Company recognized a write down of assets held-for-sale of $874 related to its Oregon operations within Write down of assets held-for-sale on the Unaudited Condensed Consolidated Statements of Operations.

F-12

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
4.    INTANGIBLE ASSETS AND GOODWILL
Intangible assets
The following table details the intangible asset balances by major asset classes:
IntangiblesJune 30, 2023December 31, 2022
Finite-lived intangible assets:
Customer relationships1,000 1,000 
Total finite-lived intangible assets1,000 1,000 
Accumulated amortization on finite-lived intangible assets:
Customer relationships(1,000)(1,000)
Total accumulated amortization on finite-lived intangible assets(1,000)(1,000)
Finite-lived intangible assets, net  
Indefinite-lived intangible assets
Cannabis licenses35,124 35,124 
Total intangibles, net$35,124 $35,124 
During the year ended December 31, 2022, the Company amended the purchase price allocation related to its acquisition of certain Ohio operations based upon final valuations within the measurement period. As a result, $17,000 was re-allocated from Goodwill to Intangible assets, net on the Unaudited Condensed Consolidated Statements of Financial Position.

There was no amortization expense recorded for the six months ended June 30, 2023. Amortization expense associated with the Company’s intangible assets was $296 and $992 for the three and six months ended June 30, 2022, respectively.
Goodwill
The following table details the changes in the carrying amount of goodwill:
GoodwillTotal
December 31, 2022$13,761 
Acquisitions24,933 
June 30, 2023$38,694 
During the six months ended June 30, 2023, the Company recognized $24,933 of goodwill based on the preliminary purchase price allocation related to the acquisition of Northeast Patients Group. Refer to Note 3 for further discussion.
5.    INVESTMENTS
The carrying values of the Company’s investments in the Unaudited Condensed Consolidated Statements of Financial Position as of June 30, 2023 and December 31, 2022 are as follows:
InvestmentsJune 30, 2023December 31, 2022
Investments held at FV-NI$33,287 $34,046 
Total long-term investments$33,287 $34,046 
F-13

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations during the three and six months ended June 30, 2023 and 2022 is as follows:
Investment income (loss)Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Short-term investments$ $2 $ $3 
Investments held at FV-NI322 (998)(20)134 
Income (loss) from investments, net$322 $(996)$(20)$137 
Investments held at FV-NI
The Company has investments in equity of other companies that do not result in significant influence or control. These investments are carried at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.
As further described under the “6.10% Secured debenture due September 2030” in Note 10, on September 23, 2020, a subsidiary of the Company, Universal Hemp, LLC ("Universal Hemp") was advanced gross proceeds of $50,000 (less transaction costs) pursuant to the terms of a secured debenture. The Company subsequently engaged an investment advisor, which under the investment advisor's sole discretion, on September 28, 2020 invested $34,019 of these proceeds on behalf of Universal Hemp. As a result, Universal Hemp acquired 34,019 class B units, at $1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the institutional investor holds Class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The Class B units are held by the Investment Advisor as an agent for Universal Hemp.
Universal Hemp, through its investment with the Investment Advisor, was originally determined to hold significant influence in the Investment Partnership in accordance with ASC 810 due to (1) the economic financial interest, and (2) the entitlement to matters as they pertain to ‘Extraordinary Resolution’ items as defined within the Investment Partnership Agreement. As a result, the Company accounted for the investment in the Investment Partnership under the equity method until December 2020. Refer to Note 10 for further discussion. In December 2020, the Company no longer held significant influence due to the removal of the Extraordinary Resolution entitlements and other revisions in the Investment Partnership Agreement. As a result, the Company changed its accounting for the Investment Partnership to recognize the investment at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.
6.     NOTES RECEIVABLE, NET

Notes receivable as of June 30, 2023 and December 31, 2022 consisted of the following:
June 30, 2023December 31, 2022
Promissory notes receivable$7,212 $34,088 
Line of credit receivable4,3315,831
Interest receivable3,552 4,147 
Allowance for notes and interest receivable(15,095)(14,875)
Total notes receivable$ $29,191 
Less: Notes receivable, current 29,191 
Notes receivable, non-current$ $ 
Interest income (loss) from loans receivable during the three and six months ended June 30, 2023 was $(6) and $10, respectively, and $365 and $782 for the three and six months ended June 30, 2022, respectively.
At each reporting date, the Company applies its judgment to evaluate the collectability of the note receivable and makes a provision based on the assessed amount of expected credit loss. This judgment is based on parameters such as interest rates, market conditions and creditworthiness of the creditor.
F-14

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
The Company determined that the collectability of certain notes receivables is doubtful based on information available. As of June 30, 2023 and December 31, 2022, the Company’s allowance for notes receivable of $15,095 and $14,875, respectively, included $11,543 and $12,041 of principal outstanding and $3,552 and $2,834 of accrued interest, respectively, and represents the full value of such loan balances.
Activity during the six months ended June 30, 2023

In January 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine and the amounts outstanding under the promissory notes receivable were converted into equity in Northeast Patients Group. Refer to Note 3 for further discussion.

In April 2023, the Company’s subsidiary Prime Alternative Treatment Center Consulting, LLC (“NH-PATCC”) received $1,500 from Prime Alternative Treatment Center, Inc. ("PATC") in settlement of the principal balance related to a promissory note that was extended to “PATC”.

In May 2023, the Company received a $500 cash payment towards the principal balance on a promissory note receivable from Grown Rogue.

Activity during the six months ended June 30, 2022

In February 2022, the Company received a $5,279 cash payment in full on a line of credit due from Patient Centric Martha’s Vineyard, and subsequently closed the line of credit.

7.    CAPITAL ASSETS, NET
Net property, plant and equipment consisted of:
June 30, 2023December 31, 2022
Land$9,778 $9,605 
Building58,524 58,334 
Right-of-use asset, finance leases6,297 5,077 
Furniture, fixtures and equipment40,698 46,811 
Leasehold improvements49,587 6,178 
Construction in progress11,415 34,435 
Capital assets, gross$176,299 $160,440 
Less: accumulated depreciation and amortization(40,214)(27,035)
Capital assets, net$136,085 $133,405 
Depreciation of capital assets for the three and six months ended June 30, 2023 is comprised of $994 and $1,991 of depreciation expense, and $2,090 and $4,377 that was capitalized to inventory, respectively, and $2,868 and $3,980 of depreciation expense and $1,794 and $3,716 that was capitalized to inventory for the three and six months ended June 30, 2022, respectively.
During the six months ended June 30, 2022, the Company determined that it was unable to find a satisfactory buyer for the held-for-sale assets related to its Michigan operations and, as such, these assets were reclassified as held-and-used. This conclusion was considered a triggering event for capital asset impairment testing. Upon assessment, these specific capital assets were not considered to have future economic value. As such, the fair value of the assets was considered to be nil and the Company recognized an impairment charge of $1,907 within Impairments, net on the Statements of Operations during the six months ended June 30, 2022. Refer to Note 3 for further discussion on changes in held-for-sale entities.

F-15

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
8.    LEASES
The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments and accounts for non-lease components separately from leases.
Balance Sheet InformationClassificationJune 30, 2023December 31, 2022
Right-of-use assets
OperatingOperating lease right-of-use assets$19,067 $22,443 
FinanceCapital assets, net4,690 4,269 
Total right-of-use assets$23,757 $26,712 
Lease liabilities
Current
OperatingOperating lease liability, current$2,268 $2,443 
FinancingDebt, current109 1 
Non-current
OperatingOperating lease liability, non-current18,839 21,692 
FinancingDebt, non-current5,860 5,305 
Total lease liabilities$27,076 $29,441 
Three Months Ended June 30,Six Months Ended June 30,
Statement of Operations InformationClassification2023202220232022
Short-term lease expenseGeneral and administrative$58 $170 $209 $218 
Operating lease expenseGeneral and administrative1,277 1,144 2,615 2,392 
Finance lease expense:
Amortization of right of use assetDepreciation and amortization92 64 185 127 
Interest expense on lease liabilitiesInterest expense211 329 420 541 
Net operating and finance lease cost$1,580 $1,537 $3,220 $3,060 
Six Months Ended June 30,
Statement of Cash Flows InformationClassification20232022
Cash paid for operating leasesNet cash used in operating activities$2,727 $2,447 
Cash paid for finance leases - interestNet cash used in operating activities$493 $522 
F-16

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of June 30, 2023:
Maturity of lease liabilitiesOperating LeasesFinance Leases
2023$2,030 $453 
20244,153 923 
20254,098 946 
20264,307 969 
20273,890 992 
Thereafter13,267 11,705 
Total lease payments$31,745 $15,988 
Less: interest10,638 10,019 
Present value of lease liabilities$21,107 $5,969 
Weighted average remaining lease term (years)812
Weighted average discount rate10%12%
As of June 30, 2023, there have been no leases entered into that have not yet commenced.
9.    INVENTORY
The Company’s inventory balance consists of the following:
June 30, 2023December 31, 2022
Retail inventory$3,714 $3,255 
Wholesale inventory36,478 35,885 
Cultivation inventory5,070 7,133 
Supplies & other2,676 3,173 
Total$47,938 $49,446 
Inventory is valued at the lower of cost and net realizable value (“NRV”), defined as estimated selling price in the ordinary course of business, less estimated costs of disposal. During the six months ended June 30, 2023, the Company analyzed its inventory balances, and recorded wholesale inventory adjustments as a result of (i) having excess or obsolete inventory and (ii) reducing the carrying value to ensure inventory balances are properly recorded at the lower of cost and NRV. The Company recognized $4,484 and $6,721 of wholesale inventory adjustments within Cost of goods sold, wholesale on the Statements of Operations for the three and six months ended June 30, 2023, respectively.
10.    DEBT
The Company’s debt balances consist of the following:
Debt balancesJune 30, 2023December 31, 2022
Financing liability (failed sale-leaseback)$15,253 $15,253 
Finance lease liabilities5,969 5,306 
7.50% Loan due April 2026
31,549 31,288 
6.10% Secured debenture due September 2030
46,727 46,502 
Note due December 20242,375 3,167 
Prime rate credit facilities due January 2026, as amended129,982 113,564 
Note backed by ERTC12,113  
Total debt$243,968 $215,080 
Less: current portion of debt13,805 1,584 
Total long-term debt$230,163 $213,496 
F-17

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Scheduled maturities of debt, excluding amortization of discount and issuance costs, are as follows:
2023$12,904 
20241,584 
2025 
2026173,011 
202739 
Thereafter71,172 
Total payments (excluding amortization of discount and issuance costs)
$258,710 
During the three and six months ended June 30, 2023, the Company incurred interest expense of $8,862 and $16,936, respectively, and $5,520 and $10,301 during the three and six months ended June 30, 2022, respectively, on the Unaudited Condensed Consolidated Statements of Operations. Interest expense for the three and six months ended June 30, 2023 included debt discount amortization of $525 and $1,015, respectively, and amortization of debt issuance costs of $698 and $1,388, respectively. Interest expense for the three and six months ended June 30, 2022 included debt discount amortization of $377 and $751, respectively, and amortization of debt issuance costs of $294 and $552, respectively. As of June 30, 2023 and December 31, 2022, the Company had unamortized discount $5,578 and $6,093, respectively, and debt issuance costs of $9,164 and $10,522, respectively, which is netted against the gross carrying value of long-term debt in Debt, non-current on Unaudited Condensed Unaudited Condensed Consolidated Statements of Financial Position. Additionally, as of June 30, 2023 and December 31, 2022, the Company had accrued interest of $2,824 and $2,575, respectively, within Interest payable on the Unaudited Condensed Consolidated Statements of Financial Position.
Financing liability (failed sales leaseback)
In connection with the Company’s failed sale-leaseback transaction in November 2020, a financing liability was recognized equal to the cash proceeds received. The Company will recognize the cash payments made on the lease as interest expense, and the principal will be de-recognized upon expiration of the lease.

6.10% Secured debenture due September 2030
On September 23, 2020, pursuant to the implementation of the Amended Arrangement (Refer to Note 13 for further discussion), a subsidiary of Canopy Growth advanced gross proceeds of $50,000 (less transaction costs of approximately $4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture (“6.1% Loan”). In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. An additional $50,000 may be advanced pursuant to the debenture subject to the satisfaction of certain conditions by Universal Hemp. The debenture bears interest at a rate of 6.1% per annum, matures 10 years from the date hereof or such earlier date in accordance with the terms of the debenture and all interest payments made pursuant to the debenture are payable in cash by Universal Hemp. The debenture is secured by substantially all of the assets of Universal Hemp and its subsidiaries and, further, is not convertible and is not guaranteed by Acreage.
With a portion of the proceeds for the 6.1% Loan received by Universal Hemp, Acreage engaged an Investment Advisor which, under the Investment Advisor’s sole discretion, invested on behalf of Universal Hemp $34,019 on September 28, 2020. As a result, Universal Hemp acquired 34,019 class B units, at $1.00 par value per unit, which represented 100% financial interest in the Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Investment Advisor as an agent for Universal Hemp. Upon execution of the limited partnership agreement, $1,019 was distributed to the class A unit holders of the Investment Partnership.
F-18

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
7.50% Loan due April 2026
On September 28, 2020, the Company received gross proceeds of $33,000 (less transaction costs of approximately $959) from an affiliate of the Institutional Investor (the “Lender”) and used a portion of the proceeds of this loan to retire its short-term $11,000 convertible note (as described above) and its short-term note aggregating approximately $18,000 in October 2020, with the remainder being used for working capital purposes. The loan is unsecured, matures in 3 years and bears interest at a 7.5% annual interest rate. The Lender is controlled by the Institutional Investor. The Investment Partnership is the investor in the Lender. On December 16, 2021, the Company paid an amendment fee of $413 to extend the maturity date from September 28, 2023 to April 2, 2026. The amendment was treated as a debt extinguishment.

Note due December 2024

In November 2020, the Company issued a promissory note with a third party, which is non-interest bearing and payable based on a payment schedule with ten payments in the aggregate amount of $7,750 through December 31, 2024, as a result of a settlement described under the “CanWell Dispute” in Note 13.
Prime rate credit facilities due January 2026, as amended
On December 16, 2021, the Company entered into a $150,000 senior secured credit facility with a syndicate of lenders consisting of a $75,000 initial draw, a $25,000 delayed draw that must be advanced within 12 months and a $50,000 committed accordion facility that is available after December 1, 2022, provided certain financial covenants are met, and with a maturity of January 1, 2026. Upon closing, gross proceeds of $75,000 were drawn (before origination discounts and issuance costs of approximately $4,000 and $1,500, respectively, which were capitalized). In April 2022, the Company drew down on the $25,000 delayed draw. Refer to Note 14 for further discussion of the syndicated related party lender.

The Company obtained a waiver of the financial covenants for the three month periods ended March 31, 2022 and June 30, 2022. This waiver included a $500 waiver fee that was paid to the lenders

On October 24, 2022, the Company amended the senior secured credit facility such that $25,000 of the committed accordion was available for immediate draw by Acreage, which was drawn down in the fourth quarter of 2022, with the remaining $25,000 available from January 1, 2023, provided certain predetermined milestones are achieved. The Company paid an amendment fee of $1,250 to the syndicate of lenders and the amendment was treated as a debt modification.

On April 28, 2023, the Company reached an agreement with the lenders of the Prime rate credit facilities due January 2026 that would allow it to draw a further $15,000 under its current Credit Agreement, but such funds would be maintained in a segregated account until dispersed and be restricted for use to only eligible capital expenditures. As part of this agreement, the Company agreed to limit the total amounts outstanding under the Credit Agreement to $140,000 and to at all times subsequent to the amendment, maintain collateral (as defined in the Credit Agreement) equal to or greater than the outstanding amount under the Credit Agreement.

The loan is secured by pledged equity interests and substantially all of the assets of the Company. Advances under the facility bear interest at a variable rate of U.S. prime (“Prime”) plus 5.75% per annum, payable monthly in arrears, with a Prime floor of 5.50% plus an additional 1.0% per annum until certain collateral assignment agreements are delivered.

The facility has a maturity date of January 1, 2026 and the Company has the option to extend the maturity date to January 1, 2027 prior to January 1, 2024, for a fee equal to 1.0% of the total loan amount. If the Company chooses to extend the maturity date, it will also be required to make monthly installment payments, each of which shall be an amount equal to five percent per year of the outstanding amount of the loan.

The loan is subject to various financial covenants, including (i) a fixed charge coverage ratio and two leverage ratios in respect of all periods beginning on or after December 31, 2023 and (ii) a minimum cash requirement of $9.0 million at each quarter end of the Company. Finally, the Amended Credit Facility includes approval for Canopy USA to acquire control of Acreage without requiring repayment of all amounts outstanding under the Amended Credit Facility, provided certain conditions are satisfied. As of June 30, 2023 the Company was in compliance with all covenants.

ERTC Factoring Agreement
On April 11, 2023, the Company received $12,113 pursuant to a financing agreement with a third-party lender (the “Financing Agreement”), which is included in “Debt, current” as of June 30, 2023. The Company assigned to the lender its interests in
F-19

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Employee Retention Tax Credits (“ERTC”) that it submitted for a claim of approximately $14,251. If the Company does not receive the ERTC, in whole or in part, the Company is required to repay the related portion of the funds received plus 10% interest accrued from the date of the Financing Agreement through the repayment date. The Financing Agreement does not have a stated maturity date and the discount is being accreted to interest expense over an expected term. The Company’s obligations under the Financing Agreement will be satisfied upon receipt of the ERTC or other full repayment. Finally, the Company determined the ERTC did not meet the criteria to record as a receivable as of June 30, 2023 due to the uncertain nature of such claims.
11.    SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS
The table below details the change in Pubco shares outstanding by class for the three and six months ended June 30, 2023:

Shareholders’ EquityFixed SharesFloating SharesFixed Shares Held in TreasuryFloating Shares Held in TreasuryFixed Multiple SharesTotal Shares Outstanding
December 31, 202279,047 34,114 (589)(253)118 112,437 
Issuances607 159    766 
NCI conversions      
June 30, 202379,654 34,273 (589)(253)118 113,203 
Warrants
A summary of the warrants activity outstanding is as follows:

WarrantsFixed SharesFloating Shares
December 31, 20225,817 2,524 
Expired  
June 30, 20235,817 2,524 

The exercise price of each Fixed Share warrant ranged from $3.15 to $4.00, respectively, and the exercise price of each Floating Share warrant ranged from $3.01 to $4.00, respectively. The warrants are exercisable for a period of 4 years. The weighted-average remaining contractual life of the warrants outstanding is approximately 1.5 years. There was no aggregate intrinsic value for warrants outstanding as of June 30, 2023.
Non-controlling interests - convertible units
The Company has NCIs in consolidated subsidiaries USCo2 and HSCP. The non-voting shares of USCo2 and HSCP units make up substantially all of the NCI balance as of June 30, 2023 and are convertible for either 0.7 of a Fixed Share and 0.3 of a Floating Share of Pubco or cash, as determined by the Company. Summarized financial information of HSCP is presented below. USCo2 does not have discrete financial information separate from HSCP.
HSCP net asset reconciliationJune 30, 2023December 31, 2022
Current assets$94,126 $118,193 
Non-current assets261,072 237,665 
Current liabilities(6,986)(9,141)
Non-current liabilities(266,212)(239,525)
Other NCI balances(726)(725)
Accumulated equity-settled expenses(242,438)(240,760)
Net assets$(161,164)$(134,293)
HSCP/USCo2 ownership % of HSCP16.24 %16.33 %
Net assets allocated to USCo2/HSCP$(26,175)$(21,930)
Net assets attributable to other NCIs726 725 
Total NCI$(25,449)$(21,205)
F-20

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Three Months Ended June 30,Six Months Ended June 30,
HSCP Summarized Statement of Operations2023202220232022
Net loss allocable to HSCP/USCo2$(12,801)$(3,958)$(22,403)$(11,040)
HSCP/USCo2 weighted average ownership % of HSCP16.28 %16.98 %16.29 %17.13 %
Net loss allocated to HSCP/USCo2$(2,084)$(672)$(3,650)$(1,891)
Net loss allocated to other NCIs (2)(1) 
Net loss attributable to NCIs$(2,084)$(674)$(3,651)$(1,891)
As of June 30, 2023, USCo2’s non-voting shares owned approximately 0.22% of HSCP units. USCo2’s capital structure is comprised of voting shares, all of which are held by the Company, and of non-voting shares held by certain former HSCP members. Certain executive employees and profits interests holders own approximately 16.07% of HSCP units. The remaining 83.71% interest in HSCP is held by USCo and represents the members’ equity attributable to shareholders of the parent.
A reconciliation of the beginning and ending amounts of convertible units is as follows:
Convertible UnitsJune 30, 2023December 31, 2022
Beginning balance22,698 23,076 
NCI units converted to Pubco (378)
Ending balance22,698 22,698 
12.    EQUITY-BASED COMPENSATION EXPENSE
Amended Arrangement with Canopy Growth
On September 23, 2020, the Company announced the implementation of the Amended Arrangement (as defined in Note 13). Pursuant to the Amended Arrangement, the Company’s articles have been amended to create new Fixed Shares, Floating Shares and Fixed Multiple Shares. Consequently, the Company’s equity-based compensation was modified into new equity awards of the Company. Refer to Note 13 for further discussion.

Equity-based compensation - Plan (Acreage Holdings, Inc. Omnibus Incentive Plan)
In connection with the RTO transaction, the Company’s Board of Directors adopted an Omnibus Incentive Plan, as amended September 23, 2020 (the “Plan”), which permits the issuance of stock options, stock appreciation rights, stock awards, share units, performance shares, performance units and other stock-based awards up to an amount equal to 15% of the issued and outstanding Subordinate Voting Shares of the Company.
Pursuant to the Amended Arrangement, the Company retained the Plan described above, the upper limit of issuances being up to an amount equal to 15% of the issued and outstanding Fixed Shares and Floating Shares of the Company. As of June 30, 2023, the Company had 5,308 shares authorized and available for grant under the Plan.
Restricted Share Units (“RSUs”)

Fixed SharesFloating Shares
Restricted Share Units
(Fair value information expressed in whole dollars)
RSUsWeighted Average Grant Date Fair ValueRSUsWeighted Average Grant Date Fair Value
Unvested, January 1, 20236,324 $1.80 464 $6.68 
Granted $  $ 
Forfeited(245)$1.00 (1)$2.15 
Vested(711)$2.50 (228)$2.59 
Unvested, June 30, 2023
5,368 $1.75 235 $10.65 
Vested and unreleased(1)
21 $15.31 11 $17.35 
Outstanding, June 30, 2023
5,389 $1.80 246 $10.94 
F-21

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
(1) RSUs that are vested and unreleased represent RSUs that are pending delivery.
RSUs of the Company generally vest over a period of three years and RSUs granted to certain executives vest based on achievement of specific performance conditions. In certain situations for specified individuals, RSUs vest on an accelerated basis on separation. The fair value for RSUs is based on the Company’s share price on the date of the grant. The Company recorded $470 and $1,228 as Equity-based compensation expense on Unaudited Condensed Consolidated Statements of Operations during the three and six months ended June 30, 2023, respectively, and $1,512 and $5,389 during the three and six months ended June 30, 2022, respectively. The fair value of RSUs vested during the three and six months ended June 30, 2023 was $157 and $599, respectively, and $1,451 and $3,333 during the three and six months ended June 30, 2022, respectively.
The total weighted average remaining contractual life and aggregate intrinsic value of unvested RSUs as of June 30, 2023 was approximately 1.7 years and $962, respectively. Unrecognized compensation expense related to these awards at June 30, 2023 was $10,471 and is expected to be recognized over a weighted average period of approximately 1.5 years.
Stock options
Fixed SharesFloating Shares
Stock Options
(Exercise price expressed in whole dollars)
OptionsWeighted Average Exercise PriceOptionsWeighted Average Exercise Price
Options outstanding, January 1, 20237,337 $2.75 2,267 $3.10 
Granted $  $ 
Forfeited $  $ 
Expired $ (35)$2.55 
Options outstanding, June 30, 2023
7,337 $2.75 2,232 $3.11 
Options exercisable, June 30, 2023
1,834 $9.14 2,101 $3.10 
Stock options of the Company generally vest over a period of three years and options granted to certain executives vest based on achievement of specific performance conditions. Stock options of the Company have an expiration period of 5 or 10 years from the date of grant. The weighted average contractual life remaining for Fixed Share options outstanding and exercisable as of June 30, 2023 was approximately 4.5 and 6 years, respectively. The weighted average contractual life remaining for Floating Share options outstanding and exercisable as of June 30, 2023 was approximately 6 and 6 years, respectively. The Company recorded $224 and $450 as Equity-based compensation expense on Unaudited Condensed Consolidated Statements of Operations during the three and six months ended June 30, 2023 and $143 and $425 during the three and six months ended June 30, 2022, respectively, in connection with these awards.

As of June 30, 2023, unamortized expense related to stock options totaled $1,447 and is expected to be recognized over a weighted-average period of approximately 2 years. As of June 30, 2023, the aggregate intrinsic value for unvested options and for vested and exercisable options was nil, respectively.

13.    COMMITMENTS AND CONTINGENCIES
Commitments
The Company provides revolving lines of credit to certain of its portfolio companies. As of June 30, 2023, only one revolving line of credit remained outstanding and the maximum obligation under this arrangement was equal to the balance advanced of $4,331 (refer to Note 6 for further discussion).

Prior Plan of Arrangement with Canopy Growth

On June 19, 2019, the shareholders of the Company and of Canopy Growth separately approved the proposed plan of arrangement (the “Prior Plan of Arrangement”) involving the two companies, and on June 21, 2019, the Supreme Court of British Columbia granted a final order approving the Prior Plan of Arrangement. Effective June 27, 2019, the articles of the Company were amended pursuant to the Prior Plan of Arrangement to provide that, upon the occurrence (or waiver by Canopy Growth) of the Triggering Event, subject to the satisfaction of the conditions set out in the arrangement agreement entered into between Acreage and Canopy Growth on April 18, 2019, as amended on May 15, 2019 (the “Original Arrangement
F-22

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Agreement”), Canopy Growth will acquire (the “Acquisition”) all of the issued and outstanding shares in the capital of the Company (each, an “Acreage Share”).
Second Amendment to the Arrangement Agreement with Canopy Growth
On September 23, 2020, Acreage and Canopy Growth entered into an amending agreement (the “Amending Agreement” or “Amended Arrangement”) (and together with the Original Arrangement Agreement and any further amendments thereto, the “Amended Plan of Arrangement”) and the Amended Arrangement became effective at 12:01 a.m. (Vancouver time) (the “Amendment Time”) on September 23, 2020 (the “Amendment Date”). Pursuant to the Amended Plan of Arrangement, Canopy Growth made a cash payment of $37,500 which was delivered to Acreage’s shareholders and certain holders of securities convertible or exchangeable into shares of Acreage. Acreage also completed a capital reorganization (the “Capital Reorganization”) effective as of the Amendment Time whereby: (i) each existing SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share; (ii) each issued and outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and (iii) each issued and outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share.
At the Amendment Time, each option, restricted share unit, compensation option, and warrant to acquire existing SVS (each a “Security”) that was outstanding immediately prior to the Amendment Time, was exchanged for a replacement Security to acquire Fixed Shares (a “Fixed Share Replacement Security”) and a replacement Security to acquire Floating Shares (a “Floating Share Replacement Security”) to account for the Capital Reorganization.
Pursuant to the Amended Plan of Arrangement, upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event (the “Triggering Event Date”), Canopy Growth will, subject to the satisfaction or waiver of certain closing conditions set out in the Arrangement Agreement: (i) acquire all of the issued and outstanding Fixed Shares (following the mandatory conversion of the Fixed Multiple Shares into Fixed Shares) on the basis of 0.3048 of a common share of Canopy Growth (each whole common share, a “Canopy Growth Share”) for each Fixed Share held (the “Fixed Exchange Ratio”) at the time of the acquisition of the Fixed Shares (the “Acquisition Time”), subject to adjustment in accordance with the terms of the Amended Plan of Arrangement (the “Canopy Call Option”). The Canopy Call Option and the Floating Call Option will expire 10 years from the Amendment Time.
At the Acquisition Time, on the terms and subject to the conditions of the Amended Plan of Arrangement, each Fixed Share Replacement Security will be exchanged for a replacement Security from Canopy Growth equal to: (i) the number of Fixed Shares that were issuable upon exercise of such Fixed Share Replacement Security immediately prior to the Acquisition Time, multiplied by (ii) the Fixed Exchange Ratio in effect immediately prior to the Acquisition Time (provided that if the foregoing would result in the issuance of a fraction of a Canopy Growth Share, then the number of Canopy Growth Shares to be issued will be rounded down to the nearest whole number).
The Amended Plan of Arrangement provides for, among other things, Amendments to the definition of Purchaser Approved Share Threshold (as defined therein) to change the number of shares of Acreage available to be issued by Acreage without an adjustment in the Fixed Exchange Ratio such that Acreage may issue a maximum of 32,700 shares. Furthermore, Acreage generally may not issue any equity securities without Canopy Growth’s prior consent. Additionally, the Amended Plan of Arrangement allows for various Canopy Growth rights that extend beyond the Acquisition Date, including, among others: (i) rights to nominate a majority of Acreage’s Board of Directors following the Acquisition Time; (ii) restrictive covenants in respect of the business conduct in favor of Canopy Growth; (iii) termination of non-competition and exclusivity rights granted to Acreage by Canopy Growth in the event that Acreage does not meet certain specified financial targets; (iv) implementation of further restrictions on Acreage’s ability to operate its business in the event that Acreage does not meet certain specified financial targets; and (v) termination of the Amended Plan of Arrangement in the event that Acreage does not meet certain specified financial targets in the trailing 12 month period. Each of the financial targets referred to above is specified in the Amending Agreement and related to the performance of Acreage relative to a business plan for Acreage for each fiscal year ended December 31, 2020 through December 31, 2029 set forth in the Proposal Agreement (the “Initial Business Plan”).

Further, the Amended Plan of Arrangement imposes restrictions on Acreage entering into any contracts in respect of Company Debt if: (i) such contract would be materially inconsistent with market standards for companies operating in the United States cannabis industry; (ii) such contract prohibits a prepayment of the principal amount of such Company Debt; and (iii) such contract would provide for interest payments to be paid through the issuance of securities as opposed to cash, among other restrictions. The Amended Plan of Arrangement also provides for the following: (i) certain financial reporting obligations to Canopy Growth; (ii) certain specified criteria related to any new directors or officers of Acreage, and (iii) a limit to Acreage’s operations to the Identified States (as defined therein).

F-23

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Third Amendment to the Arrangement Agreement with Canopy Growth
On October 24, 2022, the Company entered into an arrangement agreement (the “Floating Share Agreement”) with Canopy Growth and Canopy USA, LLC (“Canopy USA”), Canopy Growth’s newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the “Floating Shares”) and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the “Floating Share Arrangement”) for consideration of 0.4500 of a common share of Canopy Growth (each whole share a “Canopy Share”) in exchange for each Floating Share. A special meeting of the holders of Floating Shares was held on March 15, 2023, where the holders of Floating Shares approved the Floating Share Arrangement (the “Special Meeting”).
Concurrently with entering the Floating Share Agreement, Canopy Growth irrevocably waived its option to acquire the Floating Shares pursuant to the Amended Arrangement.
Subject to the provisions of the Floating Share Agreement, Canopy Growth has agreed to exercise the fixed option pursuant to the Amended Agreement to acquire all outstanding Fixed Shares, representing approximately 70% of the total shares of Acreage as at the date hereof, at a fixed exchange ratio of 0.3048 of a Canopy Share for each Fixed Share.
Acreage expects the Floating Share Arrangement to close upon the satisfaction or waiver of all conditions under the Floating Share Agreement and the Amended Arrangement. It is anticipated that the acquisition by Canopy USA of the Fixed Shares pursuant to the Fixed Option will be completed immediately following closing of the Floating Share Agreement. In the event that Canopy USA exercises the Fixed Option and acquires the Floating Shares pursuant to the Floating Share Arrangement, Acreage will be wholly-owned subsidiary of Canopy USA.
On March 17, 2023, Acreage, Canopy and Canopy USA entered into a first amendment to the Floating Share Arrangement Agreement (the “First Amendment”). Pursuant to the terms of the First Amendment, Acreage, Canopy and Canopy USA agreed to amend the Exercise Outside Date (as defined in the Floating Share Arrangement Agreement) from March 31, 2023 to May 31, 2023. On May 31, 2023, the parties entered into a second amendment to the Floating Share Arrangement, further extending the Exercise Outside date from May 31, 2023 to August 31, 2023.

Tax Receivable Agreement and Tax Receivable Bonus Plans
The Company is a party to (i) a tax receivable agreement dated November 14, 2018 and subsequently amended (the “Tax Receivable Agreement”) between the Company and certain current and former unit holders of HSCP and (ii) tax receivable bonus plans dated November 14, 2018 and subsequently amended (the “Tax Receivable Bonus Plans”) between the Company and certain directors, officers and consultants of the Company (together the “Tax Receivable Recipients”). Under the Tax Receivable Agreement and the Tax Receivable Bonus Plans, the Company is required to make cash payments to the Tax Receivable Recipients equal to 85% of the tax benefits, if any, that the Company actually realizes, or in certain circumstances is deemed to realize, as a result of (i) the increases in its share of the tax basis of assets of HSCP resulting from any redemptions or exchanges of Units from the HSCP Members, and (ii) certain other tax benefits related to the Company making payments under the Tax Receivable Agreement and the Tax Receivable Bonus Plan. Although the actual timing and amount of any payments that the Company makes to the Tax Receivable Recipients cannot be estimated, it expects those payments will be significant. Any payments made by the Company to the Tax Receivable Recipients may generally reduce the amount of overall cash flow that might have otherwise been available to it. Payments under the Tax Receivable Agreement are not conditioned on any Tax Receivable Recipient’s continued ownership of Units or our shares after the completion of the RTO. Payments under the Tax Receivable Bonus Plan may, at times, be conditioned on the Tax Receivable Recipient’s continued employment by the Company. As of June 30, 2023, the Company has not made any payments in relation to the Tax Receivable Agreement or the Tax Receivable Bonus Plans.

Concurrently with the execution of the Floating Share Arrangement Agreement, Canopy Growth, Canopy USA, High Street, Acreage Holdings America, Inc. and certain individuals party to the Tax Receivable Agreement, amended the Tax Receivable Agreement in accordance with the Floating Share Agreement. Pursuant to the Floating Share Agreement, Canopy Growth, on behalf of Canopy USA agreed to: (i) issue Canopy Shares with a value of approximately $30,500 to the Tax Receivable Agreement Members in exchange for each such individual executing an assignment of rights agreement assigning such individual’s rights under the Tax Receivable Agreement to Canopy USA, such that following assignment, Canopy USA is the sole member and beneficiary under the Tax Receivable Agreement; and (ii) fund a payment with a value of approximately $19,500 to be made by the Company in Canopy Shares to certain eligible participants pursuant to the Tax Receivable Bonus Plans, as amended on October 24, 2022, both in order to reduce a potential liability of approximately $121,000 under the Tax Receivable Agreement and the Tax Receivable Bonus Plans. In connection with the foregoing, Canopy Growth issued 5,648,927 Canopy Shares on or about November 4, 2022 and 7,102,081 Canopy Shares on or about March 17, 2023 to the Tax Receivable Agreement Members. In addition, the Tax Receivable Agreement Bonuses with an aggregate value of approximately $19,500 in Canopy Shares will be issued by Canopy to certain eligible participants under the Tax Receivable
F-24

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Bonus Plans on the closing of the Floating Share Arrangement or, if the Floating Share Arrangement does not close or is terminated but the Amended Arrangement closes, then on the closing of the acquisition. The Tax Receivable Agreement Bonuses will be paid to recipients to be determined by Kevin Murphy, the administrator of the Tax Receivable Bonus Plans, and may include one or more of Kevin Murphy, John Boehner, Brian Mulroney, and Peter Caldini, each of whom are directors of Acreage and other current and former officers or consultants of Acreage as may be determined by Kevin Murphy. Canopy Growth has also agreed to register the resale of such Canopy Shares under the Securities Act of 1933, as amended.
Debenture

In connection with the implementation of the Amended Arrangement, pursuant to a secured debenture dated September 23, 2020 (the “Debenture”) issued by Universal Hemp, LLC, an affiliate of Acreage that operates solely in the hemp industry in full compliance with all applicable laws (the “Borrower”), to 11065220 Canada Inc., an affiliate of Canopy Growth (the “Lender”), the Lender agreed to provide a loan of up to $100,000 (the “Loan”), $50,000 of which was advanced on the Amendment Date (the “Initial Advance”), and $50,000 of the Loan will be advanced in the event that the following conditions, among others, are satisfied: (a) the Borrower’s EBITDA (as defined in the Debenture) for any 90 day period is greater than or equal to 2.0 times the interest costs associated with the Initial Advance; and (b) the Borrower’s business plan for the 12 months following the applicable 90 day period supports an Interest Coverage Ratio (as defined in the Debenture) of at least 2.00:1.
The principal amount of the Loan will bear interest from the date of advance, compounded annually, and be payable on each anniversary of the date of the Debenture in cash in U.S. dollars at a rate of 6.1% per annum. The Loan will mature 10 years from the date of the Initial Advance.
The Loan must be used exclusively for U.S. hemp-related operations and on the express condition that such amount will not be used, directly or indirectly, in connection with or for the operation or benefit of any of the Borrower’s affiliates other than subsidiaries of the Borrower exclusively engaged in U.S. hemp-related operations and not directly or indirectly, towards the operation or funding of any activities that are not permissible under applicable law. The Loan proceeds must be segregated in a distinct bank account and detailed records of debits to such distinct bank account will be maintained by the Borrower.

No payment due and payable to the Lender by the Borrower pursuant to the Debenture may be made using funds directly or indirectly derived from any cannabis or cannabis-related operations in the United States, unless and until the Triggering Event Date.
The Debenture includes usual and typical events of default for a financing of this nature, including, without limitation, if: (i) Acreage is in breach or default of any representation or warranty in any material respect pursuant to the Arrangement Agreement; (ii) Operations deemed to be non-core must cease within 18 months from the Amendment Date; and (iii) Acreage fails to perform or comply with any covenant or obligation in the Arrangement Agreement which is not remedied within 30 days after written notice is given to the Borrower by the Lender. The Debenture also includes customary representations and warranties, positive covenants and negative covenants of the Borrower.

Advisor fee

In connection with the Prior Plan of Arrangement, the Company entered into an agreement with its financial advisor providing for a fee payment of $7,000 in either cash, Acreage shares or Canopy Growth shares, at the discretion of the Company, upon the successful acquisition of Acreage by Canopy Growth. During the fourth quarter of 2022, the Company amended the terms of the agreement with its financial advisors providing for a fee payment of $3,000 in cash, less a $500 initial payment, and $2,000 in shares of the Company, upon the successful acquisition of Acreage by Canopy Growth.

Surety bonds

The Company has indemnification obligations with respect to surety bonds primarily used as security against non-performance in the amount of $5,000 as of June 30, 2023, for which no liabilities are recorded on the Unaudited Condensed Consolidated Statements of Financial Position.
The Company is subject to other capital commitments and similar obligations. As of June 30, 2023 and 2022, such amounts were not material.
CanWell Settlement

F-25

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
In November 2020, the Company entered into a final confidential settlement agreement with CanWell, LLC for certain outstanding proceedings. As part of that agreement, the Company accrued for $7,750 in Legal settlements, net on the Statements of Operations for the year ended December 31, 2020. In connection with this settlement agreement, the Company issued a promissory note in the amount of $7,750 to CanWell, which is non-interest bearing and is payable in periodic payments through December 31, 2024. Through June 30, 2023, the Company has paid $5,375 of the promissory note.

Contingencies
The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company’s applicable subsidiaries ceasing operations. While management of the Company believes that the Company’s subsidiaries are in compliance with applicable local and state regulations as of June 30, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company’s subsidiaries may be subject to regulatory fines, penalties, or restrictions in the future.
The Company and its subsidiaries may be, from time to time, subject to various administrative, regulatory and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated.
New York outstanding litigation

On November 2, 2018, EPMMNY LLC (“EPMMNY”) filed a complaint in the Supreme Court of the State of New York, County of New York, asserting claims against 16 defendants, including NYCANNA, Impire State Holdings LLC (“Impire”), NY Medicinal Research & Caring, LLC (“NYMRC”) (each, a wholly owned subsidiary of High Street) and High Street. The Index Number for the action is 655480/2018. EPMMNY alleges that it was wrongfully deprived of a minority equity interest and management role in NYCANNA by its former partner, New Amsterdam Distributors, LLC (“New Amsterdam”), which attempted to directly or indirectly sell or transfer EPMMNY’s alleged interest in NYCANNA to other entities in 2016 and 2017, including Impire, NYMRC and High Street.

EPMMNY alleges that it is entitled to the value of its alleged minority interest in NYCANNA or minority ownership in NYCANNA. EPMMNY also alleges that certain defendants misused its alleged intellectual property and/or services, improperly solicited its employees, and aided and abetted or participated in the transfer of equity and/or business opportunities from EPMMNY.

High Street, along with the other Defendants, filed motions to dismiss on April 1, 2019. The motions were fully briefed and submitted to the Court as of July 18, 2019, and oral argument was heard on September 6, 2019. Following a hearing held during April 2022, in ruling on one dismissal argument advanced by several Defendants, the Court ruled that Plaintiff had the capacity to bring this action on behalf of EPMMNY. On July 13, 2023, the Court ruled on the remaining dismissal arguments, granting the vast majority of them. As part of its ruling, the Court dismissed without prejudice every claim against NYCANNA, Impire, NYMRC, and High Street, except the claims for unjust enrichment and quantum meruit (which also were permitted to proceed against other Defendants). The only other claim that the Court did not dismiss was for breach of contract against New Amsterdam.
On July 24, 2023, EPMMNY moved for leave to file a proposed amended complaint. The proposed amended complaint names several defendants, including NYCANNA, Impire, NYMRC, High Street, and Kevin Murphy, and contains similar allegations to those in the original complaint. High Street intends to oppose the motion for leave to amend and,if necessary, move to dismiss the new complaint.
High Street intends to continue vigorously defend this action, which the Company firmly believes is without merit. High Street also believes it is entitled to full indemnity from the claims asserted against it by EPMMNY pursuant to the purchase agreement pertaining to its acquisition of NYCANNA and personal guarantee by the largest shareholders of the seller.
Health Circle, Inc. litigation
On April 13, 2023, Health Circle, Inc., a licensed cannabis dispensary operator in Massachusetts, initiated a civil action against the Company and MA RMD SVCS, LLC in Plymouth County, Massachusetts for alleged breaches of that certain Revolving Line of Credit, dated October 31, 2017, by and between Health Circle, Inc. and MA RMD SVCS, LLC (the “HCI Credit Agreement”) and certain torts. High Street has filed a second civil action against Michael Westort, individually, in the Business Litigation Section, located in Boston, MA, predicated upon that certain Membership Interest Purchase Agreement, dated June
F-26

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
30, 2018, by and between Mr. Westort and High Street. The Company previously moved to dismiss the complaint in Plymouth County, which was recently amended. The Company is assessing the amended complaint, and will file counterclaims against Health Circle, Inc. based on the outstanding debt under the HCI Credit Agreement. High Street intends to vigorously defend against this action, which the Company believes is without merit, and to pursue its claims against Mr. Westort and Health Circle, Inc.
Alfred’s Finest, Inc. arbitration
On June 22, 2023, Alfred’s Finest, Inc. (“AFI”) filed a demand for arbitration relating to that certain Asset Purchase Agreement, dated June 24, 2021, by and between Alfred’s Finest, Inc., Robert M. Andrews, Jr and The Botanist, Inc., a wholly owned subsidiary of High Street, and the Company (the “AFI APA”). The AFI APA provided for the payment of $2,000 to AFI upon closing and an additional $3,000 payable on or before the 18-month anniversary of the closing date. Pursuant to its termination rights provided under the APA, the Company sent a notice of termination of the AFI APA on June 29, 2022 before the closing occurred. AFI alleges that the Company breached the terms of the APA and claims that the notice of termination sent by the Company has no basis in the language of the AFI APA. AFI is seeking relief from the Company consisting of specific performance of the AFI APA and recovery of its damages, including arbitration fees and costs. The Company believes the plain language of the AFI APA supports its position and intends to vigorously defend this action, which the Company believes is without merit. The Company has filed a counterclaim against AFI for breach of the AFI APA based on AFI’s failure to act in good faith as required by the AFI APA.
On June 28, 2023, in response to AFI’s demand for arbitration, the Company asserted its right under the AFI APA to submit the dispute to mediation before it proceeds to arbitration. The parties are in the process of scheduling the mediation and identifying a mediator.
14.    RELATED PARTY TRANSACTIONS
Transactions with related parties are entered into in the normal course of business and are measured at the amount established and agreed to by the parties.
6.10% Secured debenture due September 2030
As disclosed in Note 10, “6.10% Secured debenture due September 2030”, on September 23, 2020, pursuant to the implementation of the Amended Arrangement, a subsidiary of Canopy Growth advanced gross proceeds of $50,000 (less transaction costs of approximately $4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture. In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. Acreage then engaged an investment advisor (the “Investment Advisor”) which, under the Investment Advisor’s sole discretion, invested on behalf of Universal Hemp, $34,019 of the proceeds on September 28, 2020. During the three and six months ended June 30, 2023, the Company incurred interest expense attributable to the 6.10% Secured debenture due September 2030 of $763.

As a result of the transaction above, Universal Hemp, a subsidiary of the Company, acquired 34,019 class B units, at $1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds Class A Units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Institutional Investor as agent for Universal Hemp. On September 28, 2020, the Company received gross proceeds of $33,000 (less transaction costs of approximately $959) from an affiliate of the Institutional Lender (the “Lender”) and used a portion of the proceeds of this loan to retire its short-term $11,000 convertible note and its short-term note aggregating approximately $18,000 in October 2020, with the remainder being used for working capital purposes. The Lender is controlled by the Institutional Lender. The Investment Partnership is the investor in the Lender.

Prime rate credit facilities due January 2026, as amended
On December 16, 2021, the Company entered into the Prime rate credit facilities due January 2026 with a syndicate of lenders, including Viridescent Realty Trust, Inc. (“Viridescent”), an entity controlled by Kevin Murphy. Refer to Note 10 for further discussion. On October 24, 2022, the Company amended these credit facilities and the Company paid an amendment fee of $1,250 to the lenders, with $375 paid to Viridescent. On April 28, 2023, the Company and the lenders further amended the Prime rate credit facilities. Refer to Note 10 for further discussion.

F-27

ACREAGE HOLDINGS, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except per share data)
Viridescent has committed $42,000 of the $140,000 drawn down under the Credit Facility, with third-party syndicated affiliates committing the additional $98,000. During the six months ended June 30, 2023, the Company incurred interest expense attributable to Viridescent of $2,690. The loan is secured by first-lien mortgages on Acreage’s wholly owned real estate and other commercial security interests. A third-party syndicate served as Administrative Agent for the transaction.

15.    REPORTABLE SEGMENTS
The Company prepares its segment reporting on the same basis that its Chief Operating Decision Maker manages the business, and makes operating decisions. The Company operates under one operating segment, which is its only reportable segment: the production and sale of cannabis products. The Company’s measure of segment performance is net income, and derives its revenue primarily from the sale of cannabis products, as well as related management or consulting services which were not material in all periods presented. All of the Company’s operations are located in the United States.
16.    EARNINGS PER SHARE
Basic earnings per share are computed by dividing net loss attributable to common shareholders of the Company by the weighted average number of outstanding shares for the period. Diluted earnings per share are calculated based on the weighted number of outstanding common shares plus the dilutive effect of stock options and warrants, as if they were exercised, and restricted stock units and profits interests, as if they vested and NCI convertible units, as if they converted.

Basic and diluted loss per share is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Net loss attributable to common shareholders of the Company$(16,156)$(9,929)$(30,746)$(22,623)
Weighted average shares outstanding - basic112,810 108,230 112,679 107,569 
Effect of dilutive securities    
Weighted average shares - diluted112,810 108,230 112,679 107,569 
Net loss per share attributable to common shareholders of the Company - basic$(0.14)$(0.09)$(0.27)$(0.21)
Net loss per share attributable to common shareholders of the Company - diluted$(0.14)$(0.09)$(0.27)$(0.21)
During the six months ended June 30, 2023, 5,817 Fixed warrants, 2,524 Floating warrants, 5,389 Fixed Share RSUs, 246 Floating Share RSUs, 7,337 Fixed Share stock options, 2,232 Floating Share stock options and 22,698 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive. During the six months ended June 30, 2022, 5,817 Fixed warrants, 2,524 Floating warrants, 1,604 Fixed Share RSUs, 652 Floating Share RSUs, 1,493 Fixed Share stock options, 2,306 Floating Share stock options and 23,076 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive.
17.    SUBSEQUENT EVENTS
Management has reviewed all events subsequent to June 30, 2023 through the date of issuing these financial statements and determined that no further subsequent events require adjustment or disclosure.
F-28


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to assist in the understanding and assessing the trends and significant changes in our results of operations and financial condition. Historical results may not be indicative of future performance. This discussion includes forward-looking statements that reflect our plans, estimates and beliefs. Such statements involve risks and uncertainties. Our actual results may differ materially from those contemplated by these forward-looking statements as a result of various factors, including those set forth in “Risk Factors” in Part I, Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”), and “Cautionary Statement Regarding Forward-Looking Statements” set forth below.

This MD&A should be read in conjunction with the Company’s unaudited condensed consolidated financial statements for the three and six month period ended June 30, 2023 and related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report” or “Form 10-Q) and the 2022 Form 10-K. Financial information presented in this MD&A is presented in thousands of U.S. dollars, unless otherwise indicated.
Cautionary Statement Regarding Forward Looking-Statements
This Quarterly Report of the Company contains statements that include forward-looking information and are forward-looking statements within the meaning of applicable Canadian and United States securities legislation (“forward-looking statements”), including the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. All statements, other than statements of historical fact, included herein are forward-looking statements, including, for greater certainty, statements regarding the proposed transactions with Canopy Growth Corporation (“Canopy Growth or “Canopy”), including the anticipated benefits and likelihood of completion thereof.
Generally, forward-looking statements may be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. There can be no assurance that such forward-looking statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking statements. Forward-looking statements reflect Acreage’s current beliefs and are based on information currently available to Acreage and on assumptions Acreage believes are reasonable. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Acreage to be materially different from those expressed or implied by such forward-looking statements. Such risks and other factors may include, but are not limited to:
The US Federal Illegality of the Company’s Business Activities
the anticipated benefits of the Floating Share Arrangement with Canopy Growth;
the likelihood of Canopy Growth completing the acquisition of the Fixed Shares and/or Floating Shares;
risks related to the ability to finance Acreage’s business and fund its obligations;
other expectations and assumptions concerning the transactions contemplated between Canopy Growth and Acreage;
in the event that the Floating Share Arrangement is completed, the likelihood of Canopy completing the Acquisition in accordance with the Existing Arrangement Agreement;
the risk of a change of control of either Canopy or Canopy USA;
the impact of material non-recurring expenses in connection with the Floating Share Arrangement on Acreage’s future results of operations, cash flows and financial condition;
the ability of Canopy, Canopy USA and Acreage to leverage each other’s respective capabilities and resources;
the available funds of Acreage and the anticipated use of such funds;
the availability of financing opportunities for Acreage and the risks associated with the completion thereof;
regulatory and licensing risks;
changes in general economic, business and political conditions, including changes in the financial and stock markets;
legal and regulatory risks inherent in the cannabis industry;
risks associated with economic conditions, dependence on management and currency risk;
risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks;
risks relating to anti-money laundering laws and regulation;
other governmental and environmental regulation;
public opinion and perception of the cannabis industry;
risks related to contracts with third-party service providers;
risks related to the enforceability of contracts and lack of access to U.S. bankruptcy protections;
reliance on the expertise and judgment of senior management of Acreage;
risks related to proprietary intellectual property and potential infringement by third parties;
the concentrated voting control of Acreage’s founder and the unpredictability caused by Acreage’s capital structure;
29


the dual structure of the Fixed and Floating Shares
risks relating to the management of growth;
increasing competition in the industry;
risks inherent in an agricultural business;
risks relating to energy costs;
risks associated with cannabis products manufactured for human consumption including potential product recalls;
reliance on key inputs, suppliers and skilled labor;
cybersecurity risks;
ability and constraints on marketing products;
fraudulent activity by employees, contractors and consultants;
tax and insurance related risks;
risks related to the economy generally;
risk of litigation;
conflicts of interest;
risks relating to certain remedies being limited and the difficulty of enforcement judgments and effecting service outside of Canada;
risks related to future acquisitions or dispositions;
sales by existing shareholders; and
limited research and data relating to cannabis.

A description of additional assumptions used to develop such forward-looking statements and a description of additional risk factors that may cause actual results to differ materially from forward-looking statements can be found in Part I, Item 1A of the Company’s Annual Report on Form 10-K, under the heading “Risk Factors”, dated May 1, 2023, as filed with the Securities and Exchange Commission. Although Acreage has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking statements contained in this Form 10-Q are expressly qualified by this cautionary statement. The forward-looking statements contained in this Form 10-Q represent the expectations of Acreage as of the date of this Form 10-Q and, accordingly, are subject to change after such date. However, Acreage expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Management’s discussion and analysis of financial condition and results of operations is intended to help provide an understanding of the Company’s financial condition, changes in financial condition and results of operations. This discussion is organized as follows:
Overview—This section provides a general description of the Company’s businesses, its strategic objectives, as well as developments that occurred during the three and six months ended June 30, 2023 and 2022 that the Company believes are important in understanding its results of operations and financial condition or to disclose known trends.
Results of Operations—This section provides an analysis of the Company’s results of operations for the three and six months ended June 30, 2023 and 2022. This analysis is presented on a consolidated basis. In addition, a brief description is provided of significant transactions and events that impact the comparability of the results being analyzed.
Liquidity and Capital Resources—This section provides an analysis of the Company’s cash flows for the three and six months ended June 30, 2023 and 2022, as well as a discussion on the Company’s outstanding debt and commitments that existed as of June 30, 2023. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to fund the Company’s future commitments and obligations, as well as a discussion of other financing arrangements.
30


Overview
Acreage, a vertically integrated, multi-state operator of cannabis licenses and assets in the U.S, was continued into the Province of British Columbia under the Business Corporations Act (British Columbia). Acreage Fixed Shares and Floating Shares (as such terms are defined at Note 13 of the unaudited condensed consolidated financial statements) are each listed on the Canadian Securities Exchange under the symbols “ACRG.A.U” and “ACRG.B.U”, respectively, and are quoted on the OTCQX® Best Market by OTC Markets Group under the symbols “ACRHF” and “ACRDF”, respectively and on the Open Market of the Frankfurt Stock Exchange under the symbols “0VZ1” and “0VZ2”, respectively. Acreage operates through its consolidated subsidiary High Street Capital Partners, LLC (“HSCP”), a Delaware limited liability company. HSCP, which does business as “Acreage Holdings”, was formed on April 29, 2014. The Company became an indirect parent of HSCP on November 14, 2018 in connection with a reverse takeover (“RTO”) transaction. The Company’s operations include (i) cultivating cannabis plants, (ii) manufacturing branded consumer products, (iii) distributing cannabis flower and manufactured products, and (iv) retailing high-quality, effective and dosable cannabis products to consumers. The Company appeals to medical and adult-use customers through brand strategies intended to build trust and loyalty.

As of June 30, 2023, Acreage owned and operated a total of twenty-three dispensaries - four in New York, three in New Jersey, three in Connecticut, two in Massachusetts, two in Illinois, five in Ohio, and four in Maine. As of June 30, 2023, Acreage owned and operated a total of nine cultivation and processing facilities, one each in California, Illinois, Maine, New Jersey, New York, Ohio and Pennsylvania, respectively, and two in Massachusetts.
Strategic Priorities
The Company believes its focused strategy is the key to continued improvements in its financial results and shareholder value. For the past few years, the Company was focused on three key strategic objectives - accelerating growth in its core markets, driving profitability, and strengthening the balance sheet. For 2023 and onwards, the Company has modified its strategic objectives in response to Company and industry developments - focus on cash, accelerate growth in core markets with core brands and prepare for Canopy USA.
Focus on Cash: A combination of economic conditions, lack of regulatory change and industry competition impacting pricing have negatively impacted the Company’s ability to generate cash flow to support operational requirements and capital activities. Additionally, these factors have likely limited the additional capital that might be available to the Company. While these factors continue, the Company will focus on maximizing the cash flow generated by operating activities and limit capital expenditures to only those projects that can be funded from existing resources and are expected to generate near-term returns.
Accelerating Growth in Core Markets with Core Brands: Through prior acquisitions and capital expenditures, management believes Acreage is well positioned for future success in several key markets as regulations regarding the use of cannabis continue to evolve. The Company will continue to focus its growth in its core markets where it can take advantage of and expand on the presence already established. Additionally, the Company has developed a portfolio of core brands that resonate with its customers. The Company will focus on ensuring that these core brands feature prominently in the markets where they are available.
Prepare for Canopy USA: During the fourth quarter of 2022, the Company entered into a new strategic arrangement with Canopy Growth that, would allow Canopy Growth to acquire 100% of Acreage by (i) waiving its existing Floating Share option and entering into a new Floating Share arrangement agreement; and (ii) committing to exercise its Fixed Share option, all subject to required approvals and terms of the related agreements. Throughout 2023, the Company has taken all steps necessary to date to prepare for the eventual closing of these transactions, including holding a special meeting of shareholders to approve the Floating Share arrangement agreement.

Highlights from the three and six months ended June 30, 2023:
The Company ended the quarter with a cash balance of $30,029, including $16,401 of cash and cash equivalents and $13,628 of restricted cash, respectively.
The Company’s total consolidated revenue declined 5% and 4% as compared with the three and six months ended June 30, 2022, respectively. After adjusting for acquisitions and divestitures, revenue for the three and six month periods ended June 30, 2023 declined by 4% and 2%, respectively. On a sequential basis, revenue increased by 4% for the three months ended June 30, 2023 as compared to the prior three month period ended March 31, 2023.
Adjusted EBITDA for the three and six months ended June 30, 2023 was $6.8 million and $17.4 million, respectively, compared to adjusted EBITDA of $10.4 million and $19.0 million, respectively during the same period in 2022. This marks ten consecutive quarters of positive adjusted EBITDA. Refer to section “Non-GAAP Information” for a discussion of Adjusted EBITDA as a non-GAAP measure.
31


On January 2, 2023, the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine.
On January 10, 2023, the Company commenced adult-use operations in Connecticut, offering a range of products from our flagship brand The Botanist for adult-use sales in Montville.
On January 31, 2023, the Company launched “Fast-Acting Gummies” or “TiME Gummies” under its flagship brand The Botanist in Illinois, Maine, Massachusetts, and Ohio.
The Floating Share Arrangement was approved at a special meeting of the holders of Floating Shares held on March 15, 2023. Refer to Note 13 for further discussion.
On April 11, 2023, the Company sold, for total proceeds of $12,113, the rights to receive certain Employee Retention Tax Credits (“ERTC”) with an aggregate receivable value of $14,251.
On April 28, 2023, the Company reached an agreement with the lenders of the Prime rate credit facilities due January 2026 that would allow it to draw a further $15,000 under its current Credit Agreement, but such funds would be maintained in a segregated account until dispersed and be restricted for use to only eligible capital expenditures. As part of this agreement, the Company has agreed to limit the total amounts outstanding under the Credit Agreement to $140,000.

Operational and Regulation Overview (all amounts in thousands, except per share amounts)

The Company believes its operations are in material compliance with all applicable state and local laws, regulations and licensing requirements in the states in which it operates. However, cannabis is illegal under U.S. federal law. Substantially all of the Company’s revenue is derived from U.S. cannabis operations. For information about risks related to U.S. cannabis operations, please refer to Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Results of Operations
The following table presents selected financial data derived from the unaudited condensed consolidated financial statements of the Company for the three and six months ended June 30, 2023 and 2022. The selected financial information set out below may not be indicative of the Company’s future performance.
Summary Results of Operations
Better/(Worse)Better/(Worse)
in thousands, except per share amountsThree Months Ended June 30,2023 vs. 2022Six Months Ended June 30,2023 vs. 2022
20232022$%20232022$%
Revenues, net$58,115 $61,351 $(3,236)(5)%$114,078 $118,230 $(4,152)(4)%
Net operating income (loss)(5,055)3,310 (8,365)n/m(3,910)588 (4,498)n/m
Net loss attributable to Acreage(16,156)(9,929)(6,227)(63)(30,746)(22,623)(8,123)(36)
Basic and diluted loss per share attributable to Acreage$(0.14)$(0.09)$(0.05)(56)%$(0.27)$(0.21)$(0.06)(29)%
Revenues, Cost of goods sold and Gross profit

The Company derives its revenues from sales of cannabis and cannabis-infused products through retail dispensary, wholesale and manufacturing and cultivation businesses, as well as from management or consulting fees from entities for whom the Company provides management or consulting services.
Gross profit is revenue less cost of goods sold. Cost of goods sold includes costs directly attributable to inventory sold such as direct material, labor, and overhead, including depreciation. Such costs are further affected by various state regulations that limit the sourcing and procurement of cannabis and cannabis-related products, which may create fluctuations in gross profit over comparative periods as the regulatory environment changes.
32


Better/(Worse)Better/(Worse)
in thousandsThree Months Ended June 30,2023 vs. 2022Six Months Ended June 30,2023 vs. 2022
20232022$%20232022$%
Retail revenue, net$44,913 $46,685 $(1,772)(4)%$86,794 $88,112 $(1,318)(1)%
Wholesale revenue, net13,202 14,360 (1,158)(8)27,200 29,532 (2,332)(8)
Other revenue, net— 306 (306)n/m84 586 (502)(86)
Total revenues, net$58,115 $61,351 $(3,236)(5)%$114,078 $118,230 $(4,152)(4)%
Cost of goods sold, retail(23,484)(23,466)(18)— (43,898)(44,234)336 
Cost of goods sold, wholesale(13,509)(7,271)(6,238)(86)(22,473)(13,872)(8,601)(62)
Total cost of goods sold$(36,993)$(30,737)$(6,256)(20)%$(66,371)$(58,106)$(8,265)(14)%
Gross profit$21,122 $30,614 $(9,492)(31)%$47,707 $60,124 $(12,417)(21)%
Gross margin36 %50 %(14)%42 %51 %(9)%
n/m - Not Meaningful
Three months ended June 30, 2023 vs. 2022
Total revenues for the three months ended June 30, 2023 declined by $3,236, or 5%, compared to the three months ended June 30, 2022. The decline in total revenue was primarily due to a decrease of $873 related to the divestiture of the Company’s operations in Oregon in 2022 and continued competitive pressure across most of the Company’s markets and was somewhat offset by revenue growth in both New Jersey and Connecticut after commencement of adult use sales. Excluding divestitures, total revenue decreased by $2,363 or 4% for the three months ended June 30, 2023, as compared to 2022.

Retail revenue for the three months ended June 30, 2023 declined by $1,772, or 4%, compared to the three months ended June 30, 2022. Excluding the impact of the divestiture of the Company’s operations in Oregon, retail revenue decreased by $899, or 2%, for the three months ended June 30, 2023 compared to 2022. This decline was primarily driven by price compression and was offset by the commencement of adult use sales in New Jersey in April 2022 and Connecticut in January 2023.
Wholesale revenue for the three months ended June 30, 2023 decreased by $1,158, or 8%, compared to the three months ended June 30, 2022. The decline in wholesale revenue was primarily due to price compression and decreased wholesale demand in select markets, particularly in those markets where integrated operators put a greater focus on the sales of their own internally produced products.
Retail cost of goods sold increased $18 for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. This increase was driven by inflation-driven cost increases, which was offset by lower volumes and cost efficiencies.
Wholesale cost of goods sold increased $6,238, or 86%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The growth in wholesale cost of goods sold contrasted with an 8% decrease in wholesale revenue. Wholesale cost of goods sold increased due to $4,484 of non-cash inventory adjustments made in the three months ended June 30, 2023 as a result of excess inventory in select markets and reducing the carrying value of wholesale inventory to reflect the lower of cost and net realizable value. Excluding these non-cash inventory adjustments, wholesale costs of goods sold for the three months ended June 30, 2023 increased $1,754 or 24% compared to 2022. Inflation-driven cost increases were greater than the cost reductions associated with lower volumes.
Gross profit decreased $9,492, or 31%, for the three months ended June 30, 2023 to $21,122 from $30,614 in the three months ended June 30, 2022. Gross margin decreased from 50% of revenue for the three months ended June 30, 2022 to 36% of revenue in 2023, or 14%. Efficiencies gained from further economies of scale were unable to offset (i) overall selling price declines, (ii) cost increases due to inflation, (iii) volume declines relative to a portion of the expenditures that are fixed in nature and, (iv) the aforementioned wholesale non-cash inventory adjustments. Excluding these non-cash inventory adjustments, margin decreased to 44%.
Six months ended June 30, 2023 vs. 2022
Total revenues for the six months ended June 30, 2023 decreased by $4,152, or 4%, compared to the six months ended June 30, 2022. The decline in total revenue was, in part, due to a decrease of $2,111 related to the divestiture of the Company’s operations in Oregon, offset by an increase of $485 due to the acquisitions of a Maine dispensary in 2022. Excluding these acquisitions and divestitures, total revenue decreased by $2,526, or 2% for the six months ended June 30, 2023, as compared to 2022. Continued competitive pressure across most of the Company’s markets was somewhat offset by revenue growth in both New Jersey and Connecticut after the commencement of adult use sales.
33


Retail revenue for the six months ended June 30, 2023 decreased by $1,318, or 1%, compared to the six months ended June 30, 2022. Excluding the impact of acquisitions and divestitures, retail revenue increased by $309 for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. Revenue growth due to the commencement of adult use sales in New Jersey in April 2022 and Connecticut in January 2023 was somewhat offset by price compression.
Wholesale revenue for the six months ended June 30, 2023 decreased by $2,332, or 8%, compared to the six months ended June 30, 2022. The decline in wholesale revenue was primarily due to price compression and decreased wholesale demand in select markets, particularly in those markets where integrated operators put a greater focus on the sales of their own internally produced products.
Retail cost of goods sold decreased $336, or 1%, for the six months ended June 30, 2023 compared to the six months ended 2022, which was generally consistent with the 1% decrease in retail revenue. Inflation-driven cost increases were generally offset by cost efficiencies.
Wholesale cost of goods sold increased $8,601, or 62%, for the six months ended June 30, 2023 compared to the six months ended 2022. The growth in wholesale cost of goods sold contrasted with an 8% decrease in wholesale revenue. Wholesale cost of goods sold increased due to $6,721 of non-cash inventory adjustments made during the six months ended June 30, 2023 as a result of excess inventory in select markets, reducing the carrying value of wholesale inventory to reflect the lower of cost and net realizable value. Excluding these non-cash inventory adjustments, wholesale costs of goods sold decreased $1,880 or 14%. Inflation driven cost increases and product mix shifts, which were greater than the cost reductions associated with lower volumes, drove the increase in wholesale cost of goods sold.
Gross profit decreased $12,417, or 21%, for the six months ended June 30, 2023 to $47,707 from $60,124 in the six months ended 2022, and Gross margin decreased from 51% of revenue for the six months ended June 30, 2022 to 42% of revenue in 2023, or 9%, due to the factors discussed above. Efficiencies gained from further economies of scale were unable to offset (i) overall selling price declines, (ii) cost increases due to inflation, (iii) volume declines relative to a portion of the expenditures that are fixed in nature, and (iv) the aforementioned wholesale non-cash inventory adjustments. Excluding the non-cash inventory adjustments, margin decreased slightly to 48%.
Revenue by geography
While the Company operates under one operating segment for the production and sale of cannabis products, the below revenue breakout by geography is included as management believes it provides relevant and useful information to investors.
Revenue by regionBetter/(Worse)Better/(Worse)
in thousandsThree Months Ended June 30,2023 vs. 2022Six Months Ended June 30,2023 vs. 2022
20232022$%20232022$%
New England$17,571 $16,386 1,185 %32,659 $32,812 (153)— %
Mid-Atlantic21,099 19,535 1,564 %41,375 34,890 6,485 19 %
Midwest19,210 23,794 (4,584)(19)%39,527 46,963 (7,436)(16)%
West235 1,636 (1,401)(86)%517 3,565 (3,048)(85)%
Total revenues, net$58,115 $61,351 (3,236)(5)%114,078 $118,230 (4,152)(4)%
Total operating expenses

Total operating expenses consist primarily of loss on impairments, compensation expense at our corporate offices as well as operating subsidiaries, professional fees, which includes, but is not limited to, legal and accounting services, depreciation and other general and administrative expenses.
34


Operating expensesBetter/(Worse)Better/(Worse)
in thousandsThree Months Ended June 30,2023 vs. 2022Six Months Ended June 30,2023 vs. 2022
20232022$%20232022$%
General and administrative$7,073 $8,922 $1,849 21 %$17,585 $17,309 $(276)(2)%
Compensation expense13,203 12,579 (624)(5)25,406 26,774 1,368 
Equity-based compensation expense694 1,655 961 58 1,678 5,814 4,136 71 
Marketing656 964 308 32 1,400 1,661 261 16 
Impairments, net— 329 329 n/m— 2,467 2,467 n/m
Write down (recovery) of assets held-for-sale3,557 — (3,557)n/m3,557 874 (2,683)(307)
Legal settlements (recoveries)— (310)(310)n/m— (335)(335)n/m
Depreciation and amortization994 3,165 2,171 69 1,991 4,972 2,981 60 
Total operating expenses$26,177 $27,304 $1,127 %$51,617 $59,536 $7,919 13 %
n/m - Not Meaningful
Three months ended June 30, 2023 vs. 2022
Total operating expenses for the three months ended June 30, 2023 were $26,177, a decrease of $1,127, or 4%, compared to the three months ended 2022. The primary drivers of the decrease in operating expenses were as follows:
General and administrative expenses decreased $1,849 during the three months ended June 30, 2023 compared to 2022, primarily due to (i) decreases in professional fees as the Company has become less reliant on consultants as the organization has matured and (ii) decreases in both office expenses and other expenses, which was driven by measures put in place by management to reduce costs.
Compensation expense increased $624 during the three months ended June 30, 2023 as compared to 2022, primarily due to increased human capital costs and employee benefits.
Equity-based compensation expense decreased $961, or 58%, during the three months ended June 30, 2023 as compared to 2022, primarily due to staffing reductions and changes made to the Company’s long-term incentive compensation plans.
Write down (recovery) of assets held-for-sale of $3,557 during the three months ended June 30, 2023 related to the Company’s adult-use cannabis cultivation and processing operations in the state of California.
Depreciation and amortization expenses decreased by $2,171 during the three months ended June 30, 2023 compared to 2022, primarily due to the impairment of certain intangible assets in 2022.
Six months ended June 30, 2023 vs. 2022
Total operating expenses for the six months ended June 30, 2023 were $51,617, a decrease of $7,919, or 13%, compared to the six months ended June 30, 2022. The primary drivers of the increase in operating expenses were as follows:
Compensation expense decreased $1,368 during the six months ended June 30, 2023 as compared to 2022, primarily due to the reversal of bonus provisions related to the prior year.
Equity-based compensation expense decreased $4,136, or 71%, during the six months ended June 30, 2023 as compared to 2022, primarily due to the fully vesting, prior to the three months ended March 31, 2023 of certain historic equity-based compensation grants and no annual grants have been issued to employees during 2023 under the Company’s normal long-term incentive plan.
There were no impairments in the six months ended June 30, 2023. Impairments, net of $2,467 for the six months ended June 30, 2022 was primarily driven by an impairment of $1,907 related to certain Michigan locations during the six months ended June 30, 2022.
Write down (recovery) of assets held-for-sale of $3,557 for the six months ended June 30, 2023 related to the Company’s adult-use cannabis cultivation and processing operations in the state of California. The write downs of assets held-for-sale in the comparative period of 2022 relate to the Company’s Oregon operations which were disposed of in the year ended December 31, 2022.
Depreciation and amortization expenses decreased by $2,981 during the six months ended June 30, 2023 compared to 2022, primarily due to an acceleration of the amortization of certain intangible assets as a result of a reduction in the expected useful lives of such assets during the six months ended June 30, 2022 and due to the impairment of certain intangible assets in the year ended December 31, 2022.
35



Total other income (loss)
Other income (loss)Better/(Worse)Better/(Worse)
in thousandsThree Months Ended June 30,2023 vs. 2022Six Months Ended June 30,2023 vs. 2022
20232022$%20232022$%
Income (loss) from investments, net$322 $(996)$1,318 n/m$(20)$137 $(157)n/m
Interest income (loss) from loans receivable(6)365 (371)n/m10 782 (772)(99)%
Interest expense(8,862)(5,520)(3,342)(61)(16,936)(10,301)(6,635)(64)
Other income (loss), net1,355 286 1,069 374 (198)276 (474)n/m
Total other loss$(7,191)$(5,865)$(1,326)(23)%$(17,144)$(9,106)$(8,038)(88)%
n/m - Not Meaningful
Three months ended June 30, 2023 vs. 2022
Total other loss for the three months ended June 30, 2023 was $7,191, an increase of $1,326 compared to the three months ended June 30, 2022. The primary drivers of the increase in Total other income (loss) were as follows:
Income from investments, net of $322 for the three months ended June 30, 2023 has increased $1,318 as compared to 2022 due to fair value adjustments to the investment in equity in other companies.
Interest expense for the three months ended June 30, 2023 of $8,862, increased by $3,342 as a result of the Company having a larger debt balance as compared to 2022 and due to an increased interest rate on a substantial portion of the Company’s debt.
Other income (loss), net for the three months ended June 30, 2023 of $1,355, increased by $1,069 as compared to 2022, which was primarily due to income provided from Employee Retention Tax Credits.

Six months ended June 30, 2023 vs. 2022
Total other loss for the six months ended June 30, 2023 was $17,144, an increase of $8,038 compared to the six months ended June 30, 2022. The primary drivers of the increase in Total other loss were as follows:
Interest income from loans receivable of $10 for the six months ended June 30, 2023 has decreased $772 as compared to 2022 due to a reduction in loans receivable outstanding during the comparative period.
Interest expense for the six months ended June 30, 2023 of $16,936 increased by $6,635 as a result of the Company having a larger debt balance as compared to 2022 and due to an increased interest rate on a substantial portion of the Company’s debt.

Net loss
Net lossBetter/(Worse)Better/(Worse)
in thousandsThree Months Ended June 30,2023 vs. 2022Six Months Ended June 30,2023 vs. 2022
20232022$%20232022$%
Net loss$(18,240)$(10,603)$(7,637)(72)%$(34,397)$(24,514)$(9,883)(40)%
Less: net loss attributable to non-controlling interests(2,084)(674)(1,410)(209)(3,651)(1,891)(1,760)(93)%
Net loss attributable to Acreage Holdings, Inc.$(16,156)$(9,929)$(6,227)(63)%$(30,746)$(22,623)$(8,123)(36)%
The changes in net loss are driven by the factors discussed above.
Non-GAAP Information
This statement includes Adjusted EBITDA, which is a non-GAAP performance measure that we use to supplement our results presented in accordance with U.S. GAAP. The Company uses Adjusted EBITDA to evaluate its actual operating performance and for planning and forecasting future periods. The Company believes that the adjusted results presented provide relevant and useful information for investors because they clarify the Company’s actual operating performance, make it easier to compare our results with those of other companies and allow investors to review performance in the same way as our management. Since
36


these measures are not calculated in accordance with U.S. GAAP, they should not be considered in isolation of, or as a substitute for, net loss or our other reported results of operations as reported under U.S. GAAP as indicators of our performance, and they may not be comparable to similarly named measures from other companies.
The Company defines Adjusted EBITDA as net income before interest, income taxes and, depreciation and amortization and excluding the following: (i) income from investments, net (the majority of the Company's investment income relates to remeasurement to net asset value of previously-held interests in connection with our roll-up of affiliates, and the Company expects income from investments to be a non-recurring item as its legacy investment holdings diminish), (ii) equity-based compensation expense, (iii) non-cash impairment losses, (iv) transaction costs, (v) non-cash inventory adjustments and (vi) other non-recurring expenses (other expenses and income not expected to recur).

Adjusted EBITDABetter/(Worse)Better/(Worse)
in thousandsThree Months Ended June 30,2023 vs. 2022Six Months Ended June 30,2023 vs. 2022
20232022$%20232022$%
Net loss (U.S. GAAP)$(18,240)$(10,603)$(34,397)$(24,514)
Income tax expense5,994 8,048 13,343 15,996 
Interest expense, net8,868 5,155 16,926 9,519 
Depreciation and amortization(1)
3,511 4,456 6,549 7,347 
EBITDA (non-GAAP)$133 $7,056 $(6,923)(98)%$2,421 $8,348 $(5,927)(71)%
Adjusting items:
Loss (income) from investments, net(322)996 20 (137)
Impairments, net— 134 — 2,090 
Non-cash inventory adjustments
4,484 — 6,721 — 
Loss on extraordinary events(2)
200 194 1,692 376 
Write down (recovery) of assets held-for-sale3,557 — 3,557 874 
Legal settlements, net— (310)— (335)
Gain on business divestiture— (292)— (296)
Equity-based compensation expense694 1,655 1,678 5,814 
Other non-recurring expenses(3)
(1,910)952 1,339 2,278 
Adjusted EBITDA (non-GAAP)$6,836 $10,385 $(3,549)(34)%$17,428 $19,012 $(1,584)(8)%
(1) Depreciation and amortization for the three and six months ended June 30, 2023 and 2022 contains depreciation and amortization included in cost of goods sold.
(2) Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence.
(3) Other non-recurring expenses relates to certain compensation, general and administrative, and other miscellaneous expenses. The Company excludes these items as they are not expected to recur.

The increases in adjusted EBITDA are driven by the factors discussed above.
37


LIQUIDITY AND CAPITAL RESOURCES
Liquidity
Sources and uses of cash (all amounts in thousands, except per share amounts)
The Company’s primary uses of capital include operating expenses, income taxes, capital expenditures and the servicing of outstanding debt. The Company’s primary sources of capital include funds generated by cannabis sales as well as financing activities. Through June 30, 2023, the Company had primarily used private financing as a source of liquidity for short-term working capital needs and general corporate purposes.
As of June 30, 2023, the Company had cash of $30,029, including $16,401 of cash and cash equivalents and $13,628 of restricted cash, respectively, on the Unaudited Condensed Consolidated Statements of Financial Position. The Company’s ability to fund its operations, capital expenditures, acquisitions, and other obligations depends on its future operating performance and ability to obtain financing, which are subject to prevailing economic conditions, as well as financial, business and other factors, some of which are beyond the Company’s control.
The Company’s future contractual obligations include the following:
Leases
As of June 30, 2023, the Company had future operating lease obligations and future finance lease obligations of $31,745 and $15,988, respectively, with $2,030 and $453 payable within the next six months, respectively. The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments, and accounts for non-lease components separately from leases. Refer to Note 8 of the Unaudited Condensed Consolidated Financial Statements for further discussion.
Debt
As of June 30, 2023, the Company had outstanding debt with varying maturities for an aggregate principal amount of $243,968 (net of $14,741 of unamortized discounts and debt issuance costs), with $12,904 payable within the remaining six months. The Company has related future interest payments of $73,514, with $16,279 payable within the remaining six months. In April 2023, the Company reached an agreement with its lenders that would allow it to draw a further $15,000 under its current credit agreement, but such funds would be restricted for use to only eligible capital expenditures. As part of this agreement, the Company agreed to not draw additional funds under the Credit Agreement. Refer to Notes 10 and 17 of the Unaudited Condensed Consolidated Financial Statements for further discussion.
The Company expects that its Cash and cash equivalents of $16,401 as of June 30, 2023, will be adequate to support the future obligations discussed above as well as the capital needs of the existing operations and expansion plans over the next twelve months.
Going Concern
As reflected in the unaudited condensed consolidated financial statements, the Company had an accumulated deficit as of June 30, 2023, as well as a net loss and negative cash flow from operating activities for the six months ended June 30, 2023. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements.
However, management believes that substantial doubt about the Company’s ability to meet its obligations for the next twelve months from the date these financial statements are issued, can be mitigated by, but not limited to, (i) expected long-term sales growth from the Company’s consolidated operations, (ii) latitude as to the timing and amount of certain operating expenses as well as capital expenditures, (iii) expense reduction plans that have already been put in place to improve the Company’s results, (iv) access to the U.S. and Canadian public equity markets.
38


Cash flows
Cash and cash equivalents and restricted cash were $30,029 as of June 30, 2023, which represents a net increase of $5,962 for the six months ended June 30, 2023. The following table details the change in cash, cash equivalents, restricted cash and cash related to assets held for sale for the six months ended June 30, 2023 and 2022.
Cash flowsBetter/(Worse)
in thousandsSix Months Ended June 30,2023 vs. 2022
20232022$%
Net cash used in operating activities$(15,107)$(23,466)$8,359 36 %
Net cash used in investing activities(716)(9,488)8,772 92 
Net cash provided by financing activities21,785 18,017 3,768 21 
Net increase (decrease) in cash, cash equivalents, restricted cash, and cash held for sale$5,962 $(14,937)$20,899 n/m
n/m - Not Meaningful
Net cash used in operating activities
During the six months ended June 30, 2023, the Company used $15,107 of net cash in operating activities compared to $23,466 of net cash provided through operating activities in the same period for 2022, which represented a decrease of $8,359, or 36%, when compared with 2022. Although the reported net loss increased by $9,883 during the six months ended June 30, 2023 when compared to the same period of 2022, the net loss excluding non-cash items such as impairments, equity-based compensation, write-offs and recoveries, gains and losses on disposals and depreciation and amortization increased by $8,788 when compared to the same period of 2022.
Net cash used in investing activities
During the six months ended June 30, 2023, the Company used $716 of net cash through investing activities compared to $9,488 of net cash used in investing activities in the same period for 2022, which represented an improvement of $8,772. Net cash used in investing activities for the six months ended June 30, 2023 included $3,232 on the purchase of capital assets and intangibles which was partially offset by collection of notes receivable of $2,000.
Net cash provided by financing activities
During the six months ended June 30, 2023, the Company had $21,785 of net cash provided through financing activities compared to $18,017 of net cash provided through financing activities in the same period for 2022, which represented an improvement of $3,768. Net cash used in financing activities for the six months ended June 30, 2023 included $868 of debt repayments.
39


Capital Resources
Capital structure and debt
Our debt outstanding as of June 30, 2023 and December 31, 2022 is as follows:
Debt balancesJune 30, 2023December 31, 2022
Financing liability (failed sale-leaseback)$15,253 $15,253 
Finance lease liabilities5,969 5,306 
7.50% Loan due April 202631,549 31,288 
6.10% Secured debenture due September 203046,727 46,502 
Note due December 20242,375 3,167 
Prime rate credit facilities due January 2026, as amended129,982 113,564 
Note backed by ERTC12,113 — 
Total debt$243,968 $215,080 
Less: current portion of debt13,805 1,584 
Total long-term debt$230,163 $213,496 
Commitments and contingencies
Commitments
The Company provides revolving lines of credit to several third parties. Refer to Note 6 of the Unaudited Condensed Consolidated Financial Statements for further discussion.
Arrangement with Canopy Growth
On June 19, 2019, the shareholders of the Company and of Canopy Growth separately approved the Prior Plan of Arrangement involving the two companies. Subsequently, on September 23, 2020, Acreage and Canopy Growth entered into an amending agreement and the Amended Arrangement became effective on September 23, 2020.
During the fourth quarter of 2022, the Company entered into a new strategic arrangement with Canopy Growth that, would allow Canopy Growth to acquire 100% of Acreage by (i) waiving its existing Floating Share option and entering into a new Floating Share acquisition agreement; and (ii) committing to exercise its Fixed Share option, all subject to required approvals and terms of the related agreements.
Refer to Note 13 of the Unaudited Condensed Consolidated Financial Statements for further discussion.
Advisor fee
In connection with the Prior Plan of Arrangement, the Company entered into an agreement with its financial advisor providing for a fee payment of $7,000 in either cash, Acreage shares or Canopy Growth shares, at the discretion of the Company, upon the successful acquisition of Acreage by Canopy Growth. During the fourth quarter of 2022, the Company amended the terms of the agreement with its financial advisors providing for a fee payment of $3,000 in cash, less a $500 initial payment, and $2,000 in shares of the Company, upon the successful acquisition of Acreage by Canopy Growth.

Tax Receivable Agreement

The Company is a party to (i) a tax receivable agreement dated November 14, 2018 and subsequently amended (the “Tax Receivable Agreement”) between the Company, certain current and former unit holders of HSCP and, Canopy Growth and Canopy USA and (ii) tax receivable bonus plans dated November 14, 2018 and subsequently amended (the “Tax Receivable Bonus Plans”) between the Company and certain directors, officers, consultants of the Company, Canopy Growth and Canopy USA (together the “Tax Receivable Recipients”). Under the Tax Receivable Agreement and the Tax Receivable Bonus Plans, the Company is required to make cash payments to the Tax Receivable Recipients equal to 85% of the tax benefits, if any, that the Company actually realizes, or in certain circumstances is deemed to realize, as a result of (i) the increases in its share of the tax basis of assets of HSCP resulting from any redemptions or exchanges of Units from the HSCP Members, and (ii) certain other tax benefits related to the Company making payments under the Tax Receivable Agreement and the Tax Receivable Bonus Plan.
40



Surety bonds

The Company has indemnification obligations with respect to surety bonds primarily used as security against non-performance in the amount of $5,000 as of June 30, 2023, for which no liabilities are recorded on the Unaudited Condensed Consolidated Statements of Financial Position.
The Company is subject to other capital commitments and similar obligations. As of June 30, 2023, such amounts were not material.
Contingencies
The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company’s applicable subsidiaries ceasing operations. While management of the Company believes that the Company’s subsidiaries are in compliance with applicable local and state regulations as of June 30, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company’s subsidiaries may be subject to regulatory fines, penalties, or restrictions in the future.
The Company and its subsidiaries may be, from time to time, subject to various administrative, regulatory and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated. Refer to Note 13 of the Unaudited Condensed Consolidated Financial Statements for further discussion.
Critical accounting policies and estimates
We have adopted various accounting policies to prepare the Unaudited Condensed Consolidated Financial Statements in accordance with GAAP. Certain of our accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. In our 2022 Annual Report on Form 10-K, we identified the critical accounting policies which affect our more significant estimates and assumptions used in preparing our consolidated financial statements.

As of June 30, 2023 there have been no material changes to our critical accounting policies and estimates from those previously disclosed in our 2022 Annual Report on Form 10-K for the year ended December 31, 2022.
Item 3. Quantitative and Qualitative Disclosures About Market Risk (presented in thousands, except share amounts).
The Company has exposure to certain risks, including market, credit, liquidity, asset forfeiture, banking and interest rate risk, and assesses the impact and likelihood of those risks. However, there have been no material changes in our market risk during the three and six months ended June 30, 2023. For additional information, refer to our 2022 Annual Report on Form 10-K for the year ended December 31, 2022.

Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Based on an evaluation under the supervision and with the participation of the Company’s management, and due to the material weakness in internal controls over financial reporting described below, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were not effective for the period ending June 30, 2023 to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Inherent Limitations Over Internal Controls

The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. The Company’s internal control over financial reporting includes those policies and procedures that:

41


(i)    pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets;

(ii)    provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that the Company’s receipts and expenditures are being made only in accordance with authorizations of the Company’s management and directors; and

(iii)    provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Management, including the Company’s Chief Executive Officer and Chief Financial Officer, does not expect that the Company’s internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Material Weaknesses in Internal Control Over Financial Reporting

A material weakness in internal controls over financial reporting is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

The review, testing and evaluation of key internal controls over financial reporting completed by the Company resulted in the Company’s principal executive officer and principal financial officer concluding that a material weakness in the Company’s internal controls over financial reporting remained present as of June 30, 2023. Specifically, as a result of turnover and the availability of resources with the appropriate level of technical capabilities (including the impacts on staffing and recruiting and the general global labor shortage brought about by the global COVID-19 pandemic), the Company did not have effective staffing levels and adequate segregation of duties within several finance and accounting processes. Further, and as a result of this material weakness, the Company’s financial disclosures for the quarterly period ending June 30, 2021 incorrectly disclosed certain debt that was due 11 months after the balance sheet date as long-term rather than as current liabilities. Additionally, and as a result of this material weakness, the Company’s financial disclosures for the quarterly and annual periods ended June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, and September 30, 2021 incorrectly reported the weighted average shares outstanding which resulted in an incorrect determination of earnings per share and diluted earnings per share. Finally, for the year ended December 31, 2022, the Company did not have adequate processes or sufficient resources to adequately assess the impairment of goodwill and intangible assets and cutoff over inventory.

The Company has begun to address the material weaknesses described above through the following actions. Although the Company previously believed the material weaknesses would be addressed by the second half of 2023, due to continued staff turnover and the availability of resources with appropriate levels of technical capabilities, the Company now expects to complete these actions in 2024:

a.Engaging third-party consultants with appropriate expertise to assist the finance and accounting department on an interim basis until key roles are filled;
b.Assessing finance and accounting resources to identify the areas and functions that lack sufficient personnel and recruiting for experienced personnel to assume these roles;
c.Further centralization of key accounting processes to enable greater segregation of duties;
d.Developing further training on segregation of duties; and
e.Designing and implementing additional compensating controls where necessary.

The Company is working diligently to remediate this material weakness by hiring qualified and capable personnel. Further, we will continue to evaluate and assess the staffing needs of the Company as the landscape and needs of the Company continue to evolve. While we are working diligently to remediate this material weakness, there is no assurance that this material weakness will be fully remediated by December 31, 2024, given continuing lasting impacts of COVID-19 on staffing and labor for companies within our industry and otherwise.

Changes in Internal Control Over Financial Reporting
42



Other than the changes discussed above in connection with our implementation of the remediation plan, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a–15(f) and 15d–15(f) under the Exchange Act) that occurred during our most recent quarter, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II
Item 1. Legal Proceedings.
For information on legal proceedings, refer to Note 13 to the Unaudited Condensed Consolidated Financial Statements included this report.
Item 1A. Risk Factors.
There have been no material changes to the risk factors described in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.
Item 3. Defaults Upon Senior Securities.

None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Not applicable.
43


Item 6. Exhibits.
Incorporated by Reference
Exhibit No.Description of DocumentSchedule FormFile NumberExhibit/FormFiling DateFiled or Furnished Herewith
8-K000-560216/5/2023
10.28-K000-560216/5/2023
10.38-K000-560217/3/2023
Certification of Periodic Report by Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.X
Certification of Periodic Report by Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.X
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*X
101
Attached as Exhibit 101 to this report are the following documents formatted in iXBRL (Extensible Business Reporting Language):): (i) Consolidated Statements of Financial Position as of June 30, 2023 (unaudited) and December 31, 2022 (audited), (ii) Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and June 30, 2022, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and June 30, 2022, (iv) Unaudited Condensed Consolidated Statements of Shareholders’ Equity for the three and six months ended June 30, 2023 and June 30, 2022 and (v) Notes to Unaudited Condensed Consolidated Financial Statements.
X
* Document has been furnished, is not deemed filed and is not to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in any such filing.
+ Portions of this exhibit are redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
44


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: August 9, 2023
Acreage Holdings, Inc.
By:/s/ Carl Nesbitt
Carl Nesbitt
Chief Financial Officer
45

Exhibit 31.1
Certification of Chief Executive Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act and Rule 13a-14(a) or 15d-14(a)
Under the Securities and Exchange Act of 1934

I, Dennis Curran, certify that:
1.    I have reviewed this Quarterly report on Form 10-Q for the period ended June 30, 2023 of Acreage Holdings, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and




(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 9, 2023
By: /s/ Dennis Curran
Dennis Curran
Chief Executive Officer


Exhibit 31.2
Certification of Chief Financial Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act and Rule 13a-14(a) or 15d-14(a)
Under the Securities and Exchange Act of 1934

I, Carl Nesbitt, certify that:
1.    I have reviewed this Quarterly report on Form 10-Q for the period ended June 30, 2023 of Acreage Holdings, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and




(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 9, 2023
By: /s/ Carl Nesbitt
Carl Nesbitt
Chief Financial Officer


Exhibit 32.1
Certifications of the
Chief Executive Officer and Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350

Solely for the purposes of complying with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, we, the undersigned Chief Executive Officer and Chief Financial Officer of Acreage Holdings, Inc. (the “Company”), hereby certify, based on our knowledge, that the Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Dennis Curran
Dennis Curran
Chief Executive Officer
 
/s/ Carl Nesbitt
Carl Nesbitt
Chief Financial Officer

Date: August 9, 2023


v3.23.2
COVER - shares
6 Months Ended
Jun. 30, 2023
Aug. 02, 2023
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 000-56021  
Entity Registrant Name ACREAGE HOLDINGS, INC.  
Entity Incorporation, State or Country Code A1  
Entity Tax Identification Number 98-1463868  
Entity Address, Address Line One 366 Madison Ave, 14th floor  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10017  
City Area Code 646  
Local Phone Number 600-9181  
Title of 12(g) Security Class D Subordinate Voting Shares, no par value; Class E Subordinate Voting Shares, no par value.  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Entity Central Index Key 0001762359  
Class E Subordinate Voting Shares    
Entity Information [Line Items]    
Entity Common Stock, Shares Outstanding   80,652,047
Class D Subordinate Voting Shares    
Entity Information [Line Items]    
Entity Common Stock, Shares Outstanding   34,274,128
Class F Multiple Voting Shares    
Entity Information [Line Items]    
Entity Common Stock, Shares Outstanding   117,600
v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
ASSETS    
Cash and cash equivalents $ 16,401 $ 24,067
Restricted cash 13,628 0
Accounts receivable, net 8,953 10,512
Inventory 47,938 49,446
Notes receivable, net 0 29,191
Assets held-for-sale 1,788 0
Other current assets 5,418 4,977
Total current assets 94,126 118,193
Long-term investments 33,287 34,046
Capital assets, net 136,085 133,405
Operating lease right-of-use assets 19,067 22,443
Intangible assets, net 35,124 35,124
Goodwill 38,694 13,761
Other non-current assets 3,531 3,601
Total non-current assets 265,788 242,380
TOTAL ASSETS 359,914 360,573
LIABILITIES AND SHAREHOLDERS’ EQUITY    
Accounts payable and accrued liabilities 31,078 29,566
Taxes payable 33,959 24,226
Interest payable 2,824 2,575
Operating lease liability, current 2,268 2,443
Debt, current 13,805 1,584
Liabilities related to assets held for sale 1,288 0
Other current liabilities 9,071 11,939
Total current liabilities 94,293 72,333
Debt, non-current 230,163 213,496
Operating lease liability, non-current 18,839 21,692
Deferred tax liability 10,620 9,623
Other liabilities 3,004 3,250
Total non-current liabilities 262,626 248,061
TOTAL LIABILITIES 356,919 320,394
Commitments and contingencies
Common stock, no par value - unlimited authorized, 113,203 and 112,437 issued and outstanding, respectively 0 0
Additional paid-in capital 758,702 760,529
Treasury stock, 842 common stock held in treasury (21,054) (21,054)
Accumulated deficit (709,204) (678,091)
Total Acreage Shareholders' equity 28,444 61,384
Non-controlling interests (25,449) (21,205)
TOTAL EQUITY 2,995 40,179
TOTAL LIABILITIES AND EQUITY $ 359,914 $ 360,573
v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) - shares
shares in Thousands
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, issued (in shares) 113,203 112,437
Common stock, shares, outstanding (in shares) 113,203 112,437
Treasury stock (in shares) 842 842
v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
REVENUE        
Total revenues, net $ 58,115 $ 61,351 $ 114,078 $ 118,230
Total cost of goods sold (36,993) (30,737) (66,371) (58,106)
Gross profit 21,122 30,614 47,707 60,124
OPERATING EXPENSES        
General and administrative 7,073 8,922 17,585 17,309
Compensation expense 13,203 12,579 25,406 26,774
Equity-based compensation expense 694 1,655 1,678 5,814
Marketing 656 964 1,400 1,661
Impairments, net 0 329 0 2,467
Write down of assets held-for-sale 3,557 0 3,557 874
Legal recoveries 0 (310) 0 (335)
Depreciation and amortization 994 3,165 1,991 4,972
Total operating expenses 26,177 27,304 51,617 59,536
Net operating income (loss) (5,055) 3,310 (3,910) 588
Loss from investments, net 322 (996) (20) 137
Interest income (loss) from loans receivable (6) 365 10 782
Interest expense (8,862) (5,520) (16,936) (10,301)
Other income (loss), net 1,355 286 (198) 276
Total other loss (7,191) (5,865) (17,144) (9,106)
Loss before income taxes (12,246) (2,555) (21,054) (8,518)
Income tax expense (5,994) (8,048) (13,343) (15,996)
Net loss (18,240) (10,603) (34,397) (24,514)
Less: net loss attributable to non-controlling interests (2,084) (674) (3,651) (1,891)
Net loss attributable to Acreage Holdings, Inc. $ (16,156) $ (9,929) $ (30,746) $ (22,623)
Net loss per share attributable to Acreage Holdings, Inc. - basic (USD per share) $ (0.14) $ (0.09) $ (0.27) $ (0.21)
Net loss per share attributable to Acreage Holdings, Inc. - diluted (USD per share) $ (0.14) $ (0.09) $ (0.27) $ (0.21)
Weighted average shares outstanding - basic (in share) 112,810 108,230 112,679 107,569
Weighted average shares outstanding - diluted (in shares) 112,810 108,230 112,679 107,569
Retail        
REVENUE        
Total revenues, net $ 44,913 $ 46,685 $ 86,794 $ 88,112
Total cost of goods sold (23,484) (23,466) (43,898) (44,234)
Wholesale        
REVENUE        
Total revenues, net 13,202 14,360 27,200 29,532
Total cost of goods sold (13,509) (7,271) (22,473) (13,872)
Other        
REVENUE        
Total revenues, net $ 0 $ 306 $ 84 $ 586
v3.23.2
UNAUDITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Share Capital
Treasury Stock
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Shareholders’ Equity
Shareholders’ Equity
Cumulative Effect, Period of Adoption, Adjustment
Non-controlling Interests
LLC Membership Units
Pubco Shares (as converted)
Beginning balance (in shares) at Dec. 31, 2021                   3,861 106,903
Beginning balance at Dec. 31, 2021 $ 204,270   $ 756,536 $ (21,054) $ (538,215)   $ 197,267   $ 7,003    
Increase (Decrease) in Stockholders' Equity                      
NCI adjustments for changes in ownership 0   5       5   (5)    
Equity-based compensation expense and related issuances (in shares)                     508
Equity-based compensation expense and related issuances 4,159   4,159       4,159        
Net loss (13,911)       (12,694)   (12,694)   (1,217)    
Ending balance (in shares) at Mar. 31, 2022                   3,861 107,411
Ending balance at Mar. 31, 2022 194,518   760,700 (21,054) (550,909)   188,737   5,781    
Beginning balance (in shares) at Dec. 31, 2021                   3,861 106,903
Beginning balance at Dec. 31, 2021 204,270   756,536 (21,054) (538,215)   197,267   7,003    
Increase (Decrease) in Stockholders' Equity                      
Net loss (24,514)                    
Ending balance (in shares) at Jun. 30, 2022                   3,861 109,189
Ending balance at Jun. 30, 2022 180,036   757,831 (21,054) (560,838)   175,939   4,097    
Beginning balance (in shares) at Mar. 31, 2022                   3,861 107,411
Beginning balance at Mar. 31, 2022 194,518   760,700 (21,054) (550,909)   188,737   5,781    
Increase (Decrease) in Stockholders' Equity                      
NCI adjustments for changes in ownership 0   (4,524)       (4,524)   4,524    
Capital contributions, net (5,534)               (5,534)    
Equity-based compensation expense and related issuances (in shares)                     1,778
Equity-based compensation expense and related issuances 1,655   1,655       1,655        
Net loss (10,603)       (9,929)   (9,929)   (674)    
Ending balance (in shares) at Jun. 30, 2022                   3,861 109,189
Ending balance at Jun. 30, 2022 180,036   757,831 (21,054) (560,838)   175,939   4,097    
Beginning balance (in shares) at Dec. 31, 2022                   3,861 112,437
Beginning balance at Dec. 31, 2022 40,179 $ (367) 760,529 (21,054) (678,091) $ (367) 61,384 $ (367) (21,205)    
Increase (Decrease) in Stockholders' Equity                      
NCI adjustments for changes in ownership 0   14       14   (14)    
Equity-based compensation expense and related issuances (in shares)                     287
Equity-based compensation expense and related issuances 984   984       984        
Net loss (16,157)       (14,590)   (14,590)   (1,567)    
Ending balance (in shares) at Mar. 31, 2023                   3,861 112,724
Ending balance at Mar. 31, 2023 24,639   761,527 (21,054) (693,048)   47,425   (22,786)    
Beginning balance (in shares) at Dec. 31, 2022                   3,861 112,437
Beginning balance at Dec. 31, 2022 40,179 $ (367) 760,529 (21,054) (678,091) $ (367) 61,384 $ (367) (21,205)    
Increase (Decrease) in Stockholders' Equity                      
Net loss (34,397)                    
Ending balance (in shares) at Jun. 30, 2023                   3,861 113,203
Ending balance at Jun. 30, 2023 2,995   758,702 (21,054) (709,204)   28,444   (25,449)    
Beginning balance (in shares) at Mar. 31, 2023                   3,861 112,724
Beginning balance at Mar. 31, 2023 24,639   761,527 (21,054) (693,048)   47,425   (22,786)    
Increase (Decrease) in Stockholders' Equity                      
NCI adjustments for changes in ownership 0   (3,389)       (3,389)   3,389    
Capital contributions, net (3,968)               (3,968)    
Other equity transactions (130)   (130)       (130)        
Equity-based compensation expense and related issuances (in shares)                     479
Equity-based compensation expense and related issuances 694   694       694        
Net loss (18,240)       (16,156)   (16,156)   (2,084)    
Ending balance (in shares) at Jun. 30, 2023                   3,861 113,203
Ending balance at Jun. 30, 2023 $ 2,995   $ 758,702 $ (21,054) $ (709,204)   $ 28,444   $ (25,449)    
v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (34,397) $ (24,514)
Adjustments for:    
Depreciation and amortization 1,991 4,972
Depreciation and amortization included in COGS 8,935 2,877
Equity-based compensation expense 1,678 5,814
Gain on business divestiture 0 (290)
Loss on disposal of capital assets 0 49
Loss on impairment 0 2,467
Bad debt expense 339 14
Non-cash interest expense 2,457 1,470
Non-cash operating lease expense (112) (55)
Loss on lease termination (200) 338
Deferred tax income (18) (791)
Non-cash loss from investments, net 759 552
Write-down of assets held-for-sale 3,557 874
Change, net of acquisitions in:    
Accounts receivable, net 6,068 (2,304)
Inventory (5,194) (10,460)
Other assets (469) (197)
Interest receivable (360) (782)
Accounts payable and accrued liabilities (5,670) (2,331)
Taxes payable 8,540 (3,246)
Interest payable 249 2,022
Other liabilities (3,260) 55
Net cash used in operating activities (15,107) (23,466)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of capital assets (3,232) (11,876)
Collection of notes receivable 2,000 5,999
Business acquisitions, net of cash acquired 516 0
Purchases of intangible assets 0 (900)
Distributions from investments 0 689
Cash paid for short-term investment 0 (3,400)
Net cash used in investing activities (716) (9,488)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from related party debt 27,121 25,000
Deferred financing costs paid (500) (511)
Repayment of debt (868) (938)
Capital distributions - non-controlling interests (3,968) (5,534)
Net cash provided by financing activities 21,785 18,017
Net increase (decrease) in cash, cash equivalents, restricted cash, and cash held for sale 5,962 (14,937)
Cash, cash equivalents, restricted cash, and cash held for sale - Beginning of period 24,067 44,501
Cash, cash equivalents, restricted cash, and cash held for sale - End of period 30,029 29,564
RECONCILIATION OF CASH FLOW INFORMATION:    
Cash and cash equivalents 16,401 29,235
Restricted cash 13,628 95
Cash held for sale 0 234
Total cash, cash equivalents, restricted cash, and cash held for sale at end of period 30,029 29,564
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Interest paid - non-lease 14,222 5,586
Income taxes paid 4,280 21,476
OTHER NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Capital assets not yet paid for 3,729 5,505
Non-cash proceeds from business divestiture 0 2,000
Non-cash proceeds from finance lease 0 5,785
Reclassification of assets held-for-sale to in-use 0 0
Cumulative effect of change in accounting principle for current expected credit losses, net of tax 121 0
NCI adjustments for changes in ownership $ (14) $ 0
v3.23.2
NATURE OF OPERATIONS
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS NATURE OF OPERATIONS
Acreage Holdings, Inc. (the “Company”, “Pubco” or “Acreage”) is a vertically integrated, multi-state operator in the United States (“U.S.”) cannabis industry and has contractual relationships with cannabis cultivation facilities, dispensaries and other cannabis-related companies in the U.S. The Company’s operations include (i) cultivating and processing cannabis plants, (ii) manufacturing branded consumer products, (iii) distributing cannabis flower and manufactured products, and (iv) retailing dosable cannabis products to consumers. The Company’s products appeal to medical and adult recreational use customers through brand strategies intended to build trust and loyalty. The Company’s Class E subordinate voting shares (“Fixed Shares”) and Class D subordinate voting shares (“Floating Shares”) are listed on the Canadian Securities Exchange under the symbols “ACRG.A.U” and “ACRG.B.U”, respectively, quoted on the OTCQX under the symbols “ACRHF” and “ACRDF”, respectively, and traded on the Frankfurt Stock Exchange under the symbols “0VZ1” and “0VZ2”, respectively.
High Street Capital Partners, LLC, a Delaware limited liability company doing business as “Acreage Holdings” (“HSCP”), was formed on April 29, 2014. The Company became the indirect parent of HSCP on November 14, 2018 in connection with the reverse takeover (“RTO”) transaction described below.
The Company’s principal place of business is located at 366 Madison Ave, 14th floor, New York, New York in the U.S. The Company’s registered and records office address is Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia in Canada.
The RTO transaction

On September 21, 2018, the Company, HSCP, HSCP Merger Corp. (a wholly-owned subsidiary of the Company), Acreage Finco B.C. Ltd. (a special purpose corporation) (“Finco”), Acreage Holdings America, Inc. (“USCo”) and Acreage Holdings WC, Inc. (“USCo2”) entered into a business combination agreement (the “Business Combination Agreement”) whereby the parties thereto agreed to combine their respective businesses, which would result in the RTO of Pubco by the security holders of HSCP, which was deemed to be the accounting acquiror. On November 14, 2018, the parties to the Business Combination Agreement completed the RTO.
Canopy Growth Corporation transaction

On June 27, 2019, the Company and Canopy Growth Corporation (“Canopy Growth” or “CGC”) implemented the Prior Plan of Arrangement (as defined in Note 13) contemplated by the Original Arrangement Agreement (as defined in Note 13). Pursuant to the Prior Plan of Arrangement, Canopy Growth was granted an option to acquire all of the issued and outstanding shares of the Company in exchange for the payment of 0.5818 of a common share in the capital of Canopy Growth for each Class A subordinate voting share (each, a “SVS”) held (with the Class B proportionate voting shares (the “PVS”) and Class C multiple voting shares (the “MVS”) being automatically converted to SVS immediately prior to consummation of the Acquisition (as defined in Note 13), which original exchange ratio was subject to adjustment in accordance with the Original Arrangement Agreement. Canopy Growth was required to exercise the option upon a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”) and, subject to the satisfaction or waiver of certain closing conditions set out in the Original Arrangement Agreement, Canopy Growth was required to acquire all of the issued and outstanding SVS (following the mandatory conversion of the PVS and MVS into SVS).
On June 24, 2020, Canopy Growth and the Company entered into an agreement to, among other things, amend the terms of the Original Arrangement Agreement and the terms of the Prior Plan of Arrangement (the “Amended Arrangement”). On September 16, 2020, the Company’s shareholders voted in favor of a special resolution authorizing and approving the terms of, among other things, the Amended Arrangement. Subsequently, on September 18, 2020, the Company obtained a final order from the Supreme Court of British Columbia approving the Amended Arrangement, and on September 23, 2020 the Company and Canopy Growth entered into the Amending Agreement (as defined in Note 13) and implemented the Amended Arrangement. Pursuant to the Amended Arrangement, the Company’s articles were amended to create the Fixed Shares, the Floating Shares and the Class F multiple voting shares (the “Fixed Multiple Shares”), and each outstanding SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share, each outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and each outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share. Pursuant to the Amended Arrangement, Canopy Growth was granted the option to acquire all of the issued and outstanding Fixed Shares on the basis of 0.3048 (the “Fixed Exchange Ratio”) of a common share of Canopy Growth (each, a “Canopy Share”) for each Fixed Share held at the time of the acquisition of the Fixed Shares (the “Acquisition” or “Acquisition Time”), subject to
adjustment in accordance with the terms of the Amended Arrangement (the “Canopy Call Option”), which Canopy Growth is required to exercise upon the occurrence, or waiver (at the discretion of Canopy Growth), of a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event” and the date on which the Triggering Event occurs, the “Triggering Event Date”). Refer to Note 13 for further discussion.
Pursuant to the implementation of the Amended Arrangement, on September 23, 2020, a subsidiary of Canopy Growth advanced gross proceeds of $50,000 to Universal Hemp, LLC, an affiliate of the Company. The debenture bears interest at a rate of 6.1% per annum. Refer to Note 10 for further discussion.
On October 24, 2022, the Company entered into an arrangement agreement (the “Floating Share Agreement”) with Canopy Growth and Canopy USA, LLC (“Canopy USA”), Canopy Growth’s newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the “Floating Shares”) and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the “Floating Share Arrangement”) for consideration of 0.4500 of a common share of Canopy Growth (each whole share a “Canopy Share”) in exchange for each Floating Share. On March 15, 2023, the Company received the required approval of the holders of Floating Shares in connection with the Floating Share Arrangement at its special meeting of holders of Floating Shares. On March 21, 2023, the Corporation obtained a final order form from the Supreme Court of British Columbia approving the Floating Share Arrangement. Upon the satisfaction or waiver of all other conditions set out in the Floating Share Arrangement Agreement, which the parties continue to work towards, the parties will complete the Floating Share Arrangement. Refer to Note 13 for further discussion.
v3.23.2
SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation and going concern

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair presentation have been reflected in these unaudited condensed consolidated financial statements. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any other period.

As reflected in the unaudited condensed consolidated financial statements, the Company had an accumulated deficit as of June 30, 2023, as well as a net loss and negative cash flow from operating activities for the six months ended June 30, 2023. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements.

However, management believes that substantial doubt about the Company’s ability to meet its obligations for the next twelve months from the date these financial statements are issued, can be mitigated by, but not limited to, (i) expected long-term sales growth from the Company’s consolidated operations, (ii) latitude as to the timing and amount of certain operating expenses as well as capital expenditures, (iii) expense reduction plans that have already been put in place to improve the Company’s results, (iv) access to the U.S. and Canadian public equity markets.

If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its footprint build-out or other operational activities until such time as additional capital becomes available. Such limitation of the Company’s activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase the Company’s need to raise additional capital on an immediate basis.

These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, dated May 1, 2023, as filed with the Securities and Exchange Commission (the “2022 Form 10-K”).
Use of estimates

Preparation of financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the dates presented and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates. Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include the fair value of assets acquired and liabilities assumed in business combinations, assumptions relating to equity-based compensation expense, estimated useful lives for property, plant and equipment and intangible assets, the valuation allowance against deferred tax assets and the assessment of potential charges on goodwill, intangible assets and investments in equity and notes receivable.
Emerging growth company
The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.
Functional and presentation currency

The unaudited condensed consolidated financial statements and the accompanying notes are expressed in U.S. dollars. Financial metrics are presented in thousands. Other metrics, such as shares outstanding, are presented in thousands unless otherwise noted.
Basis of consolidation

The Company’s unaudited condensed consolidated financial statements include the accounts of Acreage, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in business entities in which Acreage lacks control but is able to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations.
Non-controlling interests (“NCI”)

Non-controlling interests represent ownership interests in consolidated subsidiaries by parties that are not shareholders of Pubco. They are shown as a component of Total equity in the Unaudited Condensed Consolidated Statements of Financial Position, and the share of loss attributable to non-controlling interests is shown as a component of Net loss in the Unaudited Condensed Consolidated Statements of Operations. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions.
Cash and cash equivalents

The Company defines cash equivalents as highly liquid investments held for the purpose of meeting short-term cash commitments that are readily convertible into known amounts of cash, with original maturities of three months or less. The Company maintains cash with various U.S. banks and credit unions with balances in excess of the Federal Deposit Insurance Corporation and National Credit Union Share Insurance Fund limits, respectively. The failure of a bank or credit union where the Company has significant deposits could result in a loss of a portion of such cash balances in excess of the insured limit, which could materially and adversely affect the Company’s business, financial condition, results of operations and the market price of the Company’s Fixed Shares and Floating Shares. Cash and cash equivalents belonging to entities the Company has classified as held-for-sale have been reclassified to Assets held-for-sale on the Unaudited Condensed Consolidated Statements of Financial Position. Refer to Note 3 for further discussion.
Restricted cash
Restricted cash represents funds contractually held for specific purposes and, as such, not available for general corporate purposes.
Cash and restricted cash, as presented on the Unaudited Condensed Consolidated Statements of Cash Flows, consists of $16,401 and $13,628 as of June 30, 2023, respectively, and $29,235 and $95 as of June 30, 2022, respectively.
Accounts receivable and notes receivable valuations

The Company reports accounts receivable at their net realizable value, which is management’s best estimate of the cash that will ultimately be received from customers. The Company's notes receivable represent notes due from various third parties. The Company maintains an allowance for expected credit losses to reflect the expected uncollectability of accounts receivable and notes receivable based on historical collection data and specific risks identified among uncollected accounts, as well as management’s expectation of future economic conditions. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the companies receivables and the expected future losses. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Trade accounts receivable and notes receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible. As of June 30, 2023, the Company’s allowance for doubtful accounts was $373, all of which relates to the allowance for credit losses over accounts receivable. As of June 30, 2023, the allowance on loans receivable was $15,095, of which the allowance for credit losses over notes receivable was nil as the receivables were fully reserved for. Refer to Note 6 for further discussion.

Net loss per share
Net loss per share represents the net loss attributable to shareholders divided by the weighted average number of shares outstanding during the period on an as converted basis. Basic and diluted loss per share are the same as of June 30, 2023, 2022 and 2021, as the issuance of shares upon conversion, exercise or vesting of outstanding units would be anti-dilutive in each period. There were 46,243 and 37,472 anti-dilutive shares outstanding as of June 30, 2023 and 2022, respectively.
Accounting Pronouncements Recently Adopted
As of January 1, 2023, the Company adopted ASU 2016-13 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which was subsequently revised by ASU 2018-19 and ASU 2020-02. This standard applies to financial assets, measured at amortized cost, including loans, held-to-maturity debt securities, net investments in leases and trade accounts receivable. The guidance must be adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings in the period of adoption. The adoption of ASU 2016-13 did not have a material effect on the Company’s unaudited condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted
In October 2021, the FASB issued ASU 2021-08 - Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The new standard requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606 - Revenue from Contracts with Customers. The ASU will be effective for the Company’s first interim period of fiscal 2024. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company does not anticipate a material impact on the Company’s unaudited condensed consolidated financial statements upon adoption.
v3.23.2
ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE
6 Months Ended
Jun. 30, 2023
Business Combinations, Discontinued Operations And Disposal Groups [Abstract]  
ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE
Acquisitions

On January 2, 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine. Under the terms of the agreement, the consideration paid consisted of the settlement of a pre-existing relationship, which included a line-of credit, other advances and the related interest receivable, all totaling $27,691, which were previously recorded in Notes receivable, net on the Statements of Financial Position.
The purchase price allocation is based upon preliminary valuations, estimates and assumptions which are subject to change within the measurement period, generally one year from the acquisition date. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the capital assets, tangible assets acquired and the residual goodwill resulting from the transaction.
Purchase Price AllocationNortheast Patients Group
Assets acquired:
Cash and cash equivalents$516 
Inventory384 
Other current assets5,580 
Capital assets2,404 
Operating lease right-of-use asset1,695 
Goodwill24,933 
Liabilities assumed:
Accounts payable and accrued liabilities(3,679)
Taxes payable(1,112)
Operating lease liability, current(160)
Operating lease liability, non-current(1,844)
Notes payable(11)
Deferred tax liability(1,015)
Fair value of net assets acquired$27,691 
Consideration paid:
Settlement of pre-existing relationship27,691 
Total consideration$27,691 
During the year ended December 31, 2022, the Company did not complete any business acquisitions.
Divestitures
During the three and six months ended June 30, 2023 and 2022, the Company did not complete any divestitures.
Assets Held for Sale
The Company determined certain businesses and assets met the held-for-sale criteria. As such, the related assets and liabilities within these disposal groups were transferred into Assets held-for-sale and Liabilities related to assets held for sale on the Unaudited Condensed Consolidated Statements of Financial Position.

The tables below present the assets and liabilities classified as held for sale on the Unaudited Condensed Consolidated Statements of Financial Position as of June 30, 2023, and are subject to change based on developments during the sales process. As of December 31, 2022, the Company did not have any business or assets that met the held-for-sale criteria.
June 30, 2023
CWG
Cash165 
Accounts receivable, net53 
Inventory685 
Other current assets64 
Total current assets classified as held-for-sale967 
Capital assets, net471 
Operating lease right-of-use assets310 
Non-current assets40 
Total assets classified as held for sale1,788 
Accounts payable and accrued liabilities(242)
Taxes payable81 
Operating lease liability, current(271)
Total current liabilities classified as held-for-sale(432)
Operating lease liability, non-current(856)
Total liabilities classified as held-for-sale(1,288)
The Company determined certain businesses and assets met the held-for-sale criteria. Upon classification of the disposal groups as held for sale, the Company tested each disposal group for impairment and recognized charges of $3,557 within Write down of assets held-for-sale on the Unaudited Condensed Consolidated Statements of Operations related to CWG for three and six months ended June 30, 2023, respectively. Additionally, all assets and liabilities determined within these disposal groups were transferred into Assets held-for-sale and Liabilities related to assets held for sale on the Consolidated Statements of Financial Position as of June 30, 2023

During the three and six months ended June 30, 2022, the Company recognized a write down of assets held-for-sale of $874 related to its Oregon operations within Write down of assets held-for-sale on the Unaudited Condensed Consolidated Statements of Operations.
v3.23.2
INTANGIBLE ASSETS AND GOODWILL
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS AND GOODWILL INTANGIBLE ASSETS AND GOODWILL
Intangible assets
The following table details the intangible asset balances by major asset classes:
IntangiblesJune 30, 2023December 31, 2022
Finite-lived intangible assets:
Customer relationships1,000 1,000 
Total finite-lived intangible assets1,000 1,000 
Accumulated amortization on finite-lived intangible assets:
Customer relationships(1,000)(1,000)
Total accumulated amortization on finite-lived intangible assets(1,000)(1,000)
Finite-lived intangible assets, net— — 
Indefinite-lived intangible assets
Cannabis licenses35,124 35,124 
Total intangibles, net$35,124 $35,124 
During the year ended December 31, 2022, the Company amended the purchase price allocation related to its acquisition of certain Ohio operations based upon final valuations within the measurement period. As a result, $17,000 was re-allocated from Goodwill to Intangible assets, net on the Unaudited Condensed Consolidated Statements of Financial Position.

There was no amortization expense recorded for the six months ended June 30, 2023. Amortization expense associated with the Company’s intangible assets was $296 and $992 for the three and six months ended June 30, 2022, respectively.
Goodwill
The following table details the changes in the carrying amount of goodwill:
GoodwillTotal
December 31, 2022$13,761 
Acquisitions24,933 
June 30, 2023$38,694 
During the six months ended June 30, 2023, the Company recognized $24,933 of goodwill based on the preliminary purchase price allocation related to the acquisition of Northeast Patients Group. Refer to Note 3 for further discussion.
v3.23.2
INVESTMENTS
6 Months Ended
Jun. 30, 2023
Investments [Abstract]  
INVESTMENTS INVESTMENTS
The carrying values of the Company’s investments in the Unaudited Condensed Consolidated Statements of Financial Position as of June 30, 2023 and December 31, 2022 are as follows:
InvestmentsJune 30, 2023December 31, 2022
Investments held at FV-NI$33,287 $34,046 
Total long-term investments$33,287 $34,046 
Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations during the three and six months ended June 30, 2023 and 2022 is as follows:
Investment income (loss)Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Short-term investments$— $$— $
Investments held at FV-NI322 (998)(20)134 
Income (loss) from investments, net$322 $(996)$(20)$137 
Investments held at FV-NI
The Company has investments in equity of other companies that do not result in significant influence or control. These investments are carried at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.
As further described under the “6.10% Secured debenture due September 2030” in Note 10, on September 23, 2020, a subsidiary of the Company, Universal Hemp, LLC ("Universal Hemp") was advanced gross proceeds of $50,000 (less transaction costs) pursuant to the terms of a secured debenture. The Company subsequently engaged an investment advisor, which under the investment advisor's sole discretion, on September 28, 2020 invested $34,019 of these proceeds on behalf of Universal Hemp. As a result, Universal Hemp acquired 34,019 class B units, at $1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the institutional investor holds Class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The Class B units are held by the Investment Advisor as an agent for Universal Hemp.
Universal Hemp, through its investment with the Investment Advisor, was originally determined to hold significant influence in the Investment Partnership in accordance with ASC 810 due to (1) the economic financial interest, and (2) the entitlement to matters as they pertain to ‘Extraordinary Resolution’ items as defined within the Investment Partnership Agreement. As a result, the Company accounted for the investment in the Investment Partnership under the equity method until December 2020. Refer to Note 10 for further discussion. In December 2020, the Company no longer held significant influence due to the removal of the Extraordinary Resolution entitlements and other revisions in the Investment Partnership Agreement. As a result, the Company changed its accounting for the Investment Partnership to recognize the investment at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.
v3.23.2
NOTES RECEIVABLE, NET
6 Months Ended
Jun. 30, 2023
Receivables [Abstract]  
NOTES RECEIVABLE, NET NOTES RECEIVABLE, NET
Notes receivable as of June 30, 2023 and December 31, 2022 consisted of the following:
June 30, 2023December 31, 2022
Promissory notes receivable$7,212 $34,088 
Line of credit receivable4,3315,831
Interest receivable3,552 4,147 
Allowance for notes and interest receivable(15,095)(14,875)
Total notes receivable$ $29,191 
Less: Notes receivable, current— 29,191 
Notes receivable, non-current$— $— 
Interest income (loss) from loans receivable during the three and six months ended June 30, 2023 was $(6) and $10, respectively, and $365 and $782 for the three and six months ended June 30, 2022, respectively.
At each reporting date, the Company applies its judgment to evaluate the collectability of the note receivable and makes a provision based on the assessed amount of expected credit loss. This judgment is based on parameters such as interest rates, market conditions and creditworthiness of the creditor.
The Company determined that the collectability of certain notes receivables is doubtful based on information available. As of June 30, 2023 and December 31, 2022, the Company’s allowance for notes receivable of $15,095 and $14,875, respectively, included $11,543 and $12,041 of principal outstanding and $3,552 and $2,834 of accrued interest, respectively, and represents the full value of such loan balances.
Activity during the six months ended June 30, 2023

In January 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine and the amounts outstanding under the promissory notes receivable were converted into equity in Northeast Patients Group. Refer to Note 3 for further discussion.

In April 2023, the Company’s subsidiary Prime Alternative Treatment Center Consulting, LLC (“NH-PATCC”) received $1,500 from Prime Alternative Treatment Center, Inc. ("PATC") in settlement of the principal balance related to a promissory note that was extended to “PATC”.

In May 2023, the Company received a $500 cash payment towards the principal balance on a promissory note receivable from Grown Rogue.

Activity during the six months ended June 30, 2022

In February 2022, the Company received a $5,279 cash payment in full on a line of credit due from Patient Centric Martha’s Vineyard, and subsequently closed the line of credit.
v3.23.2
CAPITAL ASSETS, NET
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
CAPITAL ASSETS, NET CAPITAL ASSETS, NET
Net property, plant and equipment consisted of:
June 30, 2023December 31, 2022
Land$9,778 $9,605 
Building58,524 58,334 
Right-of-use asset, finance leases6,297 5,077 
Furniture, fixtures and equipment40,698 46,811 
Leasehold improvements49,587 6,178 
Construction in progress11,415 34,435 
Capital assets, gross$176,299 $160,440 
Less: accumulated depreciation and amortization(40,214)(27,035)
Capital assets, net$136,085 $133,405 
Depreciation of capital assets for the three and six months ended June 30, 2023 is comprised of $994 and $1,991 of depreciation expense, and $2,090 and $4,377 that was capitalized to inventory, respectively, and $2,868 and $3,980 of depreciation expense and $1,794 and $3,716 that was capitalized to inventory for the three and six months ended June 30, 2022, respectively.
During the six months ended June 30, 2022, the Company determined that it was unable to find a satisfactory buyer for the held-for-sale assets related to its Michigan operations and, as such, these assets were reclassified as held-and-used. This conclusion was considered a triggering event for capital asset impairment testing. Upon assessment, these specific capital assets were not considered to have future economic value. As such, the fair value of the assets was considered to be nil and the Company recognized an impairment charge of $1,907 within Impairments, net on the Statements of Operations during the six months ended June 30, 2022. Refer to Note 3 for further discussion on changes in held-for-sale entities.
v3.23.2
LEASES
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
LEASES LEASES
The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments and accounts for non-lease components separately from leases.
Balance Sheet InformationClassificationJune 30, 2023December 31, 2022
Right-of-use assets
OperatingOperating lease right-of-use assets$19,067 $22,443 
FinanceCapital assets, net4,690 4,269 
Total right-of-use assets$23,757 $26,712 
Lease liabilities
Current
OperatingOperating lease liability, current$2,268 $2,443 
FinancingDebt, current109 
Non-current
OperatingOperating lease liability, non-current18,839 21,692 
FinancingDebt, non-current5,860 5,305 
Total lease liabilities$27,076 $29,441 
Three Months Ended June 30,Six Months Ended June 30,
Statement of Operations InformationClassification2023202220232022
Short-term lease expenseGeneral and administrative$58 $170 $209 $218 
Operating lease expenseGeneral and administrative1,277 1,144 2,615 2,392 
Finance lease expense:
Amortization of right of use assetDepreciation and amortization92 64 185 127 
Interest expense on lease liabilitiesInterest expense211 329 420 541 
Net operating and finance lease cost$1,580 $1,537 $3,220 $3,060 
Six Months Ended June 30,
Statement of Cash Flows InformationClassification20232022
Cash paid for operating leasesNet cash used in operating activities$2,727 $2,447 
Cash paid for finance leases - interestNet cash used in operating activities$493 $522 
The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of June 30, 2023:
Maturity of lease liabilitiesOperating LeasesFinance Leases
2023$2,030 $453 
20244,153 923 
20254,098 946 
20264,307 969 
20273,890 992 
Thereafter13,267 11,705 
Total lease payments$31,745 $15,988 
Less: interest10,638 10,019 
Present value of lease liabilities$21,107 $5,969 
Weighted average remaining lease term (years)812
Weighted average discount rate10%12%
As of June 30, 2023, there have been no leases entered into that have not yet commenced.
LEASES LEASES
The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments and accounts for non-lease components separately from leases.
Balance Sheet InformationClassificationJune 30, 2023December 31, 2022
Right-of-use assets
OperatingOperating lease right-of-use assets$19,067 $22,443 
FinanceCapital assets, net4,690 4,269 
Total right-of-use assets$23,757 $26,712 
Lease liabilities
Current
OperatingOperating lease liability, current$2,268 $2,443 
FinancingDebt, current109 
Non-current
OperatingOperating lease liability, non-current18,839 21,692 
FinancingDebt, non-current5,860 5,305 
Total lease liabilities$27,076 $29,441 
Three Months Ended June 30,Six Months Ended June 30,
Statement of Operations InformationClassification2023202220232022
Short-term lease expenseGeneral and administrative$58 $170 $209 $218 
Operating lease expenseGeneral and administrative1,277 1,144 2,615 2,392 
Finance lease expense:
Amortization of right of use assetDepreciation and amortization92 64 185 127 
Interest expense on lease liabilitiesInterest expense211 329 420 541 
Net operating and finance lease cost$1,580 $1,537 $3,220 $3,060 
Six Months Ended June 30,
Statement of Cash Flows InformationClassification20232022
Cash paid for operating leasesNet cash used in operating activities$2,727 $2,447 
Cash paid for finance leases - interestNet cash used in operating activities$493 $522 
The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of June 30, 2023:
Maturity of lease liabilitiesOperating LeasesFinance Leases
2023$2,030 $453 
20244,153 923 
20254,098 946 
20264,307 969 
20273,890 992 
Thereafter13,267 11,705 
Total lease payments$31,745 $15,988 
Less: interest10,638 10,019 
Present value of lease liabilities$21,107 $5,969 
Weighted average remaining lease term (years)812
Weighted average discount rate10%12%
As of June 30, 2023, there have been no leases entered into that have not yet commenced.
v3.23.2
INVENTORY
6 Months Ended
Jun. 30, 2023
Inventory Disclosure [Abstract]  
INVENTORY INVENTORY
The Company’s inventory balance consists of the following:
June 30, 2023December 31, 2022
Retail inventory$3,714 $3,255 
Wholesale inventory36,478 35,885 
Cultivation inventory5,070 7,133 
Supplies & other2,676 3,173 
Total$47,938 $49,446 
Inventory is valued at the lower of cost and net realizable value (“NRV”), defined as estimated selling price in the ordinary course of business, less estimated costs of disposal. During the six months ended June 30, 2023, the Company analyzed its inventory balances, and recorded wholesale inventory adjustments as a result of (i) having excess or obsolete inventory and (ii) reducing the carrying value to ensure inventory balances are properly recorded at the lower of cost and NRV. The Company recognized $4,484 and $6,721 of wholesale inventory adjustments within Cost of goods sold, wholesale on the Statements of Operations for the three and six months ended June 30, 2023, respectively.
v3.23.2
DEBT
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
DEBT DEBT
The Company’s debt balances consist of the following:
Debt balancesJune 30, 2023December 31, 2022
Financing liability (failed sale-leaseback)$15,253 $15,253 
Finance lease liabilities5,969 5,306 
7.50% Loan due April 2026
31,549 31,288 
6.10% Secured debenture due September 2030
46,727 46,502 
Note due December 20242,375 3,167 
Prime rate credit facilities due January 2026, as amended129,982 113,564 
Note backed by ERTC12,113 — 
Total debt$243,968 $215,080 
Less: current portion of debt13,805 1,584 
Total long-term debt$230,163 $213,496 
Scheduled maturities of debt, excluding amortization of discount and issuance costs, are as follows:
2023$12,904 
20241,584 
2025— 
2026173,011 
202739 
Thereafter71,172 
Total payments (excluding amortization of discount and issuance costs)
$258,710 
During the three and six months ended June 30, 2023, the Company incurred interest expense of $8,862 and $16,936, respectively, and $5,520 and $10,301 during the three and six months ended June 30, 2022, respectively, on the Unaudited Condensed Consolidated Statements of Operations. Interest expense for the three and six months ended June 30, 2023 included debt discount amortization of $525 and $1,015, respectively, and amortization of debt issuance costs of $698 and $1,388, respectively. Interest expense for the three and six months ended June 30, 2022 included debt discount amortization of $377 and $751, respectively, and amortization of debt issuance costs of $294 and $552, respectively. As of June 30, 2023 and December 31, 2022, the Company had unamortized discount $5,578 and $6,093, respectively, and debt issuance costs of $9,164 and $10,522, respectively, which is netted against the gross carrying value of long-term debt in Debt, non-current on Unaudited Condensed Unaudited Condensed Consolidated Statements of Financial Position. Additionally, as of June 30, 2023 and December 31, 2022, the Company had accrued interest of $2,824 and $2,575, respectively, within Interest payable on the Unaudited Condensed Consolidated Statements of Financial Position.
Financing liability (failed sales leaseback)
In connection with the Company’s failed sale-leaseback transaction in November 2020, a financing liability was recognized equal to the cash proceeds received. The Company will recognize the cash payments made on the lease as interest expense, and the principal will be de-recognized upon expiration of the lease.

6.10% Secured debenture due September 2030
On September 23, 2020, pursuant to the implementation of the Amended Arrangement (Refer to Note 13 for further discussion), a subsidiary of Canopy Growth advanced gross proceeds of $50,000 (less transaction costs of approximately $4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture (“6.1% Loan”). In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. An additional $50,000 may be advanced pursuant to the debenture subject to the satisfaction of certain conditions by Universal Hemp. The debenture bears interest at a rate of 6.1% per annum, matures 10 years from the date hereof or such earlier date in accordance with the terms of the debenture and all interest payments made pursuant to the debenture are payable in cash by Universal Hemp. The debenture is secured by substantially all of the assets of Universal Hemp and its subsidiaries and, further, is not convertible and is not guaranteed by Acreage.
With a portion of the proceeds for the 6.1% Loan received by Universal Hemp, Acreage engaged an Investment Advisor which, under the Investment Advisor’s sole discretion, invested on behalf of Universal Hemp $34,019 on September 28, 2020. As a result, Universal Hemp acquired 34,019 class B units, at $1.00 par value per unit, which represented 100% financial interest in the Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Investment Advisor as an agent for Universal Hemp. Upon execution of the limited partnership agreement, $1,019 was distributed to the class A unit holders of the Investment Partnership.
7.50% Loan due April 2026
On September 28, 2020, the Company received gross proceeds of $33,000 (less transaction costs of approximately $959) from an affiliate of the Institutional Investor (the “Lender”) and used a portion of the proceeds of this loan to retire its short-term $11,000 convertible note (as described above) and its short-term note aggregating approximately $18,000 in October 2020, with the remainder being used for working capital purposes. The loan is unsecured, matures in 3 years and bears interest at a 7.5% annual interest rate. The Lender is controlled by the Institutional Investor. The Investment Partnership is the investor in the Lender. On December 16, 2021, the Company paid an amendment fee of $413 to extend the maturity date from September 28, 2023 to April 2, 2026. The amendment was treated as a debt extinguishment.

Note due December 2024

In November 2020, the Company issued a promissory note with a third party, which is non-interest bearing and payable based on a payment schedule with ten payments in the aggregate amount of $7,750 through December 31, 2024, as a result of a settlement described under the “CanWell Dispute” in Note 13.
Prime rate credit facilities due January 2026, as amended
On December 16, 2021, the Company entered into a $150,000 senior secured credit facility with a syndicate of lenders consisting of a $75,000 initial draw, a $25,000 delayed draw that must be advanced within 12 months and a $50,000 committed accordion facility that is available after December 1, 2022, provided certain financial covenants are met, and with a maturity of January 1, 2026. Upon closing, gross proceeds of $75,000 were drawn (before origination discounts and issuance costs of approximately $4,000 and $1,500, respectively, which were capitalized). In April 2022, the Company drew down on the $25,000 delayed draw. Refer to Note 14 for further discussion of the syndicated related party lender.

The Company obtained a waiver of the financial covenants for the three month periods ended March 31, 2022 and June 30, 2022. This waiver included a $500 waiver fee that was paid to the lenders

On October 24, 2022, the Company amended the senior secured credit facility such that $25,000 of the committed accordion was available for immediate draw by Acreage, which was drawn down in the fourth quarter of 2022, with the remaining $25,000 available from January 1, 2023, provided certain predetermined milestones are achieved. The Company paid an amendment fee of $1,250 to the syndicate of lenders and the amendment was treated as a debt modification.

On April 28, 2023, the Company reached an agreement with the lenders of the Prime rate credit facilities due January 2026 that would allow it to draw a further $15,000 under its current Credit Agreement, but such funds would be maintained in a segregated account until dispersed and be restricted for use to only eligible capital expenditures. As part of this agreement, the Company agreed to limit the total amounts outstanding under the Credit Agreement to $140,000 and to at all times subsequent to the amendment, maintain collateral (as defined in the Credit Agreement) equal to or greater than the outstanding amount under the Credit Agreement.

The loan is secured by pledged equity interests and substantially all of the assets of the Company. Advances under the facility bear interest at a variable rate of U.S. prime (“Prime”) plus 5.75% per annum, payable monthly in arrears, with a Prime floor of 5.50% plus an additional 1.0% per annum until certain collateral assignment agreements are delivered.

The facility has a maturity date of January 1, 2026 and the Company has the option to extend the maturity date to January 1, 2027 prior to January 1, 2024, for a fee equal to 1.0% of the total loan amount. If the Company chooses to extend the maturity date, it will also be required to make monthly installment payments, each of which shall be an amount equal to five percent per year of the outstanding amount of the loan.

The loan is subject to various financial covenants, including (i) a fixed charge coverage ratio and two leverage ratios in respect of all periods beginning on or after December 31, 2023 and (ii) a minimum cash requirement of $9.0 million at each quarter end of the Company. Finally, the Amended Credit Facility includes approval for Canopy USA to acquire control of Acreage without requiring repayment of all amounts outstanding under the Amended Credit Facility, provided certain conditions are satisfied. As of June 30, 2023 the Company was in compliance with all covenants.

ERTC Factoring Agreement
On April 11, 2023, the Company received $12,113 pursuant to a financing agreement with a third-party lender (the “Financing Agreement”), which is included in “Debt, current” as of June 30, 2023. The Company assigned to the lender its interests in
Employee Retention Tax Credits (“ERTC”) that it submitted for a claim of approximately $14,251. If the Company does not receive the ERTC, in whole or in part, the Company is required to repay the related portion of the funds received plus 10% interest accrued from the date of the Financing Agreement through the repayment date. The Financing Agreement does not have a stated maturity date and the discount is being accreted to interest expense over an expected term. The Company’s obligations under the Financing Agreement will be satisfied upon receipt of the ERTC or other full repayment. Finally, the Company determined the ERTC did not meet the criteria to record as a receivable as of June 30, 2023 due to the uncertain nature of such claims.
v3.23.2
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS
The table below details the change in Pubco shares outstanding by class for the three and six months ended June 30, 2023:

Shareholders’ EquityFixed SharesFloating SharesFixed Shares Held in TreasuryFloating Shares Held in TreasuryFixed Multiple SharesTotal Shares Outstanding
December 31, 202279,047 34,114 (589)(253)118 112,437 
Issuances607 159 — — — 766 
NCI conversions— — — — — — 
June 30, 202379,654 34,273 (589)(253)118 113,203 
Warrants
A summary of the warrants activity outstanding is as follows:

WarrantsFixed SharesFloating Shares
December 31, 20225,817 2,524 
Expired— — 
June 30, 20235,817 2,524 

The exercise price of each Fixed Share warrant ranged from $3.15 to $4.00, respectively, and the exercise price of each Floating Share warrant ranged from $3.01 to $4.00, respectively. The warrants are exercisable for a period of 4 years. The weighted-average remaining contractual life of the warrants outstanding is approximately 1.5 years. There was no aggregate intrinsic value for warrants outstanding as of June 30, 2023.
Non-controlling interests - convertible units
The Company has NCIs in consolidated subsidiaries USCo2 and HSCP. The non-voting shares of USCo2 and HSCP units make up substantially all of the NCI balance as of June 30, 2023 and are convertible for either 0.7 of a Fixed Share and 0.3 of a Floating Share of Pubco or cash, as determined by the Company. Summarized financial information of HSCP is presented below. USCo2 does not have discrete financial information separate from HSCP.
HSCP net asset reconciliationJune 30, 2023December 31, 2022
Current assets$94,126 $118,193 
Non-current assets261,072 237,665 
Current liabilities(6,986)(9,141)
Non-current liabilities(266,212)(239,525)
Other NCI balances(726)(725)
Accumulated equity-settled expenses(242,438)(240,760)
Net assets$(161,164)$(134,293)
HSCP/USCo2 ownership % of HSCP16.24 %16.33 %
Net assets allocated to USCo2/HSCP$(26,175)$(21,930)
Net assets attributable to other NCIs726 725 
Total NCI$(25,449)$(21,205)
Three Months Ended June 30,Six Months Ended June 30,
HSCP Summarized Statement of Operations2023202220232022
Net loss allocable to HSCP/USCo2$(12,801)$(3,958)$(22,403)$(11,040)
HSCP/USCo2 weighted average ownership % of HSCP16.28 %16.98 %16.29 %17.13 %
Net loss allocated to HSCP/USCo2$(2,084)$(672)$(3,650)$(1,891)
Net loss allocated to other NCIs— (2)(1)— 
Net loss attributable to NCIs$(2,084)$(674)$(3,651)$(1,891)
As of June 30, 2023, USCo2’s non-voting shares owned approximately 0.22% of HSCP units. USCo2’s capital structure is comprised of voting shares, all of which are held by the Company, and of non-voting shares held by certain former HSCP members. Certain executive employees and profits interests holders own approximately 16.07% of HSCP units. The remaining 83.71% interest in HSCP is held by USCo and represents the members’ equity attributable to shareholders of the parent.
A reconciliation of the beginning and ending amounts of convertible units is as follows:
Convertible UnitsJune 30, 2023December 31, 2022
Beginning balance22,698 23,076 
NCI units converted to Pubco— (378)
Ending balance22,698 22,698 
v3.23.2
EQUITY-BASED COMPENSATION EXPENSE
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
EQUITY-BASED COMPENSATION EXPENSE EQUITY-BASED COMPENSATION EXPENSE
Amended Arrangement with Canopy Growth
On September 23, 2020, the Company announced the implementation of the Amended Arrangement (as defined in Note 13). Pursuant to the Amended Arrangement, the Company’s articles have been amended to create new Fixed Shares, Floating Shares and Fixed Multiple Shares. Consequently, the Company’s equity-based compensation was modified into new equity awards of the Company. Refer to Note 13 for further discussion.

Equity-based compensation - Plan (Acreage Holdings, Inc. Omnibus Incentive Plan)
In connection with the RTO transaction, the Company’s Board of Directors adopted an Omnibus Incentive Plan, as amended September 23, 2020 (the “Plan”), which permits the issuance of stock options, stock appreciation rights, stock awards, share units, performance shares, performance units and other stock-based awards up to an amount equal to 15% of the issued and outstanding Subordinate Voting Shares of the Company.
Pursuant to the Amended Arrangement, the Company retained the Plan described above, the upper limit of issuances being up to an amount equal to 15% of the issued and outstanding Fixed Shares and Floating Shares of the Company. As of June 30, 2023, the Company had 5,308 shares authorized and available for grant under the Plan.
Restricted Share Units (“RSUs”)

Fixed SharesFloating Shares
Restricted Share Units
(Fair value information expressed in whole dollars)
RSUsWeighted Average Grant Date Fair ValueRSUsWeighted Average Grant Date Fair Value
Unvested, January 1, 20236,324 $1.80 464 $6.68 
Granted— $— — $— 
Forfeited(245)$1.00 (1)$2.15 
Vested(711)$2.50 (228)$2.59 
Unvested, June 30, 2023
5,368 $1.75 235 $10.65 
Vested and unreleased(1)
21 $15.31 11 $17.35 
Outstanding, June 30, 2023
5,389 $1.80 246 $10.94 
(1) RSUs that are vested and unreleased represent RSUs that are pending delivery.
RSUs of the Company generally vest over a period of three years and RSUs granted to certain executives vest based on achievement of specific performance conditions. In certain situations for specified individuals, RSUs vest on an accelerated basis on separation. The fair value for RSUs is based on the Company’s share price on the date of the grant. The Company recorded $470 and $1,228 as Equity-based compensation expense on Unaudited Condensed Consolidated Statements of Operations during the three and six months ended June 30, 2023, respectively, and $1,512 and $5,389 during the three and six months ended June 30, 2022, respectively. The fair value of RSUs vested during the three and six months ended June 30, 2023 was $157 and $599, respectively, and $1,451 and $3,333 during the three and six months ended June 30, 2022, respectively.
The total weighted average remaining contractual life and aggregate intrinsic value of unvested RSUs as of June 30, 2023 was approximately 1.7 years and $962, respectively. Unrecognized compensation expense related to these awards at June 30, 2023 was $10,471 and is expected to be recognized over a weighted average period of approximately 1.5 years.
Stock options
Fixed SharesFloating Shares
Stock Options
(Exercise price expressed in whole dollars)
OptionsWeighted Average Exercise PriceOptionsWeighted Average Exercise Price
Options outstanding, January 1, 20237,337 $2.75 2,267 $3.10 
Granted— $— — $— 
Forfeited— $— — $— 
Expired— $— (35)$2.55 
Options outstanding, June 30, 2023
7,337 $2.75 2,232 $3.11 
Options exercisable, June 30, 2023
1,834 $9.14 2,101 $3.10 
Stock options of the Company generally vest over a period of three years and options granted to certain executives vest based on achievement of specific performance conditions. Stock options of the Company have an expiration period of 5 or 10 years from the date of grant. The weighted average contractual life remaining for Fixed Share options outstanding and exercisable as of June 30, 2023 was approximately 4.5 and 6 years, respectively. The weighted average contractual life remaining for Floating Share options outstanding and exercisable as of June 30, 2023 was approximately 6 and 6 years, respectively. The Company recorded $224 and $450 as Equity-based compensation expense on Unaudited Condensed Consolidated Statements of Operations during the three and six months ended June 30, 2023 and $143 and $425 during the three and six months ended June 30, 2022, respectively, in connection with these awards.

As of June 30, 2023, unamortized expense related to stock options totaled $1,447 and is expected to be recognized over a weighted-average period of approximately 2 years. As of June 30, 2023, the aggregate intrinsic value for unvested options and for vested and exercisable options was nil, respectively.
v3.23.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Commitments
The Company provides revolving lines of credit to certain of its portfolio companies. As of June 30, 2023, only one revolving line of credit remained outstanding and the maximum obligation under this arrangement was equal to the balance advanced of $4,331 (refer to Note 6 for further discussion).

Prior Plan of Arrangement with Canopy Growth

On June 19, 2019, the shareholders of the Company and of Canopy Growth separately approved the proposed plan of arrangement (the “Prior Plan of Arrangement”) involving the two companies, and on June 21, 2019, the Supreme Court of British Columbia granted a final order approving the Prior Plan of Arrangement. Effective June 27, 2019, the articles of the Company were amended pursuant to the Prior Plan of Arrangement to provide that, upon the occurrence (or waiver by Canopy Growth) of the Triggering Event, subject to the satisfaction of the conditions set out in the arrangement agreement entered into between Acreage and Canopy Growth on April 18, 2019, as amended on May 15, 2019 (the “Original Arrangement
Agreement”), Canopy Growth will acquire (the “Acquisition”) all of the issued and outstanding shares in the capital of the Company (each, an “Acreage Share”).
Second Amendment to the Arrangement Agreement with Canopy Growth
On September 23, 2020, Acreage and Canopy Growth entered into an amending agreement (the “Amending Agreement” or “Amended Arrangement”) (and together with the Original Arrangement Agreement and any further amendments thereto, the “Amended Plan of Arrangement”) and the Amended Arrangement became effective at 12:01 a.m. (Vancouver time) (the “Amendment Time”) on September 23, 2020 (the “Amendment Date”). Pursuant to the Amended Plan of Arrangement, Canopy Growth made a cash payment of $37,500 which was delivered to Acreage’s shareholders and certain holders of securities convertible or exchangeable into shares of Acreage. Acreage also completed a capital reorganization (the “Capital Reorganization”) effective as of the Amendment Time whereby: (i) each existing SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share; (ii) each issued and outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and (iii) each issued and outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share.
At the Amendment Time, each option, restricted share unit, compensation option, and warrant to acquire existing SVS (each a “Security”) that was outstanding immediately prior to the Amendment Time, was exchanged for a replacement Security to acquire Fixed Shares (a “Fixed Share Replacement Security”) and a replacement Security to acquire Floating Shares (a “Floating Share Replacement Security”) to account for the Capital Reorganization.
Pursuant to the Amended Plan of Arrangement, upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event (the “Triggering Event Date”), Canopy Growth will, subject to the satisfaction or waiver of certain closing conditions set out in the Arrangement Agreement: (i) acquire all of the issued and outstanding Fixed Shares (following the mandatory conversion of the Fixed Multiple Shares into Fixed Shares) on the basis of 0.3048 of a common share of Canopy Growth (each whole common share, a “Canopy Growth Share”) for each Fixed Share held (the “Fixed Exchange Ratio”) at the time of the acquisition of the Fixed Shares (the “Acquisition Time”), subject to adjustment in accordance with the terms of the Amended Plan of Arrangement (the “Canopy Call Option”). The Canopy Call Option and the Floating Call Option will expire 10 years from the Amendment Time.
At the Acquisition Time, on the terms and subject to the conditions of the Amended Plan of Arrangement, each Fixed Share Replacement Security will be exchanged for a replacement Security from Canopy Growth equal to: (i) the number of Fixed Shares that were issuable upon exercise of such Fixed Share Replacement Security immediately prior to the Acquisition Time, multiplied by (ii) the Fixed Exchange Ratio in effect immediately prior to the Acquisition Time (provided that if the foregoing would result in the issuance of a fraction of a Canopy Growth Share, then the number of Canopy Growth Shares to be issued will be rounded down to the nearest whole number).
The Amended Plan of Arrangement provides for, among other things, Amendments to the definition of Purchaser Approved Share Threshold (as defined therein) to change the number of shares of Acreage available to be issued by Acreage without an adjustment in the Fixed Exchange Ratio such that Acreage may issue a maximum of 32,700 shares. Furthermore, Acreage generally may not issue any equity securities without Canopy Growth’s prior consent. Additionally, the Amended Plan of Arrangement allows for various Canopy Growth rights that extend beyond the Acquisition Date, including, among others: (i) rights to nominate a majority of Acreage’s Board of Directors following the Acquisition Time; (ii) restrictive covenants in respect of the business conduct in favor of Canopy Growth; (iii) termination of non-competition and exclusivity rights granted to Acreage by Canopy Growth in the event that Acreage does not meet certain specified financial targets; (iv) implementation of further restrictions on Acreage’s ability to operate its business in the event that Acreage does not meet certain specified financial targets; and (v) termination of the Amended Plan of Arrangement in the event that Acreage does not meet certain specified financial targets in the trailing 12 month period. Each of the financial targets referred to above is specified in the Amending Agreement and related to the performance of Acreage relative to a business plan for Acreage for each fiscal year ended December 31, 2020 through December 31, 2029 set forth in the Proposal Agreement (the “Initial Business Plan”).

Further, the Amended Plan of Arrangement imposes restrictions on Acreage entering into any contracts in respect of Company Debt if: (i) such contract would be materially inconsistent with market standards for companies operating in the United States cannabis industry; (ii) such contract prohibits a prepayment of the principal amount of such Company Debt; and (iii) such contract would provide for interest payments to be paid through the issuance of securities as opposed to cash, among other restrictions. The Amended Plan of Arrangement also provides for the following: (i) certain financial reporting obligations to Canopy Growth; (ii) certain specified criteria related to any new directors or officers of Acreage, and (iii) a limit to Acreage’s operations to the Identified States (as defined therein).
Third Amendment to the Arrangement Agreement with Canopy Growth
On October 24, 2022, the Company entered into an arrangement agreement (the “Floating Share Agreement”) with Canopy Growth and Canopy USA, LLC (“Canopy USA”), Canopy Growth’s newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the “Floating Shares”) and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the “Floating Share Arrangement”) for consideration of 0.4500 of a common share of Canopy Growth (each whole share a “Canopy Share”) in exchange for each Floating Share. A special meeting of the holders of Floating Shares was held on March 15, 2023, where the holders of Floating Shares approved the Floating Share Arrangement (the “Special Meeting”).
Concurrently with entering the Floating Share Agreement, Canopy Growth irrevocably waived its option to acquire the Floating Shares pursuant to the Amended Arrangement.
Subject to the provisions of the Floating Share Agreement, Canopy Growth has agreed to exercise the fixed option pursuant to the Amended Agreement to acquire all outstanding Fixed Shares, representing approximately 70% of the total shares of Acreage as at the date hereof, at a fixed exchange ratio of 0.3048 of a Canopy Share for each Fixed Share.
Acreage expects the Floating Share Arrangement to close upon the satisfaction or waiver of all conditions under the Floating Share Agreement and the Amended Arrangement. It is anticipated that the acquisition by Canopy USA of the Fixed Shares pursuant to the Fixed Option will be completed immediately following closing of the Floating Share Agreement. In the event that Canopy USA exercises the Fixed Option and acquires the Floating Shares pursuant to the Floating Share Arrangement, Acreage will be wholly-owned subsidiary of Canopy USA.
On March 17, 2023, Acreage, Canopy and Canopy USA entered into a first amendment to the Floating Share Arrangement Agreement (the “First Amendment”). Pursuant to the terms of the First Amendment, Acreage, Canopy and Canopy USA agreed to amend the Exercise Outside Date (as defined in the Floating Share Arrangement Agreement) from March 31, 2023 to May 31, 2023. On May 31, 2023, the parties entered into a second amendment to the Floating Share Arrangement, further extending the Exercise Outside date from May 31, 2023 to August 31, 2023.

Tax Receivable Agreement and Tax Receivable Bonus Plans
The Company is a party to (i) a tax receivable agreement dated November 14, 2018 and subsequently amended (the “Tax Receivable Agreement”) between the Company and certain current and former unit holders of HSCP and (ii) tax receivable bonus plans dated November 14, 2018 and subsequently amended (the “Tax Receivable Bonus Plans”) between the Company and certain directors, officers and consultants of the Company (together the “Tax Receivable Recipients”). Under the Tax Receivable Agreement and the Tax Receivable Bonus Plans, the Company is required to make cash payments to the Tax Receivable Recipients equal to 85% of the tax benefits, if any, that the Company actually realizes, or in certain circumstances is deemed to realize, as a result of (i) the increases in its share of the tax basis of assets of HSCP resulting from any redemptions or exchanges of Units from the HSCP Members, and (ii) certain other tax benefits related to the Company making payments under the Tax Receivable Agreement and the Tax Receivable Bonus Plan. Although the actual timing and amount of any payments that the Company makes to the Tax Receivable Recipients cannot be estimated, it expects those payments will be significant. Any payments made by the Company to the Tax Receivable Recipients may generally reduce the amount of overall cash flow that might have otherwise been available to it. Payments under the Tax Receivable Agreement are not conditioned on any Tax Receivable Recipient’s continued ownership of Units or our shares after the completion of the RTO. Payments under the Tax Receivable Bonus Plan may, at times, be conditioned on the Tax Receivable Recipient’s continued employment by the Company. As of June 30, 2023, the Company has not made any payments in relation to the Tax Receivable Agreement or the Tax Receivable Bonus Plans.

Concurrently with the execution of the Floating Share Arrangement Agreement, Canopy Growth, Canopy USA, High Street, Acreage Holdings America, Inc. and certain individuals party to the Tax Receivable Agreement, amended the Tax Receivable Agreement in accordance with the Floating Share Agreement. Pursuant to the Floating Share Agreement, Canopy Growth, on behalf of Canopy USA agreed to: (i) issue Canopy Shares with a value of approximately $30,500 to the Tax Receivable Agreement Members in exchange for each such individual executing an assignment of rights agreement assigning such individual’s rights under the Tax Receivable Agreement to Canopy USA, such that following assignment, Canopy USA is the sole member and beneficiary under the Tax Receivable Agreement; and (ii) fund a payment with a value of approximately $19,500 to be made by the Company in Canopy Shares to certain eligible participants pursuant to the Tax Receivable Bonus Plans, as amended on October 24, 2022, both in order to reduce a potential liability of approximately $121,000 under the Tax Receivable Agreement and the Tax Receivable Bonus Plans. In connection with the foregoing, Canopy Growth issued 5,648,927 Canopy Shares on or about November 4, 2022 and 7,102,081 Canopy Shares on or about March 17, 2023 to the Tax Receivable Agreement Members. In addition, the Tax Receivable Agreement Bonuses with an aggregate value of approximately $19,500 in Canopy Shares will be issued by Canopy to certain eligible participants under the Tax Receivable
Bonus Plans on the closing of the Floating Share Arrangement or, if the Floating Share Arrangement does not close or is terminated but the Amended Arrangement closes, then on the closing of the acquisition. The Tax Receivable Agreement Bonuses will be paid to recipients to be determined by Kevin Murphy, the administrator of the Tax Receivable Bonus Plans, and may include one or more of Kevin Murphy, John Boehner, Brian Mulroney, and Peter Caldini, each of whom are directors of Acreage and other current and former officers or consultants of Acreage as may be determined by Kevin Murphy. Canopy Growth has also agreed to register the resale of such Canopy Shares under the Securities Act of 1933, as amended.
Debenture

In connection with the implementation of the Amended Arrangement, pursuant to a secured debenture dated September 23, 2020 (the “Debenture”) issued by Universal Hemp, LLC, an affiliate of Acreage that operates solely in the hemp industry in full compliance with all applicable laws (the “Borrower”), to 11065220 Canada Inc., an affiliate of Canopy Growth (the “Lender”), the Lender agreed to provide a loan of up to $100,000 (the “Loan”), $50,000 of which was advanced on the Amendment Date (the “Initial Advance”), and $50,000 of the Loan will be advanced in the event that the following conditions, among others, are satisfied: (a) the Borrower’s EBITDA (as defined in the Debenture) for any 90 day period is greater than or equal to 2.0 times the interest costs associated with the Initial Advance; and (b) the Borrower’s business plan for the 12 months following the applicable 90 day period supports an Interest Coverage Ratio (as defined in the Debenture) of at least 2.00:1.
The principal amount of the Loan will bear interest from the date of advance, compounded annually, and be payable on each anniversary of the date of the Debenture in cash in U.S. dollars at a rate of 6.1% per annum. The Loan will mature 10 years from the date of the Initial Advance.
The Loan must be used exclusively for U.S. hemp-related operations and on the express condition that such amount will not be used, directly or indirectly, in connection with or for the operation or benefit of any of the Borrower’s affiliates other than subsidiaries of the Borrower exclusively engaged in U.S. hemp-related operations and not directly or indirectly, towards the operation or funding of any activities that are not permissible under applicable law. The Loan proceeds must be segregated in a distinct bank account and detailed records of debits to such distinct bank account will be maintained by the Borrower.

No payment due and payable to the Lender by the Borrower pursuant to the Debenture may be made using funds directly or indirectly derived from any cannabis or cannabis-related operations in the United States, unless and until the Triggering Event Date.
The Debenture includes usual and typical events of default for a financing of this nature, including, without limitation, if: (i) Acreage is in breach or default of any representation or warranty in any material respect pursuant to the Arrangement Agreement; (ii) Operations deemed to be non-core must cease within 18 months from the Amendment Date; and (iii) Acreage fails to perform or comply with any covenant or obligation in the Arrangement Agreement which is not remedied within 30 days after written notice is given to the Borrower by the Lender. The Debenture also includes customary representations and warranties, positive covenants and negative covenants of the Borrower.

Advisor fee

In connection with the Prior Plan of Arrangement, the Company entered into an agreement with its financial advisor providing for a fee payment of $7,000 in either cash, Acreage shares or Canopy Growth shares, at the discretion of the Company, upon the successful acquisition of Acreage by Canopy Growth. During the fourth quarter of 2022, the Company amended the terms of the agreement with its financial advisors providing for a fee payment of $3,000 in cash, less a $500 initial payment, and $2,000 in shares of the Company, upon the successful acquisition of Acreage by Canopy Growth.

Surety bonds

The Company has indemnification obligations with respect to surety bonds primarily used as security against non-performance in the amount of $5,000 as of June 30, 2023, for which no liabilities are recorded on the Unaudited Condensed Consolidated Statements of Financial Position.
The Company is subject to other capital commitments and similar obligations. As of June 30, 2023 and 2022, such amounts were not material.
CanWell Settlement
In November 2020, the Company entered into a final confidential settlement agreement with CanWell, LLC for certain outstanding proceedings. As part of that agreement, the Company accrued for $7,750 in Legal settlements, net on the Statements of Operations for the year ended December 31, 2020. In connection with this settlement agreement, the Company issued a promissory note in the amount of $7,750 to CanWell, which is non-interest bearing and is payable in periodic payments through December 31, 2024. Through June 30, 2023, the Company has paid $5,375 of the promissory note.

Contingencies
The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company’s applicable subsidiaries ceasing operations. While management of the Company believes that the Company’s subsidiaries are in compliance with applicable local and state regulations as of June 30, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company’s subsidiaries may be subject to regulatory fines, penalties, or restrictions in the future.
The Company and its subsidiaries may be, from time to time, subject to various administrative, regulatory and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated.
New York outstanding litigation

On November 2, 2018, EPMMNY LLC (“EPMMNY”) filed a complaint in the Supreme Court of the State of New York, County of New York, asserting claims against 16 defendants, including NYCANNA, Impire State Holdings LLC (“Impire”), NY Medicinal Research & Caring, LLC (“NYMRC”) (each, a wholly owned subsidiary of High Street) and High Street. The Index Number for the action is 655480/2018. EPMMNY alleges that it was wrongfully deprived of a minority equity interest and management role in NYCANNA by its former partner, New Amsterdam Distributors, LLC (“New Amsterdam”), which attempted to directly or indirectly sell or transfer EPMMNY’s alleged interest in NYCANNA to other entities in 2016 and 2017, including Impire, NYMRC and High Street.

EPMMNY alleges that it is entitled to the value of its alleged minority interest in NYCANNA or minority ownership in NYCANNA. EPMMNY also alleges that certain defendants misused its alleged intellectual property and/or services, improperly solicited its employees, and aided and abetted or participated in the transfer of equity and/or business opportunities from EPMMNY.

High Street, along with the other Defendants, filed motions to dismiss on April 1, 2019. The motions were fully briefed and submitted to the Court as of July 18, 2019, and oral argument was heard on September 6, 2019. Following a hearing held during April 2022, in ruling on one dismissal argument advanced by several Defendants, the Court ruled that Plaintiff had the capacity to bring this action on behalf of EPMMNY. On July 13, 2023, the Court ruled on the remaining dismissal arguments, granting the vast majority of them. As part of its ruling, the Court dismissed without prejudice every claim against NYCANNA, Impire, NYMRC, and High Street, except the claims for unjust enrichment and quantum meruit (which also were permitted to proceed against other Defendants). The only other claim that the Court did not dismiss was for breach of contract against New Amsterdam.
On July 24, 2023, EPMMNY moved for leave to file a proposed amended complaint. The proposed amended complaint names several defendants, including NYCANNA, Impire, NYMRC, High Street, and Kevin Murphy, and contains similar allegations to those in the original complaint. High Street intends to oppose the motion for leave to amend and,if necessary, move to dismiss the new complaint.
High Street intends to continue vigorously defend this action, which the Company firmly believes is without merit. High Street also believes it is entitled to full indemnity from the claims asserted against it by EPMMNY pursuant to the purchase agreement pertaining to its acquisition of NYCANNA and personal guarantee by the largest shareholders of the seller.
Health Circle, Inc. litigation
On April 13, 2023, Health Circle, Inc., a licensed cannabis dispensary operator in Massachusetts, initiated a civil action against the Company and MA RMD SVCS, LLC in Plymouth County, Massachusetts for alleged breaches of that certain Revolving Line of Credit, dated October 31, 2017, by and between Health Circle, Inc. and MA RMD SVCS, LLC (the “HCI Credit Agreement”) and certain torts. High Street has filed a second civil action against Michael Westort, individually, in the Business Litigation Section, located in Boston, MA, predicated upon that certain Membership Interest Purchase Agreement, dated June
30, 2018, by and between Mr. Westort and High Street. The Company previously moved to dismiss the complaint in Plymouth County, which was recently amended. The Company is assessing the amended complaint, and will file counterclaims against Health Circle, Inc. based on the outstanding debt under the HCI Credit Agreement. High Street intends to vigorously defend against this action, which the Company believes is without merit, and to pursue its claims against Mr. Westort and Health Circle, Inc.
Alfred’s Finest, Inc. arbitration
On June 22, 2023, Alfred’s Finest, Inc. (“AFI”) filed a demand for arbitration relating to that certain Asset Purchase Agreement, dated June 24, 2021, by and between Alfred’s Finest, Inc., Robert M. Andrews, Jr and The Botanist, Inc., a wholly owned subsidiary of High Street, and the Company (the “AFI APA”). The AFI APA provided for the payment of $2,000 to AFI upon closing and an additional $3,000 payable on or before the 18-month anniversary of the closing date. Pursuant to its termination rights provided under the APA, the Company sent a notice of termination of the AFI APA on June 29, 2022 before the closing occurred. AFI alleges that the Company breached the terms of the APA and claims that the notice of termination sent by the Company has no basis in the language of the AFI APA. AFI is seeking relief from the Company consisting of specific performance of the AFI APA and recovery of its damages, including arbitration fees and costs. The Company believes the plain language of the AFI APA supports its position and intends to vigorously defend this action, which the Company believes is without merit. The Company has filed a counterclaim against AFI for breach of the AFI APA based on AFI’s failure to act in good faith as required by the AFI APA.
On June 28, 2023, in response to AFI’s demand for arbitration, the Company asserted its right under the AFI APA to submit the dispute to mediation before it proceeds to arbitration. The parties are in the process of scheduling the mediation and identifying a mediator.
v3.23.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
Transactions with related parties are entered into in the normal course of business and are measured at the amount established and agreed to by the parties.
6.10% Secured debenture due September 2030
As disclosed in Note 10, “6.10% Secured debenture due September 2030”, on September 23, 2020, pursuant to the implementation of the Amended Arrangement, a subsidiary of Canopy Growth advanced gross proceeds of $50,000 (less transaction costs of approximately $4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture. In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. Acreage then engaged an investment advisor (the “Investment Advisor”) which, under the Investment Advisor’s sole discretion, invested on behalf of Universal Hemp, $34,019 of the proceeds on September 28, 2020. During the three and six months ended June 30, 2023, the Company incurred interest expense attributable to the 6.10% Secured debenture due September 2030 of $763.

As a result of the transaction above, Universal Hemp, a subsidiary of the Company, acquired 34,019 class B units, at $1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds Class A Units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Institutional Investor as agent for Universal Hemp. On September 28, 2020, the Company received gross proceeds of $33,000 (less transaction costs of approximately $959) from an affiliate of the Institutional Lender (the “Lender”) and used a portion of the proceeds of this loan to retire its short-term $11,000 convertible note and its short-term note aggregating approximately $18,000 in October 2020, with the remainder being used for working capital purposes. The Lender is controlled by the Institutional Lender. The Investment Partnership is the investor in the Lender.

Prime rate credit facilities due January 2026, as amended
On December 16, 2021, the Company entered into the Prime rate credit facilities due January 2026 with a syndicate of lenders, including Viridescent Realty Trust, Inc. (“Viridescent”), an entity controlled by Kevin Murphy. Refer to Note 10 for further discussion. On October 24, 2022, the Company amended these credit facilities and the Company paid an amendment fee of $1,250 to the lenders, with $375 paid to Viridescent. On April 28, 2023, the Company and the lenders further amended the Prime rate credit facilities. Refer to Note 10 for further discussion.
Viridescent has committed $42,000 of the $140,000 drawn down under the Credit Facility, with third-party syndicated affiliates committing the additional $98,000. During the six months ended June 30, 2023, the Company incurred interest expense attributable to Viridescent of $2,690. The loan is secured by first-lien mortgages on Acreage’s wholly owned real estate and other commercial security interests. A third-party syndicate served as Administrative Agent for the transaction.
v3.23.2
REPORTABLE SEGMENTS
6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
REPORTABLE SEGMENTS REPORTABLE SEGMENTSThe Company prepares its segment reporting on the same basis that its Chief Operating Decision Maker manages the business, and makes operating decisions. The Company operates under one operating segment, which is its only reportable segment: the production and sale of cannabis products. The Company’s measure of segment performance is net income, and derives its revenue primarily from the sale of cannabis products, as well as related management or consulting services which were not material in all periods presented. All of the Company’s operations are located in the United States.
v3.23.2
EARNINGS PER SHARE
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
Basic earnings per share are computed by dividing net loss attributable to common shareholders of the Company by the weighted average number of outstanding shares for the period. Diluted earnings per share are calculated based on the weighted number of outstanding common shares plus the dilutive effect of stock options and warrants, as if they were exercised, and restricted stock units and profits interests, as if they vested and NCI convertible units, as if they converted.

Basic and diluted loss per share is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Net loss attributable to common shareholders of the Company$(16,156)$(9,929)$(30,746)$(22,623)
Weighted average shares outstanding - basic112,810 108,230 112,679 107,569 
Effect of dilutive securities— — — — 
Weighted average shares - diluted112,810 108,230 112,679 107,569 
Net loss per share attributable to common shareholders of the Company - basic$(0.14)$(0.09)$(0.27)$(0.21)
Net loss per share attributable to common shareholders of the Company - diluted$(0.14)$(0.09)$(0.27)$(0.21)
During the six months ended June 30, 2023, 5,817 Fixed warrants, 2,524 Floating warrants, 5,389 Fixed Share RSUs, 246 Floating Share RSUs, 7,337 Fixed Share stock options, 2,232 Floating Share stock options and 22,698 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive. During the six months ended June 30, 2022, 5,817 Fixed warrants, 2,524 Floating warrants, 1,604 Fixed Share RSUs, 652 Floating Share RSUs, 1,493 Fixed Share stock options, 2,306 Floating Share stock options and 23,076 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive.
v3.23.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTSManagement has reviewed all events subsequent to June 30, 2023 through the date of issuing these financial statements and determined that no further subsequent events require adjustment or disclosure.
v3.23.2
SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of presentation and going concern
Basis of presentation and going concern

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair presentation have been reflected in these unaudited condensed consolidated financial statements. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any other period.

As reflected in the unaudited condensed consolidated financial statements, the Company had an accumulated deficit as of June 30, 2023, as well as a net loss and negative cash flow from operating activities for the six months ended June 30, 2023. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements.

However, management believes that substantial doubt about the Company’s ability to meet its obligations for the next twelve months from the date these financial statements are issued, can be mitigated by, but not limited to, (i) expected long-term sales growth from the Company’s consolidated operations, (ii) latitude as to the timing and amount of certain operating expenses as well as capital expenditures, (iii) expense reduction plans that have already been put in place to improve the Company’s results, (iv) access to the U.S. and Canadian public equity markets.

If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its footprint build-out or other operational activities until such time as additional capital becomes available. Such limitation of the Company’s activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase the Company’s need to raise additional capital on an immediate basis.

These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, dated May 1, 2023, as filed with the Securities and Exchange Commission (the “2022 Form 10-K”).
Use of estimates
Use of estimates

Preparation of financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the dates presented and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates. Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include the fair value of assets acquired and liabilities assumed in business combinations, assumptions relating to equity-based compensation expense, estimated useful lives for property, plant and equipment and intangible assets, the valuation allowance against deferred tax assets and the assessment of potential charges on goodwill, intangible assets and investments in equity and notes receivable.
Emerging growth company
Emerging growth company
The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.
Functional and presentation currency
Functional and presentation currency

The unaudited condensed consolidated financial statements and the accompanying notes are expressed in U.S. dollars. Financial metrics are presented in thousands. Other metrics, such as shares outstanding, are presented in thousands unless otherwise noted.
Basis of consolidation
Basis of consolidation

The Company’s unaudited condensed consolidated financial statements include the accounts of Acreage, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in business entities in which Acreage lacks control but is able to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations.
Non-controlling interests (“NCI”)
Non-controlling interests (“NCI”)

Non-controlling interests represent ownership interests in consolidated subsidiaries by parties that are not shareholders of Pubco. They are shown as a component of Total equity in the Unaudited Condensed Consolidated Statements of Financial Position, and the share of loss attributable to non-controlling interests is shown as a component of Net loss in the Unaudited Condensed Consolidated Statements of Operations. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions.
Cash and cash equivalents
Cash and cash equivalents

The Company defines cash equivalents as highly liquid investments held for the purpose of meeting short-term cash commitments that are readily convertible into known amounts of cash, with original maturities of three months or less. The Company maintains cash with various U.S. banks and credit unions with balances in excess of the Federal Deposit Insurance Corporation and National Credit Union Share Insurance Fund limits, respectively. The failure of a bank or credit union where the Company has significant deposits could result in a loss of a portion of such cash balances in excess of the insured limit, which could materially and adversely affect the Company’s business, financial condition, results of operations and the market price of the Company’s Fixed Shares and Floating Shares. Cash and cash equivalents belonging to entities the Company has classified as held-for-sale have been reclassified to Assets held-for-sale on the Unaudited Condensed Consolidated Statements of Financial Position. Refer to Note 3 for further discussion.
Accounts receivable and notes receivable valuations Accounts receivable and notes receivable valuationsThe Company reports accounts receivable at their net realizable value, which is management’s best estimate of the cash that will ultimately be received from customers. The Company's notes receivable represent notes due from various third parties. The Company maintains an allowance for expected credit losses to reflect the expected uncollectability of accounts receivable and notes receivable based on historical collection data and specific risks identified among uncollected accounts, as well as management’s expectation of future economic conditions. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the companies receivables and the expected future losses. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Trade accounts receivable and notes receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible.
Net loss per share Net loss per shareNet loss per share represents the net loss attributable to shareholders divided by the weighted average number of shares outstanding during the period on an as converted basis. Basic and diluted loss per share are the same as of June 30, 2023, 2022 and 2021, as the issuance of shares upon conversion, exercise or vesting of outstanding units would be anti-dilutive in each period.
Accounting Pronouncements Recently Adopted and Accounting Pronouncements Not Yet Adopted
Accounting Pronouncements Recently Adopted
As of January 1, 2023, the Company adopted ASU 2016-13 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which was subsequently revised by ASU 2018-19 and ASU 2020-02. This standard applies to financial assets, measured at amortized cost, including loans, held-to-maturity debt securities, net investments in leases and trade accounts receivable. The guidance must be adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings in the period of adoption. The adoption of ASU 2016-13 did not have a material effect on the Company’s unaudited condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted
In October 2021, the FASB issued ASU 2021-08 - Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The new standard requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606 - Revenue from Contracts with Customers. The ASU will be effective for the Company’s first interim period of fiscal 2024. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company does not anticipate a material impact on the Company’s unaudited condensed consolidated financial statements upon adoption.
Restricted cash Restricted cashRestricted cash represents funds contractually held for specific purposes and, as such, not available for general corporate purposes.
v3.23.2
ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE (Tables)
6 Months Ended
Jun. 30, 2023
Business Combinations, Discontinued Operations And Disposal Groups [Abstract]  
Schedule of Purchase Price Allocations The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the capital assets, tangible assets acquired and the residual goodwill resulting from the transaction.
Purchase Price AllocationNortheast Patients Group
Assets acquired:
Cash and cash equivalents$516 
Inventory384 
Other current assets5,580 
Capital assets2,404 
Operating lease right-of-use asset1,695 
Goodwill24,933 
Liabilities assumed:
Accounts payable and accrued liabilities(3,679)
Taxes payable(1,112)
Operating lease liability, current(160)
Operating lease liability, non-current(1,844)
Notes payable(11)
Deferred tax liability(1,015)
Fair value of net assets acquired$27,691 
Consideration paid:
Settlement of pre-existing relationship27,691 
Total consideration$27,691 
Schedule of Assets and Liabilities Held for Sale The tables below present the assets and liabilities classified as held for sale on the Unaudited Condensed Consolidated Statements of Financial Position as of June 30, 2023, and are subject to change based on developments during the sales process. As of December 31, 2022, the Company did not have any business or assets that met the held-for-sale criteria.
June 30, 2023
CWG
Cash165 
Accounts receivable, net53 
Inventory685 
Other current assets64 
Total current assets classified as held-for-sale967 
Capital assets, net471 
Operating lease right-of-use assets310 
Non-current assets40 
Total assets classified as held for sale1,788 
Accounts payable and accrued liabilities(242)
Taxes payable81 
Operating lease liability, current(271)
Total current liabilities classified as held-for-sale(432)
Operating lease liability, non-current(856)
Total liabilities classified as held-for-sale(1,288)
v3.23.2
INTANGIBLE ASSETS AND GOODWILL (Tables)
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
The following table details the intangible asset balances by major asset classes:
IntangiblesJune 30, 2023December 31, 2022
Finite-lived intangible assets:
Customer relationships1,000 1,000 
Total finite-lived intangible assets1,000 1,000 
Accumulated amortization on finite-lived intangible assets:
Customer relationships(1,000)(1,000)
Total accumulated amortization on finite-lived intangible assets(1,000)(1,000)
Finite-lived intangible assets, net— — 
Indefinite-lived intangible assets
Cannabis licenses35,124 35,124 
Total intangibles, net$35,124 $35,124 
Schedule of Goodwill
The following table details the changes in the carrying amount of goodwill:
GoodwillTotal
December 31, 2022$13,761 
Acquisitions24,933 
June 30, 2023$38,694 
v3.23.2
INVESTMENTS (Tables)
6 Months Ended
Jun. 30, 2023
Investments [Abstract]  
Schedule of Investments
The carrying values of the Company’s investments in the Unaudited Condensed Consolidated Statements of Financial Position as of June 30, 2023 and December 31, 2022 are as follows:
InvestmentsJune 30, 2023December 31, 2022
Investments held at FV-NI$33,287 $34,046 
Total long-term investments$33,287 $34,046 
Schedule of Investment Income (Loss)
Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations during the three and six months ended June 30, 2023 and 2022 is as follows:
Investment income (loss)Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Short-term investments$— $$— $
Investments held at FV-NI322 (998)(20)134 
Income (loss) from investments, net$322 $(996)$(20)$137 
v3.23.2
NOTES RECEIVABLE, NET (Tables)
6 Months Ended
Jun. 30, 2023
Receivables [Abstract]  
Schedule of Notes Receivable
Notes receivable as of June 30, 2023 and December 31, 2022 consisted of the following:
June 30, 2023December 31, 2022
Promissory notes receivable$7,212 $34,088 
Line of credit receivable4,3315,831
Interest receivable3,552 4,147 
Allowance for notes and interest receivable(15,095)(14,875)
Total notes receivable$ $29,191 
Less: Notes receivable, current— 29,191 
Notes receivable, non-current$— $— 
v3.23.2
CAPITAL ASSETS, NET (Tables)
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Capital Assets, net
Net property, plant and equipment consisted of:
June 30, 2023December 31, 2022
Land$9,778 $9,605 
Building58,524 58,334 
Right-of-use asset, finance leases6,297 5,077 
Furniture, fixtures and equipment40,698 46,811 
Leasehold improvements49,587 6,178 
Construction in progress11,415 34,435 
Capital assets, gross$176,299 $160,440 
Less: accumulated depreciation and amortization(40,214)(27,035)
Capital assets, net$136,085 $133,405 
v3.23.2
LEASES (Tables)
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
Schedule of Lease Cost
Balance Sheet InformationClassificationJune 30, 2023December 31, 2022
Right-of-use assets
OperatingOperating lease right-of-use assets$19,067 $22,443 
FinanceCapital assets, net4,690 4,269 
Total right-of-use assets$23,757 $26,712 
Lease liabilities
Current
OperatingOperating lease liability, current$2,268 $2,443 
FinancingDebt, current109 
Non-current
OperatingOperating lease liability, non-current18,839 21,692 
FinancingDebt, non-current5,860 5,305 
Total lease liabilities$27,076 $29,441 
Three Months Ended June 30,Six Months Ended June 30,
Statement of Operations InformationClassification2023202220232022
Short-term lease expenseGeneral and administrative$58 $170 $209 $218 
Operating lease expenseGeneral and administrative1,277 1,144 2,615 2,392 
Finance lease expense:
Amortization of right of use assetDepreciation and amortization92 64 185 127 
Interest expense on lease liabilitiesInterest expense211 329 420 541 
Net operating and finance lease cost$1,580 $1,537 $3,220 $3,060 
Six Months Ended June 30,
Statement of Cash Flows InformationClassification20232022
Cash paid for operating leasesNet cash used in operating activities$2,727 $2,447 
Cash paid for finance leases - interestNet cash used in operating activities$493 $522 
Schedule of Operating Lease, Liability, Maturity
The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of June 30, 2023:
Maturity of lease liabilitiesOperating LeasesFinance Leases
2023$2,030 $453 
20244,153 923 
20254,098 946 
20264,307 969 
20273,890 992 
Thereafter13,267 11,705 
Total lease payments$31,745 $15,988 
Less: interest10,638 10,019 
Present value of lease liabilities$21,107 $5,969 
Weighted average remaining lease term (years)812
Weighted average discount rate10%12%
Schedule of Finance Lease, Liability, Maturity
The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of June 30, 2023:
Maturity of lease liabilitiesOperating LeasesFinance Leases
2023$2,030 $453 
20244,153 923 
20254,098 946 
20264,307 969 
20273,890 992 
Thereafter13,267 11,705 
Total lease payments$31,745 $15,988 
Less: interest10,638 10,019 
Present value of lease liabilities$21,107 $5,969 
Weighted average remaining lease term (years)812
Weighted average discount rate10%12%
v3.23.2
INVENTORY (Tables)
6 Months Ended
Jun. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory
The Company’s inventory balance consists of the following:
June 30, 2023December 31, 2022
Retail inventory$3,714 $3,255 
Wholesale inventory36,478 35,885 
Cultivation inventory5,070 7,133 
Supplies & other2,676 3,173 
Total$47,938 $49,446 
v3.23.2
DEBT (Tables)
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Debt
The Company’s debt balances consist of the following:
Debt balancesJune 30, 2023December 31, 2022
Financing liability (failed sale-leaseback)$15,253 $15,253 
Finance lease liabilities5,969 5,306 
7.50% Loan due April 2026
31,549 31,288 
6.10% Secured debenture due September 2030
46,727 46,502 
Note due December 20242,375 3,167 
Prime rate credit facilities due January 2026, as amended129,982 113,564 
Note backed by ERTC12,113 — 
Total debt$243,968 $215,080 
Less: current portion of debt13,805 1,584 
Total long-term debt$230,163 $213,496 
Schedule of Maturities of Debt
Scheduled maturities of debt, excluding amortization of discount and issuance costs, are as follows:
2023$12,904 
20241,584 
2025— 
2026173,011 
202739 
Thereafter71,172 
Total payments (excluding amortization of discount and issuance costs)
$258,710 
v3.23.2
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS (Tables)
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Schedule of Stock by Class
The table below details the change in Pubco shares outstanding by class for the three and six months ended June 30, 2023:

Shareholders’ EquityFixed SharesFloating SharesFixed Shares Held in TreasuryFloating Shares Held in TreasuryFixed Multiple SharesTotal Shares Outstanding
December 31, 202279,047 34,114 (589)(253)118 112,437 
Issuances607 159 — — — 766 
NCI conversions— — — — — — 
June 30, 202379,654 34,273 (589)(253)118 113,203 
Schedule of Warrants
A summary of the warrants activity outstanding is as follows:

WarrantsFixed SharesFloating Shares
December 31, 20225,817 2,524 
Expired— — 
June 30, 20235,817 2,524 
Schedule of Summarized Financial Information Summarized financial information of HSCP is presented below. USCo2 does not have discrete financial information separate from HSCP.
HSCP net asset reconciliationJune 30, 2023December 31, 2022
Current assets$94,126 $118,193 
Non-current assets261,072 237,665 
Current liabilities(6,986)(9,141)
Non-current liabilities(266,212)(239,525)
Other NCI balances(726)(725)
Accumulated equity-settled expenses(242,438)(240,760)
Net assets$(161,164)$(134,293)
HSCP/USCo2 ownership % of HSCP16.24 %16.33 %
Net assets allocated to USCo2/HSCP$(26,175)$(21,930)
Net assets attributable to other NCIs726 725 
Total NCI$(25,449)$(21,205)
Three Months Ended June 30,Six Months Ended June 30,
HSCP Summarized Statement of Operations2023202220232022
Net loss allocable to HSCP/USCo2$(12,801)$(3,958)$(22,403)$(11,040)
HSCP/USCo2 weighted average ownership % of HSCP16.28 %16.98 %16.29 %17.13 %
Net loss allocated to HSCP/USCo2$(2,084)$(672)$(3,650)$(1,891)
Net loss allocated to other NCIs— (2)(1)— 
Net loss attributable to NCIs$(2,084)$(674)$(3,651)$(1,891)
Schedule of Conversions of Stock
A reconciliation of the beginning and ending amounts of convertible units is as follows:
Convertible UnitsJune 30, 2023December 31, 2022
Beginning balance22,698 23,076 
NCI units converted to Pubco— (378)
Ending balance22,698 22,698 
v3.23.2
EQUITY-BASED COMPENSATION EXPENSE (Tables)
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Stock and Restricted Stock Unit, Activity
Restricted Share Units (“RSUs”)

Fixed SharesFloating Shares
Restricted Share Units
(Fair value information expressed in whole dollars)
RSUsWeighted Average Grant Date Fair ValueRSUsWeighted Average Grant Date Fair Value
Unvested, January 1, 20236,324 $1.80 464 $6.68 
Granted— $— — $— 
Forfeited(245)$1.00 (1)$2.15 
Vested(711)$2.50 (228)$2.59 
Unvested, June 30, 2023
5,368 $1.75 235 $10.65 
Vested and unreleased(1)
21 $15.31 11 $17.35 
Outstanding, June 30, 2023
5,389 $1.80 246 $10.94 
(1) RSUs that are vested and unreleased represent RSUs that are pending delivery.
Schedule of Option Activity
Stock options
Fixed SharesFloating Shares
Stock Options
(Exercise price expressed in whole dollars)
OptionsWeighted Average Exercise PriceOptionsWeighted Average Exercise Price
Options outstanding, January 1, 20237,337 $2.75 2,267 $3.10 
Granted— $— — $— 
Forfeited— $— — $— 
Expired— $— (35)$2.55 
Options outstanding, June 30, 2023
7,337 $2.75 2,232 $3.11 
Options exercisable, June 30, 2023
1,834 $9.14 2,101 $3.10 
v3.23.2
EARNINGS PER SHARE (Tables)
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
Basic and diluted loss per share is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Net loss attributable to common shareholders of the Company$(16,156)$(9,929)$(30,746)$(22,623)
Weighted average shares outstanding - basic112,810 108,230 112,679 107,569 
Effect of dilutive securities— — — — 
Weighted average shares - diluted112,810 108,230 112,679 107,569 
Net loss per share attributable to common shareholders of the Company - basic$(0.14)$(0.09)$(0.27)$(0.21)
Net loss per share attributable to common shareholders of the Company - diluted$(0.14)$(0.09)$(0.27)$(0.21)
v3.23.2
NATURE OF OPERATIONS (Details)
$ in Thousands
Oct. 24, 2022
Rate
Sep. 23, 2020
USD ($)
shares
Jun. 27, 2019
Jun. 30, 2023
Class of Stock [Line Items]        
Share conversion (as percent)     0.5818  
Entity reorganization, fixed exchange ratio   0.3048    
6.10% Secured debenture due September 2030        
Class of Stock [Line Items]        
Interest rate (as percent)       6.10%
6.10% Secured debenture due September 2030 | Universal Hemp        
Class of Stock [Line Items]        
Interest rate (as percent)       6.10%
Acreage Holdings | Canopy Growth and Canopy USA, LLC        
Class of Stock [Line Items]        
Consideration of common share (in shares) | Rate 45.00%      
Universal Hemp | Canopy Growth | Canopy Growth | Debenture | Universal Hemp        
Class of Stock [Line Items]        
Debenture amount, amount advanced | $   $ 50,000    
Fixed Shares        
Class of Stock [Line Items]        
Percent of share - canopy reorganization   0.7    
Floating Shares        
Class of Stock [Line Items]        
Percent of share - canopy reorganization   0.3    
PVS, Fixed Shares        
Class of Stock [Line Items]        
Canopy reorganization, shares exchanged (in shares)   28    
PVS, Floating Shares        
Class of Stock [Line Items]        
Canopy reorganization, shares exchanged (in shares)   12    
Fixed Multiple Share        
Class of Stock [Line Items]        
Percent of share - canopy reorganization   0.7    
Floating Multiple Share        
Class of Stock [Line Items]        
Percent of share - canopy reorganization   0.3    
v3.23.2
SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
shares in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Accounting Policies [Abstract]      
Cash and cash equivalents $ 16,401 $ 29,235 $ 24,067
Restricted cash 13,628 $ 95 0
Allowance for credit losses, accounts receivable 373    
Allowance for notes and interest receivable 15,095   $ 14,875
Allowance for credit losses over notes receivable $ 0    
Antidilutive shares (in shares) 46,243 37,472  
v3.23.2
ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jan. 02, 2023
USD ($)
Jun. 30, 2023
USD ($)
divestiture
Jun. 30, 2022
USD ($)
divestiture
Jun. 30, 2023
USD ($)
divestiture
Jun. 30, 2022
USD ($)
divestiture
Dec. 31, 2022
business
Business Acquisition [Line Items]            
Number of businesses acquired | business           0
Number of divestitures | divestiture   0 0 0 0  
Write down of assets held-for-sale   $ 3,557 $ 0 $ 3,557 $ 874  
Northeast Patients Group            
Business Acquisition [Line Items]            
Total consideration $ 27,691          
v3.23.2
ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE - Schedule of Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Jan. 02, 2023
Jun. 30, 2023
Dec. 31, 2022
Purchase Price Allocation      
Goodwill   $ 38,694 $ 13,761
Northeast Patients Group      
Purchase Price Allocation      
Cash and cash equivalents $ 516    
Inventory 384    
Other current assets 5,580    
Capital assets 2,404    
Operating lease right-of-use asset 1,695    
Goodwill 24,933    
Accounts payable and accrued liabilities (3,679)    
Taxes payable (1,112)    
Operating lease liability, current (160)    
Operating lease liability, non-current (1,844)    
Notes payable (11)    
Deferred tax liability (1,015)    
Fair value of net assets acquired 27,691    
Consideration paid:      
Settlement of pre-existing relationship 27,691    
Total consideration $ 27,691    
v3.23.2
ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE - Schedule of Assets and Liabilities Held for Sale (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Total current assets classified as held-for-sale $ 1,788   $ 1,788   $ 0
Total current liabilities classified as held-for-sale (1,288)   (1,288)   $ 0
Write down of assets held-for-sale 3,557 $ 0 3,557 $ 874  
Held-for-sale | CWG          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Cash 165   165    
Accounts receivable, net 53   53    
Inventory 685   685    
Other current assets 64   64    
Total current assets classified as held-for-sale 967   967    
Capital assets, net 471   471    
Operating lease right-of-use assets 310   310    
Non-current assets 40   40    
Total assets classified as held for sale 1,788   1,788    
Accounts payable and accrued liabilities (242)   (242)    
Taxes payable 81   81    
Operating lease liability, current (271)   (271)    
Total current liabilities classified as held-for-sale (432)   (432)    
Operating lease liability, non-current (856)   (856)    
Total liabilities classified as held-for-sale $ (1,288)   $ (1,288)    
Held-for-sale | Oregon          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Write down of assets held-for-sale       $ 874  
v3.23.2
INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Total finite-lived intangible assets $ 1,000 $ 1,000
Total accumulated amortization on finite-lived intangible assets (1,000) (1,000)
Finite-lived intangible assets, net 0 0
Indefinite-lived intangible assets 35,124 35,124
Total intangibles, net 35,124 35,124
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Total finite-lived intangible assets 1,000 1,000
Total accumulated amortization on finite-lived intangible assets $ (1,000) $ (1,000)
v3.23.2
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]        
Goodwill re-allocated $ 17,000      
Intangible assets, adjustments $ 17,000      
Amortization of intangible assets   $ 296 $ 0 $ 992
Acquisitions     $ 24,933  
v3.23.2
INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning balance $ 13,761
Acquisitions 24,933
Goodwill, ending balance $ 38,694
v3.23.2
INVESTMENTS - Schedule of Investments (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Investments [Abstract]    
Investments held at FV-NI $ 33,287 $ 34,046
Total long-term investments $ 33,287 $ 34,046
v3.23.2
INVESTMENTS - Schedule of Investment Income (Loss) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Net Investment Income [Line Items]        
Loss from investments, net $ 322 $ (996) $ (20) $ 137
Short-term investments        
Net Investment Income [Line Items]        
Loss from investments, net 0 2 0 3
Investments held at FV-NI        
Net Investment Income [Line Items]        
Loss from investments, net $ 322 $ (998) $ (20) $ 134
v3.23.2
INVESTMENTS - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
Sep. 28, 2020
Sep. 23, 2020
Jun. 30, 2023
Subsidiary or Equity Method Investee [Line Items]      
Proceeds from secured debenture   $ 50,000  
Amount invested $ 34,019    
6.10% Secured debenture due September 2030      
Subsidiary or Equity Method Investee [Line Items]      
Interest rate (as percent)   6.10% 6.10%
Universal Hemp | Investment Partnership      
Subsidiary or Equity Method Investee [Line Items]      
Financial interest in the investment partnership (as percent) 100.00%    
Universal Hemp | Investment Partnership | Investment Partnership      
Subsidiary or Equity Method Investee [Line Items]      
Financial interest in the investment partnership (as percent) 100.00%    
Universal Hemp | Class B Units | Investment Partnership      
Subsidiary or Equity Method Investee [Line Items]      
Number of shares acquired (in shares) 34,019    
Par value (in USD per share) $ 1.00    
Universal Hemp | Class B Units | Investment Partnership | Investment Partnership      
Subsidiary or Equity Method Investee [Line Items]      
Financial interest in the investment partnership (as percent) 100.00%    
v3.23.2
NOTES RECEIVABLE, NET - Schedule of Notes Receivable (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Interest receivable $ 3,552 $ 4,147
Allowance for notes and interest receivable 15,095 14,875
Total notes receivable 0 29,191
Less: Notes receivable, current 0 29,191
Notes receivable, non-current 0 0
Promissory notes receivable    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Principal outstanding 7,212 34,088
Line of credit receivable    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Principal outstanding $ 4,331 $ 5,831
v3.23.2
NOTES RECEIVABLE, NET - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2023
Apr. 30, 2023
Feb. 28, 2022
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]                
Interest income (loss) from loans receivable       $ (6) $ 365 $ 10 $ 782  
Allowance for notes and interest receivable       15,095   15,095   $ 14,875
Grown Rogue                
Accounts, Notes, Loans and Financing Receivable [Line Items]                
Collection of notes receivable $ 500              
Patient Centric Martha's Vineyard                
Accounts, Notes, Loans and Financing Receivable [Line Items]                
Collection of notes receivable     $ 5,279          
Prime Alternative Treatment Center Consulting, LLC (“NH-PATCC”) | Prime Alternative Treatment Center, Inc. ("PATC")                
Accounts, Notes, Loans and Financing Receivable [Line Items]                
Collection of notes receivable   $ 1,500            
Principal                
Accounts, Notes, Loans and Financing Receivable [Line Items]                
Allowance for notes and interest receivable       11,543   11,543   12,041
Accrued Interest                
Accounts, Notes, Loans and Financing Receivable [Line Items]                
Allowance for notes and interest receivable       $ 3,552   $ 3,552   $ 2,834
v3.23.2
CAPITAL ASSETS, NET - Schedule of Capital Assets, net (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Right-of-use asset, finance leases $ 6,297 $ 5,077
Capital assets, gross 176,299 160,440
Less: accumulated depreciation and amortization (40,214) (27,035)
Capital assets, net 136,085 133,405
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 9,778 9,605
Building    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 58,524 58,334
Furniture, fixtures and equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 40,698 46,811
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 49,587 6,178
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 11,415 $ 34,435
v3.23.2
CAPITAL ASSETS, NET - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]          
Depreciation expense $ 994,000 $ 2,868,000 $ 1,991,000 $ 3,980,000  
Depreciation capitalized to inventory 2,090,000 1,794,000 4,377,000 3,716,000  
Assets $ 359,914,000   $ 359,914,000   $ 360,573,000
Assets related to Michigan Operations          
Property, Plant and Equipment [Line Items]          
Assets   $ 0   0  
Impairment charge       $ 1,907,000  
v3.23.2
LEASES - Balance Sheet Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Right-of-use assets    
Operating $ 19,067 $ 22,443
Finance lease, right-of-use asset, statement of financial position Capital assets, net Capital assets, net
Finance $ 4,690 $ 4,269
Total right-of-use assets 23,757 26,712
Lease liabilities    
Operating lease liability, current $ 2,268 $ 2,443
Finance lease, liability, current, statement of financial position, extensible list Debt, current Debt, current
Finance lease liability, current $ 109 $ 1
Operating lease liability, non-current $ 18,839 $ 21,692
Finance lease, liability, non-current, statement of financial position, extensible list Debt, non-current Debt, non-current
Finance lease liability, noncurrent $ 5,860 $ 5,305
Total lease liabilities $ 27,076 $ 29,441
v3.23.2
LEASES - Income Statement Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Leases [Abstract]        
Short-term lease expense $ 58 $ 170 $ 209 $ 218
Operating lease expense 1,277 1,144 2,615 2,392
Amortization of right of use asset 92 64 185 127
Interest expense on lease liabilities 211 329 420 541
Net operating and finance lease cost $ 1,580 $ 1,537 $ 3,220 $ 3,060
v3.23.2
LEASES - Cash Flow Statement Information (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Leases [Abstract]    
Cash paid for operating leases $ 2,727 $ 2,447
Cash paid for finance leases - interest $ 493 $ 522
v3.23.2
LEASES - Lease Maturities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Operating Leases    
2023 $ 2,030  
2024 4,153  
2025 4,098  
2026 4,307  
2027 3,890  
Thereafter 13,267  
Total lease payments 31,745  
Less: interest 10,638  
Present value of lease liabilities $ 21,107  
Weighted average remaining lease term (years) 8 years  
Weighted average discount rate 10.00%  
Finance Leases    
2023 $ 453  
2024 923  
2025 946  
2026 969  
2027 992  
Thereafter 11,705  
Total lease payments 15,988  
Less: interest 10,019  
Present value of lease liabilities $ 5,969 $ 5,306
Weighted average remaining lease term (years) 12 years  
Weighted average discount rate 12.00%  
v3.23.2
LEASES - Narrative (Details)
Jun. 30, 2023
lease
Leases [Abstract]  
Number of leases not yet commenced 0
v3.23.2
INVENTORY - Schedule of Inventory (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Retail inventory $ 3,714 $ 3,255
Wholesale inventory 36,478 35,885
Cultivation inventory 5,070 7,133
Supplies & other 2,676 3,173
Total $ 47,938 $ 49,446
v3.23.2
INVENTORY - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Inventory Disclosure [Abstract]    
Inventory write-down $ 4,484 $ 6,721
v3.23.2
DEBT - Schedule of Debt (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Sep. 28, 2020
Debt Instrument [Line Items]      
Financing liability (failed sale-leaseback) $ 15,253 $ 15,253  
Finance lease liabilities 5,969 5,306  
Total debt 243,968 215,080  
Less: current portion of debt 13,805 1,584  
Total long-term debt $ 230,163 213,496  
7.50% Loan due April 2026      
Debt Instrument [Line Items]      
Interest rate (as percent) 7.50%   7.50%
Loans $ 31,549 31,288  
6.10% Secured debenture due September 2030      
Debt Instrument [Line Items]      
Interest rate (as percent) 6.10%    
Loans $ 46,727 46,502  
Note due December 2024      
Debt Instrument [Line Items]      
Loans 2,375 3,167  
Prime rate credit facilities due January 2026, as amended      
Debt Instrument [Line Items]      
Loans 129,982 113,564  
Note backed by ERTC      
Debt Instrument [Line Items]      
Loans $ 12,113 $ 0  
v3.23.2
DEBT - Schedule of Maturities of Debt (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Debt Disclosure [Abstract]  
2023 $ 12,904
2024 1,584
2025 0
2026 173,011
2027 39
Thereafter 71,172
Total payments (excluding amortization of discount and issuance costs) $ 258,710
v3.23.2
DEBT - Narrative (Details)
$ / shares in Units, shares in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 11, 2023
USD ($)
Oct. 24, 2022
USD ($)
Dec. 16, 2021
USD ($)
leverage_ratio
Sep. 28, 2020
USD ($)
$ / shares
shares
Sep. 23, 2020
USD ($)
Apr. 30, 2022
USD ($)
Nov. 30, 2020
USD ($)
payment
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Apr. 28, 2023
USD ($)
Jan. 01, 2023
USD ($)
Dec. 31, 2022
USD ($)
Debt Instrument [Line Items]                              
Interest expense               $ 8,862,000   $ 5,520,000 $ 16,936,000 $ 10,301,000      
Debt discount amortization               525,000   377,000 1,015,000 751,000      
Amortization of debt issuance costs               698,000   $ 294,000 1,388,000 $ 552,000      
Unamortized discounts               5,578,000     5,578,000       $ 6,093,000
Debt issuance costs               9,164,000     9,164,000       10,522,000
Interest payable               $ 2,824,000     $ 2,824,000       $ 2,575,000
Amount invested       $ 34,019,000                      
Repayment of short-term debt       $ 18,000,000                      
Amendment fee     $ 413,000                        
Number of debt payments | payment             10                
Amended Credit Facility                              
Debt Instrument [Line Items]                              
Fee amount   $ 1,250,000                          
Amount available for immediate draw                         $ 140,000    
Additional borrowing capacity                         $ 15,000    
Maturity extension option fee (percent)   1.00%                          
Maturity extension option, periodic payment fee (percent)   5.00%                          
Amended Credit Facility | Prime                              
Debt Instrument [Line Items]                              
Variable rate (as percent)   5.75%                          
Prime floor (as percent)   5.50%                          
CanWell Settlement                              
Debt Instrument [Line Items]                              
Accrued loss contingency loss             $ 7,750,000                
Universal Hemp | Investment Partnership                              
Debt Instrument [Line Items]                              
Financial interest in the investment partnership (as percent)       100.00%                      
Universal Hemp | Universal Hemp                              
Debt Instrument [Line Items]                              
Amount invested       $ 34,019,000                      
Universal Hemp | Canopy Growth | Canopy Growth | Debenture | Universal Hemp                              
Debt Instrument [Line Items]                              
Debenture amount, amount advanced         $ 50,000,000                    
Debt issuance costs         4,025,000                    
11065220 Canada Inc | Canopy Growth | Canopy Growth                              
Debt Instrument [Line Items]                              
Face amount         $ 100,000,000                    
11065220 Canada Inc | Canopy Growth | Canopy Growth | Debenture                              
Debt Instrument [Line Items]                              
Interest rate (as percent)         6.10%                    
Debenture amount, amount advanced         $ 50,000,000                    
Debenture amount, amount to be advanced         $ 50,000,000                    
Debt term (in years)         10 years                    
Investment Partnership | Universal Hemp | Investment Partnership                              
Debt Instrument [Line Items]                              
Financial interest in the investment partnership (as percent)       100.00%                      
Investment Partnership | Universal Hemp | Class B Units                              
Debt Instrument [Line Items]                              
Number of shares acquired (in shares) | shares       34,019                      
Par value (in USD per share) | $ / shares       $ 1.00                      
Investment Partnership | Universal Hemp | Class B Units | Investment Partnership                              
Debt Instrument [Line Items]                              
Financial interest in the investment partnership (as percent)       100.00%                      
Investment Partnership | Universal Hemp | Class A Units                              
Debt Instrument [Line Items]                              
Amount invested       $ 1,019,000                      
6.10% Secured debenture due September 2030                              
Debt Instrument [Line Items]                              
Interest rate (as percent)         6.10%     6.10%     6.10%        
6.10% Secured debenture due September 2030                              
Debt Instrument [Line Items]                              
Interest rate (as percent)               6.10%     6.10%        
6.10% Secured debenture due September 2030 | Universal Hemp                              
Debt Instrument [Line Items]                              
Interest rate (as percent)               6.10%     6.10%        
7.50% Loan due April 2026                              
Debt Instrument [Line Items]                              
Interest rate (as percent)       7.50%       7.50%     7.50%        
Debenture amount, amount advanced       $ 33,000,000                      
Debt issuance costs       $ 959,000                      
Debt term (in years)       3 years                      
Securities Purchase Agreement | Convertible Debt                              
Debt Instrument [Line Items]                              
Repayment of short-term debt       $ 11,000,000                      
Prime rate credit facilities due January 2026, as amended                              
Debt Instrument [Line Items]                              
Unamortized discounts     4,000,000                        
Debt issuance costs     1,500,000                        
Face amount     150,000,000                        
Proceeds from issuance of debt     75,000,000                        
Fee amount     $ 500,000                        
Number of leverage ratios | leverage_ratio     2                        
Minimum cash requirement     $ 9,000,000                        
Prime rate credit facilities due January 2026, as amended | Amended Credit Facility | Prime                              
Debt Instrument [Line Items]                              
Variable rate (as percent)   1.00%                          
Prime Rate Credit Facilities Due January 2026, Initial Draw                              
Debt Instrument [Line Items]                              
Face amount     75,000,000                        
Prime Rate Credit Facilities Due January 2026, Delayed Draw                              
Debt Instrument [Line Items]                              
Face amount     $ 25,000,000                        
Proceeds from delayed draw facility           $ 25,000,000                  
Delayed draw, term for issuance (in months)     12 months                        
Prime Rate Credit Facilities Due January 2026, Committed Accordion Facility                              
Debt Instrument [Line Items]                              
Face amount     $ 50,000,000                        
Amount available for immediate draw   $ 25,000                          
Delayed draw term loan                 $ 25,000            
Line of credit facility, remaining borrowing capacity                           $ 25,000  
Note backed by ERTC | ERTC Factoring Agreement                              
Debt Instrument [Line Items]                              
Interest rate (as percent) 10.00%                            
Proceeds from sale of finance receivables $ 12,113,000                            
Interest in Employee Retention Tax Credit assigned to the lender $ 14,251,000                            
v3.23.2
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Schedule of Stock by Class (Details)
shares in Thousands
6 Months Ended
Jun. 30, 2023
shares
Class Of Stock [Roll Forward]  
Common stock, outstanding, beginning (in shares) 112,437
Treasury stock, period start (in shares) (842)
Common stock, outstanding, ending (in shares) 113,203
Treasury stock, period end (in shares) (842)
Fixed Shares | Pubco  
Class Of Stock [Roll Forward]  
Common stock, outstanding, beginning (in shares) 79,047
Issuances (in shares) 607
NCI conversions (shares) 0
Common stock, outstanding, ending (in shares) 79,654
Floating Shares | Pubco  
Class Of Stock [Roll Forward]  
Common stock, outstanding, beginning (in shares) 34,114
Issuances (in shares) 159
NCI conversions (shares) 0
Common stock, outstanding, ending (in shares) 34,273
Fixed Shares Held in Treasury | Pubco  
Class Of Stock [Roll Forward]  
Treasury stock, period start (in shares) (589)
Issuances (in shares) 0
NCI conversions (shares) 0
Treasury stock, period end (in shares) (589)
Floating Shares Held in Treasury | Pubco  
Class Of Stock [Roll Forward]  
Treasury stock, period start (in shares) (253)
Issuances (in shares) 0
NCI conversions (shares) 0
Treasury stock, period end (in shares) (253)
Fixed Multiple Shares | Pubco  
Class Of Stock [Roll Forward]  
Common stock, outstanding, beginning (in shares) 118
Issuances (in shares) 0
NCI conversions (shares) 0
Common stock, outstanding, ending (in shares) 118
Total Shares Outstanding | Pubco  
Class Of Stock [Roll Forward]  
Common stock, outstanding, beginning (in shares) 112,437
Issuances (in shares) 766
NCI conversions (shares) 0
Common stock, outstanding, ending (in shares) 113,203
v3.23.2
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Schedule of Warrants (Details)
shares in Thousands
6 Months Ended
Jun. 30, 2023
shares
Fixed Shares  
Class Of Warrant Or Right [Roll Forward]  
Beginning balance (in shares) 5,817
Expired (in shares) 0
Ending balance (in shares) 5,817
Floating Shares  
Class Of Warrant Or Right [Roll Forward]  
Beginning balance (in shares) 2,524
Expired (in shares) 0
Ending balance (in shares) 2,524
v3.23.2
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Warrants (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
Class of Warrant or Right [Line Items]  
Warrants term (in years) 4 years
Warrant contractual weighted average life remaining (in years) 1 year 6 months
Aggregate intrinsic value | $ $ 0
Fixed Shares | Minimum  
Class of Warrant or Right [Line Items]  
Exercise price (USD per share) $ 3.15
Fixed Shares | Maximum  
Class of Warrant or Right [Line Items]  
Exercise price (USD per share) 4.00
Floating Shares | Minimum  
Class of Warrant or Right [Line Items]  
Exercise price (USD per share) 3.01
Floating Shares | Maximum  
Class of Warrant or Right [Line Items]  
Exercise price (USD per share) $ 4.00
v3.23.2
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Non-Controlling Interests - Convertible Units (Details)
Jun. 30, 2023
Equity [Abstract]  
USCo2 conversion, fixed share 0.7
USCo2 conversion, floating share 0.3
USCo2 Ownership of HSCP 0.22%
HSCP ownership by LLC members 16.07%
HSCP owned by Pubco 83.71%
v3.23.2
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Schedule of Summarized Financial Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Subsidiary-specific information [Line Items]    
Current assets $ 94,126 $ 118,193
Non-current assets 265,788 242,380
Current liabilities (94,293) (72,333)
Non-current liabilities (262,626) (248,061)
Total NCI (25,449) (21,205)
HSCP LLC    
Subsidiary-specific information [Line Items]    
Current assets 94,126 118,193
Non-current assets 261,072 237,665
Current liabilities (6,986) (9,141)
Non-current liabilities (266,212) (239,525)
Other NCI balances (726) (725)
Accumulated equity-settled expenses (242,438) (240,760)
Net Assets, Total (161,164) (134,293)
Net assets allocated to USCo2/HSCP (26,175) (21,930)
Net assets attributable to other NCIs $ 726 $ 725
HSCP LLC | HSCP/USCo2    
Subsidiary-specific information [Line Items]    
HSCP/USCo2 ownership % of HSCP 16.24% 16.33%
v3.23.2
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Noncontrolling Interest, P&L Allocation (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Subsidiary-specific information [Line Items]            
Net loss allocable to HSCP/USCo2 $ (18,240) $ (16,157) $ (10,603) $ (13,911) $ (34,397) $ (24,514)
Net loss attributable to NCIs (2,084)   (674)   (3,651) (1,891)
HSCP LLC            
Subsidiary-specific information [Line Items]            
Net loss allocable to HSCP/USCo2 $ (12,801)   $ (3,958)   $ (22,403) $ (11,040)
HSCP/USCo2 weighted average ownership % of HSCP 16.28%   16.98%   16.29% 17.13%
Net loss allocated to HSCP/USCo2 $ (2,084)   $ (672)   $ (3,650) $ (1,891)
Net loss allocated to other NCIs $ 0   $ (2)   $ (1) $ 0
v3.23.2
SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Schedule of Conversions by Stock (Details) - shares
shares in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Convertible Units Outstanding [Roll Forward]    
Beginning balance 22,698 23,076
NCI units converted to Pubco 0 (378)
Ending balance 22,698 22,698
v3.23.2
EQUITY-BASED COMPENSATION EXPENSE - Expense by Plan (Details) - Equity-based compensation - Plan
shares in Thousands
6 Months Ended
Jun. 30, 2023
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Percentage of outstanding stock 15.00%
Shares available for grant (in shares) 5,308
v3.23.2
EQUITY-BASED COMPENSATION EXPENSE - Schedule of Restricted Stock and Restricted Stock Unit, Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Weighted Average Grant Date Fair Value        
Weighted average remaining contractual term (in years)     4 years 6 months  
Weighted average remaining contractual term, exercisable (in years)     6 years  
Restricted Stock Units, Fixed        
RSUs        
Beginning Balance (in shares)     6,324  
Granted (in shares)     0  
Forfeited (in shares)     (245)  
Vested (in shares)     (711)  
Ending Balance (in shares) 5,368   5,368  
Vested and unreleased (in shares) 21   21  
Outstanding (in shares) 5,389   5,389  
Weighted Average Grant Date Fair Value        
Beginning Balance (in USD per share)     $ 1.80  
Granted (in USD per share)     0  
Forfeited (in USD per share)     1.00  
Vested (in USD per share)     2.50  
Ending Balance (in USD per share) $ 1.75   1.75  
Vested and unreleased (in USD per share) 15.31   15.31  
Outstanding (in USD per share) $ 1.80   $ 1.80  
Restricted Stock Units, Floating        
RSUs        
Beginning Balance (in shares)     464  
Granted (in shares)     0  
Forfeited (in shares)     (1)  
Vested (in shares)     (228)  
Ending Balance (in shares) 235   235  
Vested and unreleased (in shares) 11   11  
Outstanding (in shares) 246   246  
Weighted Average Grant Date Fair Value        
Beginning Balance (in USD per share)     $ 6.68  
Granted (in USD per share)     0  
Forfeited (in USD per share)     2.15  
Vested (in USD per share)     2.59  
Ending Balance (in USD per share) $ 10.65   10.65  
Vested and unreleased (in USD per share) 17.35   17.35  
Outstanding (in USD per share) $ 10.94   $ 10.94  
Restricted Stock Units (RSUs)        
Weighted Average Grant Date Fair Value        
Requisite service period (in years)     3 years  
Equity-based compensation expense $ 470 $ 1,512 $ 1,228 $ 5,389
Fair value 157 $ 1,451 $ 599 $ 3,333
Weighted average remaining contractual term (in years)     1 year 8 months 12 days  
Aggregate intrinsic value, outstanding 962   $ 962  
Unrecognized compensation expense $ 10,471   $ 10,471  
Unrecognized compensation expense, period (in years)     1 year 6 months  
v3.23.2
EQUITY-BASED COMPENSATION EXPENSE - Schedule of Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Weighted Average Exercise Price        
Weighted average remaining contractual term (in years)     4 years 6 months  
Weighted average remaining contractual term, exercisable (in years)     6 years  
Cost not yet recognized $ 1,447,000   $ 1,447,000  
Fixed Shares        
Options        
Beginning balance (in shares)     7,337  
Granted (in shares)     0  
Forfeited (in shares)     0  
Expired (in shares)     0  
Ending balance (in shares) 7,337   7,337  
Exercisable (in shares) 1,834   1,834  
Weighted Average Exercise Price        
Beginning balance (in USD per share)     $ 2.75  
Granted (in USD per share)     0  
Forfeited (in USD per share)     0  
Expired (in USD per share)     0  
Ending balance (in USD per share) $ 2.75   2.75  
Exercisable (in USD per share) $ 9.14   $ 9.14  
Aggregate intrinsic value for options outstanding $ 0   $ 0  
Floating Shares        
Options        
Beginning balance (in shares)     2,267  
Granted (in shares)     0  
Forfeited (in shares)     0  
Expired (in shares)     (35)  
Ending balance (in shares) 2,232   2,232  
Exercisable (in shares) 2,101   2,101  
Weighted Average Exercise Price        
Beginning balance (in USD per share)     $ 3.10  
Granted (in USD per share)     0  
Forfeited (in USD per share)     0  
Expired (in USD per share)     2.55  
Ending balance (in USD per share) $ 3.11   3.11  
Exercisable (in USD per share) $ 3.10   $ 3.10  
Options        
Weighted Average Exercise Price        
Vesting period (in years)     3 years  
Weighted average remaining contractual term (in years)     6 years  
Weighted average remaining contractual term, exercisable (in years)     6 years  
Equity-based compensation expense $ 224,000 $ 143,000 $ 450,000 $ 425,000
Unrecognized compensation expense, period (in years)     2 years  
Options | Minimum        
Weighted Average Exercise Price        
Expiration period (in years)     5 years  
Options | Maximum        
Weighted Average Exercise Price        
Expiration period (in years)     10 years  
v3.23.2
COMMITMENTS AND CONTINGENCIES - Commitments and Prior Plan of Arrangement with Canopy Growth (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
line_of_credit
Jun. 19, 2019
company
Commitments and Contingencies Disclosure [Abstract]    
Number of lines of credit | line_of_credit 1  
Credit facility amount $ 4,331  
Credit facility $ 4,331  
Number of companies involved In agreement | company   2
v3.23.2
COMMITMENTS AND CONTINGENCIES - Second Amendment to the Arrangement Agreement (Details)
$ in Thousands
Sep. 23, 2020
USD ($)
shares
Business Acquisition [Line Items]  
Cash payment | $ $ 37,500
Fixed shares percent - canopy reorganization 0.3048
Expiration period - canopy reorganization 10 years
Canopy Growth  
Business Acquisition [Line Items]  
Maximum number of shares allowed for issuance under agreement (in shares) 32,700,000
Fixed Shares  
Business Acquisition [Line Items]  
Percent of share - canopy reorganization 0.7
Floating Shares  
Business Acquisition [Line Items]  
Percent of share - canopy reorganization 0.3
PVS, Fixed Shares  
Business Acquisition [Line Items]  
Canopy reorganization, shares exchanged (in shares) 28
PVS, Floating Shares  
Business Acquisition [Line Items]  
Canopy reorganization, shares exchanged (in shares) 12
Fixed Multiple Share  
Business Acquisition [Line Items]  
Percent of share - canopy reorganization 0.7
Floating Multiple Share  
Business Acquisition [Line Items]  
Percent of share - canopy reorganization 0.3
v3.23.2
COMMITMENTS AND CONTINGENCIES - Third Amendment to the Arrangement Agreement with Canopy Growth (Details) - Acreage Holdings - Canopy Growth and Canopy USA, LLC
Oct. 25, 2022
Rate
Oct. 24, 2022
Rate
Loss Contingencies [Line Items]    
Consideration of common share (in shares)   45.00%
Amended Credit Facility    
Loss Contingencies [Line Items]    
Consideration of common share (in shares) 30.48%  
Percentage of voting interests acquired (as percent) 70.00%  
v3.23.2
COMMITMENTS AND CONTINGENCIES - Tax Receivable Agreement and Tax Receivable Bonus Plans (Details) - Canopy Growth Corporation - USD ($)
$ in Thousands
Mar. 17, 2023
Nov. 04, 2022
Oct. 24, 2022
Certain Current or Former Unit Holders Of HSCP | Canopy Growth and Canopy USA, LLC      
Loss Contingencies [Line Items]      
Value of Canopy shares issuable under the agreement     $ 30,500
Certain Directors, Officers or Consultants of Acreage | High Street Capital Partners, LLC (“HSCP”)      
Loss Contingencies [Line Items]      
Value of Canopy shares issuable under the agreement     19,500
Potential Liability     121,000
Certain Holders | High Street Capital Partners, LLC (“HSCP”) | Tax Receivable Agreement      
Loss Contingencies [Line Items]      
TRA, number of shares issued (in shares) 7,102,081 5,648,927  
Certain Eligible Participants | Canopy Growth and Canopy USA, LLC      
Loss Contingencies [Line Items]      
TRA final payment issuable     $ 19,500
v3.23.2
COMMITMENTS AND CONTINGENCIES - Debenture (Details) - 11065220 Canada Inc - Canopy Growth - Canopy Growth
Sep. 23, 2020
USD ($)
Business Acquisition [Line Items]  
Face amount $ 100,000,000
Debenture  
Business Acquisition [Line Items]  
Debenture amount, amount advanced 50,000,000
Debenture amount, amount to be advanced $ 50,000,000
EBITDA ratio measurement period 90 days
Interest coverage ratio 2.0
Interest rate (as percent) 6.10%
Debt term (in years) 10 years
Period non-core divestitures are completed 18 months
Remediation period upon receipt of written notice 30 days
v3.23.2
COMMITMENTS AND CONTINGENCIES - Advisor Fee (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2022
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]    
Advisor fee $ 3,000 $ 7,000
Intial payment of advisor 500  
Payment to advisor in share value $ 2,000  
v3.23.2
COMMITMENTS AND CONTINGENCIES - Surety Bonds (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Indemnification obligation, surety bonds $ 5,000
v3.23.2
COMMITMENTS AND CONTINGENCIES - Canwell Settlement (Details) - CanWell Settlement - USD ($)
$ in Thousands
1 Months Ended 32 Months Ended
Nov. 30, 2020
Jun. 30, 2023
Loss Contingencies [Line Items]    
Accrued loss contingency loss $ 7,750  
Repayments of promissory note   $ 5,375
v3.23.2
COMMITMENTS AND CONTINGENCIES - New York Outstanding Litigation and Lease Dispute (Details)
Nov. 02, 2018
defendant
New York Outstanding Litigation  
Loss Contingencies [Line Items]  
Number of defendants 16
v3.23.2
COMMITMENTS AND CONTINGENCIES (Alfred’s Finest, Inc. arbitration) (Details) - Alfred’s Finest, Inc
$ in Thousands
Jun. 22, 2023
USD ($)
Loss Contingencies [Line Items]  
Proceed to settlement payment $ 2,000
Litigation settlement, additional amount awarded to payment $ 3,000
v3.23.2
RELATED PARTY TRANSACTIONS (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Sep. 28, 2020
Sep. 23, 2020
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Oct. 24, 2022
Dec. 16, 2021
Related Party Transaction [Line Items]                
Amount invested $ 34,019              
Interest expense     $ 8,862 $ 5,520 $ 16,936 $ 10,301    
Repayment of short-term debt $ 18,000              
Amended Credit Facility                
Related Party Transaction [Line Items]                
Fee amount             $ 1,250  
Universal Hemp | Investment Partnership                
Related Party Transaction [Line Items]                
Financial interest in the investment partnership (as percent) 100.00%              
Universal Hemp | Investment Partnership | MB Melody LP | Class B Units                
Related Party Transaction [Line Items]                
Number of shares acquired (in shares) 34,019              
Par value (in USD per share) $ 1              
Universal Hemp | Universal Hemp                
Related Party Transaction [Line Items]                
Amount invested $ 34,019              
Universal Hemp | Canopy Growth | Canopy Growth | Debenture | Universal Hemp                
Related Party Transaction [Line Items]                
Debenture amount, amount advanced   $ 50,000            
Debt issuance costs   $ 4,025            
Viridescent Realty Trust, Inc | Amended Credit Facility                
Related Party Transaction [Line Items]                
Fee amount             $ 375  
6.10% Secured debenture due September 2030                
Related Party Transaction [Line Items]                
Interest rate (as percent)   6.10% 6.10%   6.10%      
6.10% Secured debenture due September 2030 | Related Party                
Related Party Transaction [Line Items]                
Interest expense     $ 763   $ 763      
7.50% Loan due April 2026                
Related Party Transaction [Line Items]                
Interest rate (as percent) 7.50%   7.50%   7.50%      
Debenture amount, amount advanced $ 33,000              
Debt issuance costs 959              
Securities Purchase Agreement | Convertible Debt                
Related Party Transaction [Line Items]                
Repayment of short-term debt $ 11,000              
Prime rate credit facilities due January 2026, as amended                
Related Party Transaction [Line Items]                
Fee amount               $ 500
Prime rate credit facilities due January 2026, as amended | Viridescent Realty Trust, Inc                
Related Party Transaction [Line Items]                
Debt instrument, committed amount               42,000
Prime rate credit facilities due January 2026, as amended | Viridescent Realty Trust, Inc | Related Party                
Related Party Transaction [Line Items]                
Interest expense         $ 2,690      
Prime rate credit facilities due January 2026, as amended | Third-Party Syndicated Affiliates                
Related Party Transaction [Line Items]                
Debt instrument, committed amount               98,000
Prime Rate Credit Facilities Due January 2026, Initial Draw | Viridescent Realty Trust, Inc                
Related Party Transaction [Line Items]                
Debt instrument, committed amount               $ 140,000
v3.23.2
REPORTABLE SEGMENTS (Details)
6 Months Ended
Jun. 30, 2023
segment
Segment Reporting [Abstract]  
Number of reportable segments 1
v3.23.2
EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Net loss attributable to common shareholders of the Company $ (16,156) $ (9,929) $ (30,746) $ (22,623)
Weighted average shares outstanding - basic (in share) 112,810 108,230 112,679 107,569
Effect of dilutive securities (in shares) $ 0 $ 0 $ 0 $ 0
Weighted average shares - diluted (in shares) 112,810 108,230 112,679 107,569
Net loss per share attributable to common shareholders of the Company - basic (USD per share) $ (0.14) $ (0.09) $ (0.27) $ (0.21)
Net loss per share attributable to common shareholders of the Company - diluted (USD per share) $ (0.14) $ (0.09) $ (0.27) $ (0.21)
Antidilutive shares (in shares)     46,243 37,472
Fixed Warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive shares (in shares)     5,817 5,817
Floating Warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive shares (in shares)     2,524 2,524
Restricted Stock Units, Fixed        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive shares (in shares)     5,389 1,604
Restricted Stock Units, Floating        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive shares (in shares)     246 652
Fixed Shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive shares (in shares)     7,337 1,493
Floating Shares        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive shares (in shares)     2,232 2,306
NCI convertible units        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive shares (in shares)     22,698 23,076

Acreage (QX) (USOTC:ACRHF)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Acreage (QX) Charts.
Acreage (QX) (USOTC:ACRHF)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Acreage (QX) Charts.